












								  



<!DOCTYPE html PUBLIC

    
    
        "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "https://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"
    

>
<html lang="en" xmlns="https://www.w3.org/1999/xhtml" xml:lang="en" >

  <head>  

    <title>Myocardial Infarction Treatment & Management: Approach Considerations, Prehospital Care and Initial Management, Emergency Department Care and In-Hospital Management</title>
    <link rel ="canonical"  href="https://emedicine.medscape.com/article/155919-treatment" />
    
    <link rel="preload" as="image" href="https://img.medscapestatic.com/pi/meds/ckb/17/34917tn.jpg"/>
    
    <meta name="keywords"  content="Myocardial Infarction Treatment" />
    <meta name="description" content="Myocardial infarction, commonly known as a heart attack, is the irreversible necrosis of heart muscle secondary to prolonged ischemia. This usually results from an imbalance in oxygen supply and demand, which is most often caused by plaque rupture with thrombus formation in a coronary vessel, resulting in an acute reduction of blood supply to..." />
    <meta name="title"  content="Myocardial Infarction Treatment & Management: Approach Considerations, Prehospital Care and Initial Management, Emergency Department Care and In-Hospital Management" />
    <meta name="url" content="" />
    <meta name="uri" content="155919-overview" />
    <meta name="date" content="2025-03-28-21:48" />
    <meta name="site" content="Diseases & Conditions" />
    
    
        
    
            
    <script type="application/ld+json">
        {
            "@context": "https://schema.org/",
            "@type": "MedicalWebPage",
            "mainEntityOfPage": "https://emedicine.medscape.com/article/155919-treatment",
        
        "medicalAudience":{
             "@type": "MedicalAudience",
             "name": "Clinician",
             "healthCondition": "Myocardial Infarction Treatment & Management"
				},
        
        "author": {
            "@type": "Person",
            "name": "A  Maziar Zafari, MD, PhD, FACC, FAHA"
                },
                "publishingPrinciples": "https://www.medscape.com/public/editorialpolicies",
                "lastReviewed": "2019-05-07",
                "publisher": {
                    "@type": "Organization",
                    "name": "Medscape",
                    "logo":
                    { "@type": "ImageObject", "url": " https://img.medscapestatic.com/pi/logos/mscp-logo.png" }
                },
                "about": "Myocardial Infarction Treatment & Management"
        
        ,"isAccessibleForFree": "False",
        "hasPart":
        {
            "@type": "WebPageElement",
            "isAccessibleForFree": "False",
            "cssSelector" : ".paywall"
        }
        
        }
    </script>
    
    <script type="application/ld+json">
        {
            "@context": "https://schema.org",
            "@type": "BreadcrumbList",
            "itemListElement": [{
                "@type": "ListItem",
                "position": 1,
                "name": "Drugs & Diseases",
                "item": "https://reference.medscape.com"
        
            },{
            "@type": "ListItem",
            "position": 2,
            "name": "Cardiology",
            "item": "https://reference.medscape.com/guide/cardiology"
        
        }]
    }
    </script>
    
    <!-- noscript style tag goes somewhere on page to expose menu -->
    <noscript><style>div.sections-nav>ul>li>ul{display:block;}</style></noscript>
    <script type="text/javascript">
        var pixelVarRefMap =  {"pixelVar":{"st":"0","auth":"0","spon":"0","kw":"0","env":"0","occ":"0","tid":"0","ct":"0","ssp":"2","artid":"ckb155919","usp":"0","pf":"0","scg":"315","inst":"0","tcid":"0","pub":"0"}}
 ;
    </script>
    
		<script type="text/javascript">
			var isFPFEligible =	true;
			var isFPFConceptEligible = true;
		</script>
	
    <meta name="metasegvar" content="artid=155919;pub=0;ssp=2;cg=502;pclass=content;scg=315;bc=_3e03317_b972_cust097_diet1_f03_f33_fit1_gen2_i219_i2510_i2699_i509_i519_i802_q249_r529_
" />
    
    
    

    














<meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- POC report cookie -->
    




	<script>
		if (document.getElementById('ot-stub') == null || document.cookie.match(/OptanonConsent[^;]+&groups[^;]+C0003%3A1/) != null || (document.getElementById('ot-ccpa') != null && document.cookie.match(/OptanonConsent[^;]+&groups/) == null)) {
			var guid = "";
			document.cookie = "ads_prof=" + guid + ";" + "path=/; domain=.medscape.com";
		}
	</script>
	

    <!-- /POC report cookie -->
  





<link rel="dns-prefetch" href="//z.moatads.com">
<link rel="dns-prefetch" href="//ssl.o.medscape.com">
<link rel="dns-prefetch" href="//img.medscapestatic.com">


<link rel="preload" href="//img.medscapestatic.com/medcss/fonts/proximanova/light/ProximaNova-Light-webfont.woff2" as="font" type="font/woff2" crossOrigin="anonymous">
<link rel="preload" href="//img.medscapestatic.com/medcss/fonts/proximanova/reg/ProximaNova-Reg-webfont.woff2" as="font" type="font/woff2" crossOrigin="anonymous">
<link rel="preload" href="//img.medscapestatic.com/medcss/fonts/proximanova/semibold/ProximaNova-Sbold-webfont.woff2" as="font" type="font/woff2" crossOrigin="anonymous">
<link rel="preload" href="//img.medscapestatic.com/medcss/fonts/proximanova/bold/ProximaNova-Bold-webfont.woff2" as="font" type="font/woff2" crossOrigin="anonymous">
<link rel="preload" href="//img.medscapestatic.com/medcss/fonts/eb-garamond/eb-garamond.woff2" as="font" type="font/woff2" crossOrigin="anonymous">
<link rel="preload" href="//img.medscapestatic.com/medcss/fonts/eb-garamond/eb-garamond-ext.woff2" as="font" type="font/woff2" crossOrigin="anonymous">
<link rel="preload" href="//img.medscapestatic.com/medcss/fonts/roboto-condensed/roboto-condensed.woff2" as="font" type="font/woff2" crossOrigin="anonymous">
<link rel="preload" href="//img.medscapestatic.com/medcss/fonts/roboto-condensed/roboto-condensed-ext.woff2" as="font" type="font/woff2" crossOrigin="anonymous">


<link rel="apple-touch-icon" sizes="180x180" href="//img.medscapestatic.com/pi/favicon/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="//img.medscapestatic.com/pi/favicon/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="//img.medscapestatic.com/pi/favicon/favicon-16x16.png">
<link rel="manifest" href="//img.medscapestatic.com/pi/favicon/site.webmanifest">
<link rel="mask-icon" href="//img.medscapestatic.com/pi/favicon/safari-pinned-tab.svg" color="#5bbad5">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="theme-color" content="#ffffff">


	 <script> var PageMetadata = {"reqHeaders":{"geoc":"IL","device":"PC","ep":"1","scode":"msp"},"addProfile":{"zip":"","regdate":"","status":"0","email":"","test":"","licid":"","zc":"","profstate":"","uac":"0","gender":"","age":"","occid":"","hcpvalid":"","co":"","regsite":"","spdesc":"","fn":"","dob":"","ln":"","codesc":"","profdesc":"","spid":""},"userSegVars":{"QXMD_ID":"","tar":"0","occ":"0","val":"0","vit":"0","gd":"0","usp":"0","pf":"0","ct":"0","tc":"0","st":"0","actid":"0","dt":"0","sa":"0"},"extraObject":{"actInst":"","actDtls":{},"invitationCount":0,"csStatus":"PS:1|CP:0|USRST:0|CDP:1|CPG:0|CPI:0"},"kubenv":"production","dc":"ma","authVar":{"tokenValue":"xvHk4t6LvCGSItblR0XlrC4506HSykQcdGeiWkhno57BVRtLTqq7a8oFKz44AlWpyYO9ySSe6Cl0SQI7UxUfnQ==","gs":"","authenticationChannel":"100","authLevel":"0"}}; var userTactics = ""; var userCampaign = "" </script>



	<script type="text/javascript" src="//cdn-4.convertexperiments.com/v1/js/10043627-10046183.js"></script>


<!-- GLOBAL FILES -->
<link rel="preload" href="//img.medscapestatic.com/medscape-core/common/css/global/global-header.css" as="style">
<link rel="stylesheet" href="//img.medscapestatic.com/medscape-core/common/css/global/global-header.css" type="text/css" media="screen">




<script type="text/javascript" src="//img.medscapestatic.com/medscape-core/common/js/global/medscape-script/all-scripts-no-defer.js"></script>
<script type="text/javascript" defer src="//img.medscapestatic.com/medscape-core/common/js/global/medscape-library.js"></script>
<!-- /GLOBAL FILES -->
<script>var s_responsive_design = true;</script>


<!-- Commenting Count JS files -->
<!-- todo: clean out includes for commentcount-config.jsp -->
<!-- /Commenting Count JS files -->


    
        

    <!-- HEADER -->
    <!-- DFP req segvar -->
   	
    <!-- /DFP req segvar -->

    <!-- Adobe DTM -->
<script>document.cookie = 'usrctry=' + String("IL").toLowerCase() +'; path=/; domain=' + document.domain.match(/medscape\.[^.\/]+/)[0] + '; expires=Thu, 13 Aug 2048 16:01:51 GMT';</script>
<!-- headercommon release 20.10.07 -->
<script src="//assets.adobedtm.com/2c8c1e17b98c/017edbc80c83/launch-88df53f8d9c8.min.js" id="adobelaunchjs" async></script>
    <meta property="fb:pages" content="30664024188"/>
<meta property="fb:pages" content="127603734515"/>
<meta property="fb:pages" content="131540566363"/>
<meta property="fb:pages" content="99496530973"/>
<meta property="fb:pages" content="259421619891"/>
<meta property="fb:pages" content="127463352183"/>
<meta property="fb:pages" content="310863901520"/>
<meta property="fb:pages" content="196056663770305"/>
<meta property="fb:pages" content="261142695911"/>
<!-- /Adobe DTM -->

<!-- +++++++++++++++++++++++++++++++++++++++ -->

<!-- Prof Ads Tag -->
<!-- jsp_segvar
{{{ adSuppress:  | }}}

    session segvar:   s_ssp: 2 |  s_pclass: 

-->
<script type="text/javascript">

	// X-STATIC-METADATA OR X-STATIC-DATA HEADER IS ENABLED
	
    var DFPTargetKeys = {"reqHeaders":{"domainCategory":"emedicine","domain":"emedicine","enableDomain":"www.medscape.com,decisionpoint.medscape.com,decisionpoint.staging.medscape.com,www.medscape.org,search.medscape.com,reference.medscape.com,emedicine.medscape.com,login.medscape.com,francais.medscape.com,deutsch.medscape.com,espanol.medscape.com,praxis.medscapemedizin.de,wp.medscape.com,boards.medscape.com,directory.medscape.com,modir.medscape.com,www.staging.medscape.com,www.staging.medscape.org,reference.staging.medscape.com,emedicine.staging.medscape.com,francais.staging.medscape.com,deutsch.staging.medscape.com,praxis.staging.medscapemedizin.de,espanol.staging.medscape.com,portugues.medscape.com","requestEnv":""},"webSegVars":{"pc":"content","spon":"0","env":"0","envp":"prod"},"pageSegVars":{"acb":"315_1","ac":"5004268,5000359,3031962,1119,302,64490,6002860,894,5000928,366,363,5000932,372,3031991,1920,390,5000376,1354,5004831,5001291,1356,5001300,5004382,5000056,342,2102,1360,6000073,5001503,326,5003791,3003580,64977,310,1337,3032040,5004459,862,5001656,1440,1065,543,1331,3032306,3032308,64207,5001835,3032526,3004036,1855,3032176,504,3029396,64646,701,5002613,3031955,281,1096,5001309,5004385,1346,5002712,5002713,430,5000182,3003640,355,315,5003323,1391,5003525,3032356,64428,1366,3029406,5003788,419,402,5000994,267,3032386,6004314,6000087,724,5001311,5004380,5000381,1666,6000086,1292,63596,1471,3032234,3030177,5004956,5000304,1069,307,5005131,397","art":"ckb155919","cmsid":"5","cg":"502","ck":"0","ssp":"2","asb":"2_1","as":"2,45,18,35","ctype":"10418","scg":"315","pub":"","asst":"2015110003t5"},"exclusionCategories":["3e03317","b972","cust097","diet1","f03","f33","fit1","gen2","i219","i2510","i2699","i509","i519","i802","q249","r529"],"lazyLoad":{}}; var DFPTargetKeysRefresh = ["blbll"]; var ads2_ignore = {}
;
	
    //extend PageMetadata to get reqHeaders and webSegVars from DFPTargetKeys
    if (typeof PageMetadata['reqHeaders'] === 'object' && typeof DFPTargetKeys['reqHeaders'] === 'object' && PageMetadata['reqHeaders'] !== DFPTargetKeys['reqHeaders']) {
        for (const property in DFPTargetKeys['reqHeaders']) {
            if (typeof PageMetadata['reqHeaders'][property] === 'undefined') {
                PageMetadata['reqHeaders'][property] = DFPTargetKeys['reqHeaders'][property];
            }
        }
    }
    if (typeof PageMetadata['webSegVars'] === 'object' && typeof DFPTargetKeys['webSegVars'] === 'object' && PageMetadata['webSegVars'] !== DFPTargetKeys['webSegVars']) {
        for (const property in DFPTargetKeys['webSegVars']) {
            if (typeof PageMetadata['webSegVars'][property] === 'undefined') {
                PageMetadata['webSegVars'][property] = DFPTargetKeys['webSegVars'][property];
            }
        }
    }
    //extend DFPtargetKeys to get reqHeaders from PageMetadata (dvc value for FB pixel)
    if (typeof DFPTargetKeys['reqHeaders'] === 'object' && typeof PageMetadata['reqHeaders'] === 'object' && DFPTargetKeys['reqHeaders'] !== PageMetadata['reqHeaders']) {
        for (const property in PageMetadata['reqHeaders']) {
            if (typeof DFPTargetKeys['reqHeaders'][property] === 'undefined') {
                DFPTargetKeys['reqHeaders'][property] = PageMetadata['reqHeaders'][property];
            }
        }
    }

    //PageMetadata should have all fields in DFPTargetKeys
    if (typeof window.PageMetadata == 'object' && typeof window.DFPTargetKeys == 'object' && window.DFPTargetKeys != window.PageMetadata) {
        for (const property in window.DFPTargetKeys) {
            if (typeof window.PageMetadata[property] === 'undefined') {
                window.PageMetadata[property] = window.DFPTargetKeys[property];
            }
        }
        //DFPTargetKeys should have all fields in PageMetadata
        for (const property in window.PageMetadata) {
            if (typeof window.DFPTargetKeys[property] === 'undefined') {
                window.DFPTargetKeys[property] = window.PageMetadata[property];
            }
        }
    }
	
	// Add back values that went missing for static metadata switch...
	if (typeof PageMetadata.reqHeaders.device == 'undefined') {
		var reqDevice = 'PC';
		if (navigator.userAgent.toLowerCase().indexOf('ipad') != -1) {
			reqDevice = 'IPAD';
		} else if (/blackberry|blazer|iphone|ipod|android|webos|nokia|opera mini|palm|samsung|sonyericsson|vodafone|windows ce|iemobile/i.test(navigator.userAgent.toLowerCase())) {
			reqDevice = 'MOBILE';
		}
		PageMetadata.reqHeaders['device'] = reqDevice;
		DFPTargetKeys.reqHeaders['device'] = PageMetadata.reqHeaders['device'];
	}	
	if (typeof PageMetadata.reqHeaders.ep == 'undefined') {
		PageMetadata.reqHeaders['ep'] = '0';
		if (document.referrer == '') {
			PageMetadata.reqHeaders['ep'] = '1';
		}
		DFPTargetKeys.reqHeaders['ep'] = PageMetadata.reqHeaders['ep'];
	}
	if (typeof PageMetadata.webSegVars.auth == 'undefined' && typeof (PageMetadata.authVar && PageMetadata.authVar.authLevel) != 'undefined') {
		PageMetadata.webSegVars['auth'] = '0';
		if (Number(PageMetadata.authVar.authLevel) > 0) {
			PageMetadata.webSegVars['auth'] = '1';
		}
		DFPTargetKeys.webSegVars['auth'] = PageMetadata.webSegVars['auth'];
	}	
	try {
		if (typeof PageMetadata.reqHeaders.ipAddress == 'undefined') {		
			PageMetadata.reqHeaders.ipAddress = '147.236.123.150';	
			DFPTargetKeys.reqHeaders.ipAddress = PageMetadata.reqHeaders.ipAddress;
		}
	}
	catch(e) { console.log(e); }
	
	try {
		if (typeof PageMetadata.reqHeaders.geoc == 'undefined') {		
			PageMetadata.reqHeaders.geoc = 'IL';	
			DFPTargetKeys.reqHeaders.geoc = PageMetadata.reqHeaders.geoc;
		}
	}
	catch(e) { console.log(e); }
	
    if (typeof (PageMetadata.authVar && PageMetadata.authVar.authenticationChannel) != 'undefined') {
		var s_auth_channel_id = PageMetadata.authVar.authenticationChannel;
		if (typeof PageMetadata.authVar.authLevel !== 'undefined') {
			s_auth_channel_id = PageMetadata.authVar.authenticationChannel + '-' + PageMetadata.authVar.authLevel;
		}
    }
    if (typeof (PageMetadata.userSegVars && PageMetadata.userSegVars.gd) != 'undefined' && PageMetadata.userSegVars.gd !== null && PageMetadata.userSegVars.gd !== '' && PageMetadata.userSegVars.gd !== '0') { 
        if (typeof PageMetadata.userSegVars.gd === 'number') {
            PageMetadata.userSegVars.gd = PageMetadata.userSegVars.gd.toString();
        }
        var s_registered_user_id = PageMetadata.userSegVars.gd;
    }
</script>
<script>
    try { if (window.location.pathname == '/partners/acc') { DFPTargetKeys.webSegVars.spon = "soc-acc";	} } catch(e) {}
    try { if (window.location.pathname.indexOf('/resource/') != -1) { DFPTargetKeys.webSegVars.pc = "rc";	} } catch(e) {}
    try { if (window.location.pathname.indexOf('/partners/') != -1) { DFPTargetKeys.webSegVars.pc = "indexpage";	} } catch(e) {}
    try { if (window.location.pathname.indexOf('/partners/hss') != -1) { DFPTargetKeys.webSegVars.spon = "soc-hss";	} } catch(e) {}
    try { if (window.location.pathname.indexOf('/partners/cdc') != -1) { DFPTargetKeys.webSegVars.spon = "soc-cdc";	} } catch(e) {}
    try { if (window.location.pathname.indexOf('/partners/aafp') != -1) { DFPTargetKeys.webSegVars.spon = "soc-aafp";	} } catch(e) {}
	try { if (window.location.pathname.indexOf('/digitalhub') != -1) { DFPTargetKeys.webSegVars.pc = "digitalhub";	} } catch(e) {}
</script>
<script>
    if (document.querySelector('script[src*="otSDKStub.js"]') !== null && document.querySelector('script[src*="otCCPAiab.js"]') == null && document.cookie.indexOf('OptanonAlertBoxClosed') === -1) {
        window.ads2_ignore = {
            all: true
        };
    }
</script>
<script type="text/javascript" src="//img.medscapestatic.com/medscape-core/ads/js/dfp/profads2.js"></script>
<script type="text/javascript">
    // Set Prof Specific level 1 and level 2 and ad targeting keys.
    profads.ads2.init();

</script>

<!-- /Prof Ads Tag -->

<meta name="apple-itunes-app" content="app-id=321367289" />

</head>
<body>

<!-- Include the head file (sets up meta info and includes styles) -->



<!-- 	<div class="header-meta-stuff">
	<div class="resp-container">
		[{domaincategory=emedicine, pagename=emedicine, sspid=null, sspname=null, sspurl=null, locale=en_us, ddname=null, ddshow=0, ddorder=null, headeroverride=null, footeroverride=null}]</div>
</div>
 -->

  <div id="headerbox" class="page-header medscape_emed ">

	<div class="resp-container header-row-top">

		<input type="checkbox" id="mobile-nav-checkbox" class="mobile-nav-toggle"/>

<label for="mobile-nav-checkbox" class="mobile-nav-toggle-label">
	<span></span>
	<span></span>
	<span></span>
</label>


<div class="slide-out-menu">
	<div class="slide-out-menu--tabs">
		<div class="mobile-menu-item">
		<a onclick="wmdTrack('hd-gl_news', this)" href="https://www.medscape.com" class="header-tab--news">
			News &amp; Perspective
		</a>
	</div>

	<div class="mobile-menu-item">
		<a onclick="wmdTrack('hd-gl_ref', this)" href="//reference.medscape.com" >
			Drugs &amp; Diseases
		</a>
	</div>

	<div class="mobile-menu-item">
		<a onclick="wmdPageLink('hd-gl_edu', this)" href="//www.medscape.org" class="header-tab--ed">
			CME &amp; Education
		</a>
	</div>

	<div class="mobile-menu-item">
		<a onclick="wmdTrack('hd-gl_video', this)" href="https://www.medscape.com/video" >
			Video
		</a>
	</div>

	<div class="mobile-menu-item">
		<a onclick="wmdTrack('hd-gl_dcspt', this)" href="//decisionpoint.medscape.com" >
			Decision Point
		</a>
	</div>

	</div>

	<div class="slide-out-menu--group">
		<div class="mobile-menu-item">
	
	<a href="#" class="mobile-edition-toggle js-expand-button" data-section=".mobile-edition-menu" >
		<span class="mobile-menu-item-head">Edition:</span>
				<span class="mobile-menu-item-subhead">English</span>
			<div class="sp-arrow"></div>
	</a>
			
	<div class="mobile-edition-menu">
		
		<div class="mobile-menu-item affiliate-type">
			<p class="logo-mscp">Medscape</p>
		</div>

		<div class="mobile-menu-item">
				<a href="https://www.medscape.com" class="is-current" onclick="wmdTrack('hd-gl_en');">
				   English</a>
			</div>

		<div class="mobile-menu-item">
				<a href="https://deutsch.medscape.com" class="" onclick="wmdTrack('hd-gl_de');">
				   Deutsch</a>
			</div>

		<div class="mobile-menu-item">
				<a href="https://espanol.medscape.com" class="" onclick="wmdTrack('hd-gl_es');">
				   Español</a>
			</div>

		<div class="mobile-menu-item">
				<a href="https://francais.medscape.com" class="" onclick="wmdTrack('hd-gl_fr');">
				   Français</a>
			</div>

		<div class="mobile-menu-item">
				<a href="https://portugues.medscape.com" class="" onclick="wmdTrack('hd-gl_pt');">
				   Português</a>
			</div>

		<div class="mobile-menu-item">
				<a href="https://www.medscape.co.uk" class=" external" onclick="wmdPageLink('hd-gl_uk');">
				   UK<span class="label-new">New</span></a>
			</div>

		<div class="mobile-menu-item affiliate-type">
			<p class="logo-univadis">Univadis</p>
		</div>
		<div class="mobile-menu-item-wrap univadis"></div>

	</div>
	
</div></div>

	<div class="mobile-menu-item login-link"><a href="https://login.medscape.com/login/sso/getlogin?ac=401" onclick="wmdTrack('reg-login_opt', this)">Log In</a></div>
		   <div class="mobile-menu-item register-link"><a href="https://profreg.medscape.com/px/registration.do?lang=en" onclick="wmdTrack('reg-register_opt', this)">Sign Up It's Free!</a></div></div>
<!-- Edition Menu (switches locales) -->
		<div class="header-edition">

	<div class="header-edition-link" title="language edition">
		English Edition</div>

	<div class="header-edition-menu">

		<div class="editions-mscp">
			<p class="logo-mscp">Medscape</p>
			<ul class="editions-list">
				<li class="en is-current"><a href="https://www.medscape.com"  onclick="wmdTrack('hd-gl_en');">English</a></li>
				<li class="de"><a href="https://deutsch.medscape.com"  onclick="wmdTrack('hd-gl_de');">Deutsch</a></li>
				<li class="es"><a href="https://espanol.medscape.com"  onclick="wmdTrack('hd-gl_es');">Español</a></li>
				<li class="fr"><a href="https://francais.medscape.com"  onclick="wmdTrack('hd-gl_fr');">Français</a></li>
				<li class="pt"><a href="https://portugues.medscape.com"  onclick="wmdTrack('hd-gl_pt');">Português</a></li>
				<li class="uk"><a href="https://www.medscape.co.uk" class="external" onclick="wmdPageLink('hd-gl_uk');">UK<span class="label-new">New</span></a></li>
				</ul>
		</div>
		
		<div class="editions-univadis">
			<p class="logo-univadis">Univadis</p>
			<ul class="editions-list"></ul>
		</div>

	</div>

</div>

<div class="leaving-edition">
	<div class="close-btn">X</div>
	<div class="logo-container">
		<span class="logo-univadis">Univadis</span> <span class="logo-from">from</span> <span class="logo-mscp">Medscape</span>   
	</div>
	<div class="desc">
		<div class="description lang"></div>
		<div class="description en"></div>
	</div>
	<div class="btn-container">
		<div class="continue"></div>
		<div class="return"></div>
	</div>
</div>

<div class="greyout-layer"></div><div class="right-group">
			<!-- User Links including Login/Logout, User Settings, etc -->
			<div class="user-links" id="loggedout_user_links">
		<a href="https://profreg.medscape.com/px/registration.do?lang=en&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTU1OTE5LXRyZWF0bWVudA==" onclick="wmdTrack('reg-register_opt', this)">Register</a>
			<a href="https://login.medscape.com/login/sso/getlogin?ac=401&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTU1OTE5LXRyZWF0bWVudA==" onclick="wmdTrack('reg-login_opt', this)">Log In</a></div>
<!-- Search Box -->
			<a class="mobile-search-button" href="javascript:searchView();">
	<span class="open"><svg xmlns="https://www.w3.org/2000/svg" viewBox="0 0 21 21">
  <path fill="#064aa7" fill-rule="evenodd" d="M12.018 12.468c-2.155 2.156-5.63 2.156-7.784 0-2.155-2.154-2.155-5.63 0-7.784 2.154-2.155 5.63-2.155 7.784 0 2.155 2.155 2.133 5.63 0 7.784M2.54 2.99c-3.078 3.08-3.078 8.07 0 11.15 2.727 2.727 6.927 3.035 10.006.946l5.168 5.167c.572.572 1.517.572 2.09 0 .57-.572.57-1.517 0-2.09l-5.17-5.166c2.09-3.08 1.782-7.28-.945-10.006-3.08-3.077-8.07-3.077-11.15 0"/>
</svg></span>
	<span class="close"><svg xmlns="https://www.w3.org/2000/svg" viewBox="0 0 21 21">
  <path fill="#064aa7" fill-rule="evenodd" d="M12.018 12.468c-2.155 2.156-5.63 2.156-7.784 0-2.155-2.154-2.155-5.63 0-7.784 2.154-2.155 5.63-2.155 7.784 0 2.155 2.155 2.133 5.63 0 7.784M2.54 2.99c-3.078 3.08-3.078 8.07 0 11.15 2.727 2.727 6.927 3.035 10.006.946l5.168 5.167c.572.572 1.517.572 2.09 0 .57-.572.57-1.517 0-2.09l-5.17-5.166c2.09-3.08 1.782-7.28-.945-10.006-3.08-3.077-8.07-3.077-11.15 0"/>
</svg></span>
</a>

<div id="searchbox" class="header-search">

	<input type="hidden" name="searchdbvalue" id="searchdbvalue" value="1">

		<form name="SearchFormHeader" class="search-form-header" method="get" aria-label="Search" action="javascript:subsearchheadertrack('en');">

		<input type="hidden" value="news" name="searchSrc">

		<input id="search-input" class="search-input search-input-text" aria-label="Search" type="text" autocomplete="off" autocorrect="off" name="q" maxlength="500" placeholder="Search">

		<button type="submit" class="search-submit-button" aria-label="Search" title="search">
			<svg xmlns="https://www.w3.org/2000/svg" viewBox="0 0 21 21">
  <path fill="#064aa7" fill-rule="evenodd" d="M12.018 12.468c-2.155 2.156-5.63 2.156-7.784 0-2.155-2.154-2.155-5.63 0-7.784 2.154-2.155 5.63-2.155 7.784 0 2.155 2.155 2.133 5.63 0 7.784M2.54 2.99c-3.078 3.08-3.078 8.07 0 11.15 2.727 2.727 6.927 3.035 10.006.946l5.168 5.167c.572.572 1.517.572 2.09 0 .57-.572.57-1.517 0-2.09l-5.17-5.166c2.09-3.08 1.782-7.28-.945-10.006-3.08-3.077-8.07-3.077-11.15 0"/>
</svg></button>

		<button type="button" class="search-open-button js-expand-button" data-section=".header-search" aria-label="Search">
			<svg xmlns="https://www.w3.org/2000/svg" viewBox="0 0 21 21">
  <path fill="#064aa7" fill-rule="evenodd" d="M12.018 12.468c-2.155 2.156-5.63 2.156-7.784 0-2.155-2.154-2.155-5.63 0-7.784 2.154-2.155 5.63-2.155 7.784 0 2.155 2.155 2.133 5.63 0 7.784M2.54 2.99c-3.078 3.08-3.078 8.07 0 11.15 2.727 2.727 6.927 3.035 10.006.946l5.168 5.167c.572.572 1.517.572 2.09 0 .57-.572.57-1.517 0-2.09l-5.17-5.166c2.09-3.08 1.782-7.28-.945-10.006-3.08-3.077-8.07-3.077-11.15 0"/>
</svg></button>

		<div class="ilfulllist">
			<p class="il_combo_nor">No Results</p>
			<ul class="combolist"></ul>
		</div>
		</form>



	<!-- /This is the dynamic Var set in the JSP by the logged-in Java tag -->
	<script type="text/javascript">
			var qrllog = "0";
		</script>
	</div>

<div id="searchlayer">

	<div class="layer-whiteout" id="layer-search-mobile-bg"></div>

	<div class="closeLayer btn-close">
		<a href="javascript:searchView();"></a>
	</div>

	<div class="searchContainer">
		<input type="hidden" name="searchdbvalue" id="layer-searchdbvalue" value="1" />
		<!-- /Needed For Search Database Selection Tool -->
		<!-- This is the dynamic Var set in the JSP by the logged-in Java tag -->

		<form name="SearchFormHeader" class="search-form-header" method="get" aria-label="Search" action="javascript:subsearchheadertrack('en');">

			<input type="hidden" value="news" name="searchSrc">

			<input id="layer-search-input" class="search-input search-input-text" aria-label="Search" type="text" autocomplete="off" autocorrect="off" name="q" maxlength="500" placeholder="Search">

			<button type="submit" class="search-submit-button" aria-label="Search" title="search">
				<svg xmlns="https://www.w3.org/2000/svg" viewBox="0 0 21 21">
  <path fill="#064aa7" fill-rule="evenodd" d="M12.018 12.468c-2.155 2.156-5.63 2.156-7.784 0-2.155-2.154-2.155-5.63 0-7.784 2.154-2.155 5.63-2.155 7.784 0 2.155 2.155 2.133 5.63 0 7.784M2.54 2.99c-3.078 3.08-3.078 8.07 0 11.15 2.727 2.727 6.927 3.035 10.006.946l5.168 5.167c.572.572 1.517.572 2.09 0 .57-.572.57-1.517 0-2.09l-5.17-5.166c2.09-3.08 1.782-7.28-.945-10.006-3.08-3.077-8.07-3.077-11.15 0"/>
</svg></button>


			<div class="ilfulllist">
				<p class="il_combo_nor">No Results</p>
				<ul class="combolist"></ul>
			</div>
			</form>
	</div>
</div>
</div>
		
		<!-- Invites Layer -->
		</div>




	<div class="resp-container header-row-middle">

		<!-- Menu Toggle Button (only shown on smaller screens to open side-menu) -->
		<!-- Side Menu (only on smaller screens, shown by activating menu-toggle) -->
		<!-- Site Logo -->
		<a href="https://reference.medscape.com" class="header-logo">
					<img src="//img.medscapestatic.com/pi/logos/tho-logo.png" title="Medscape Logo">
				</a>
			</div>




	<div class="header-row-bottom">
		<div class="resp-container">

			<!-- Tab Navigation -->
			<div class="header-tabs">

			<a onclick="wmdTrack('hd-gl_news', this)" href="https://www.medscape.com" class="header-tab--news header-tab ">
				News &amp; Perspective
			</a>

			<a onclick="wmdTrack('hd-gl_ref', this)" href="//reference.medscape.com" class="header-tab--ref header-tab is-current">
				Drugs &amp; Diseases
			</a>

			<a onclick="wmdPageLink('hd-gl_edu', this)" href="//www.medscape.org" class="header-tab--ed header-tab ">
				CME &amp; Education
			</a>

			<a onclick="wmdTrack('hd-gl_video', this)" href="https://www.medscape.com/video" class="header-tab--video header-tab ">
				Video
			</a>

			<a onclick="wmdTrack('hd-gl_dcspt', this)" href="//decisionpoint.medscape.com" class="header-tab--dp header-tab ">
				Decision Point
			</a>

		</div>

	</div>
	</div>

</div>

<div id="adtagheader"> 
    <!--  Adtag- dektop -->
    <!-- Adspace 4928966131&amp;pos%3D101&amp;pf%3D0&amp;usp%3D0&amp;occ%3D0&amp;tid%3D0&amp;tcid%3D0&amp;auth%3D0&amp;ct%3D0&amp;inst%3D0&amp;kw%3D0&amp;artid%3Dckb155919&amp;pub%3D0&amp;spon%3D0&amp;st%3D0&amp;env%3D0&amp;ssp%3D2&amp;cg%3D502&amp;pclass%3Dcontent&amp;scg%3D315&amp;bc%3D_3e03317_b972_cust097_diet1_f03_f33_fit1_gen2_i219_i2510_i2699_i509_i519_i802_q249_r529_&amp;valid%3D&amp;ep%3D1&amp;affiliate%3D2&amp;site%3D1&amp;leaf%3D0&amp;tile%3D5791062805&amp;pvid%3D4734581457163780671 -->
<!--
<script type="text/javascript" language="JavaScript1.2" src="https://as.medscape.com/js.ng/transactionid%3D4928966131&amp;pos%3D101&amp;pf%3D0&amp;usp%3D0&amp;occ%3D0&amp;tid%3D0&amp;tcid%3D0&amp;auth%3D0&amp;ct%3D0&amp;inst%3D0&amp;kw%3D0&amp;artid%3Dckb155919&amp;pub%3D0&amp;spon%3D0&amp;st%3D0&amp;env%3D0&amp;ssp%3D2&amp;cg%3D502&amp;pclass%3Dcontent&amp;scg%3D315&amp;bc%3D_3e03317_b972_cust097_diet1_f03_f33_fit1_gen2_i219_i2510_i2699_i509_i519_i802_q249_r529_&amp;valid%3D&amp;ep%3D1&amp;affiliate%3D2&amp;site%3D1&amp;leaf%3D0&amp;tile%3D5791062805&amp;pvid%3D4734581457163780671"></script>-->
<!-- /Adspace -->
<div id="ads-pos-101" class="AdUnit"></div>
    <script>
				webmd.ads2.defineAd({
				id: 'ads-pos-101',
				pos: 101
				});
			</script> 
    <!--  /Adtag --> 
  </div>
<div class="mobile_adlabelleft"><!--  Adtag- mobile -->
      <!-- Adspace 4928966131&amp;pos%3D1004&amp;pf%3D0&amp;usp%3D0&amp;occ%3D0&amp;tid%3D0&amp;tcid%3D0&amp;auth%3D0&amp;ct%3D0&amp;inst%3D0&amp;kw%3D0&amp;artid%3Dckb155919&amp;pub%3D0&amp;spon%3D0&amp;st%3D0&amp;env%3D0&amp;ssp%3D2&amp;cg%3D502&amp;pclass%3Dcontent&amp;scg%3D315&amp;bc%3D_3e03317_b972_cust097_diet1_f03_f33_fit1_gen2_i219_i2510_i2699_i509_i519_i802_q249_r529_&amp;valid%3D&amp;ep%3D1&amp;affiliate%3D2&amp;site%3D1&amp;leaf%3D0&amp;tile%3D5791062805&amp;pvid%3D4734581457163780671 -->
<!--
<script type="text/javascript" language="JavaScript1.2" src="https://as.medscape.com/js.ng/transactionid%3D4928966131&amp;pos%3D1004&amp;pf%3D0&amp;usp%3D0&amp;occ%3D0&amp;tid%3D0&amp;tcid%3D0&amp;auth%3D0&amp;ct%3D0&amp;inst%3D0&amp;kw%3D0&amp;artid%3Dckb155919&amp;pub%3D0&amp;spon%3D0&amp;st%3D0&amp;env%3D0&amp;ssp%3D2&amp;cg%3D502&amp;pclass%3Dcontent&amp;scg%3D315&amp;bc%3D_3e03317_b972_cust097_diet1_f03_f33_fit1_gen2_i219_i2510_i2699_i509_i519_i802_q249_r529_&amp;valid%3D&amp;ep%3D1&amp;affiliate%3D2&amp;site%3D1&amp;leaf%3D0&amp;tile%3D5791062805&amp;pvid%3D4734581457163780671"></script>-->
<!-- /Adspace -->
<div id="ads-pos-1004" class="AdUnit"></div>
      <script>                               
				webmd.ads2.defineAd({              
				id: 'ads-pos-1004',          
				pos: 1004                     
				});                                
			</script> 
    </div>


<div id="bodypadding" class="mscp-origin  logged-out">
<div class="layer-whiteout" id="layer-logout-bg"></div>

<div id="layer-logout-confirmation" class="layer-pop modal">
<a href="javascript:cancelLogoutMessage();" class="btn-close btn-close-grey"><span>close</span></a>
<div class="layer-content">
Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
<a href="https://login.medscape.com/login/sso/logout?RememberMe=No" class="layer-pop-button">Log out</a>
<a href="javascript:cancelLogoutMessage();" class="layer-pop-button alt">Cancel</a>
</div>
</div>

    <!-- /HEADER -->
    <!-- mobile viewport -->
    
    
    
    <link rel="stylesheet" href="//img.medscapestatic.com/medscape-core/reference/css/article/dd-article-header.css" type="text/css" media="screen" />
    
    
	<script>
			var ref_contentId='155919';

	             CURRENT_DRUG_ID="";
		     GENERIC_NAMES="";
		     
			     
		     
		</script>

    <!-- Bodypadding -->

    
    
        
    
    

    <script>
        var emailThis = {
            title: 'Myocardial Infarction Treatment & Management: Approach Considerations, Prehospital Care and Initial Management, Emergency Department Care and In-Hospital Management',
            publicationName: 'Cardiology',
            publicationDate: 'May 07, 2019'
        }
    </script>

    <div id="emailadexcontainer">

        <div id="adexwait" style="display:none;"><p>processing....<p></div>
        <div id="emailadexbox">	</div>

    </div>
    <!-- Header Code Here -->
    <!--   tiles:insert name="header" / -->

    <!-- /HEADER TAG ENDS HERE -->

    
 <div xmlns:xsl="https://www.w3.org/1999/XSL/Transform" id="ref-diseases" class="mscp-origin resp-container">
 <!--Article XSLTs Version=Viewreference D and D: PPE-143040 - Drug Disclaimer, PPE-138480 - MedSims for imglink , BNR, CTP=2025-03-28-21:48, HASH=48a1a04eb875db24c9257faa38c625d03409123e-->
 <div id="leftcol" class="column column-left">
  <div xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" id="drugdb">
   <div id="maincolboxdrugdbheader" class="drug_h1">
    <div class="breadcrumb">
     <a href="https://reference.medscape.com">Drugs &amp; Diseases</a><span class="crumb-divider">&gt;</span><a href="https://reference.medscape.com/guide/cardiology">Cardiology</a>
    </div><!--BNReddy: section_title_templ-->
    <h1>Myocardial Infarction Treatment &amp; Management</h1>
    <div class="condition-title-info">
     <div class="clinref_updated">
      Updated: May 07, 2019
     </div>
     <ul>
      <li><!--author heading --> Author: A Maziar Zafari, MD, PhD, FACC, FAHA; Chief Editor: Eric H Yang, MD&nbsp; <a href="javascript:showModal('author-disclosures');" onclick="wmdPageLink('cr-tl_author');">more...</a></li>
     </ul>
    </div>
    <div class="action-items">
     <ul>
      <li class="like"><span class="like-count"></span></li>
      <li class="share"><span>Share</span></li>
      <li class="print"><span>Print</span></li>
      <li class="feedback"><span>Feedback</span></li>
     </ul>
     <div class="share-layer inactive">
      <div class="close-layer">
       <span>Close</span>
      </div>
      <ul>
       <li class="facebook"><a href="#"><span>Facebook</span></a></li>
       <li class="twitter"><a href="#"><span>Twitter</span></a></li>
       <li class="linkedin"><a href="#"><span>LinkedIn</span></a></li>
       <li class="whatsapp"><a href="#"><span>WhatsApp</span></a></li>
       <li class="email"><a href="#"><span>Email</span></a></li>
      </ul>
     </div>
    </div>
   </div>
  </div>
  <div xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" id="ads-pos-421-sfp" class="AdUnit-sfp"></div>
  <script xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions">
			webmd.ads2.defineAd({
			id: 'ads-pos-421-sfp',
			pos: 421
			});
		</script>
  <div class="paywall">
   <div class="article-content">
    <div id="drugdbmain">
     <!--Multilevel menu for topnav, Inside article-content under articledbmain-->
     <div xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" id="hideRefMenu"></div>
     <div xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" id="dd_nav">
      <div id="dd_nav_wrap">
       <div id="section_tab">
        <span>Sections</span>
       </div>
       <div id="menuWrapper">
        <div id="leftnav">
         <div class="current_topic">
          <a href="https://emedicine.medscape.com/article/155919-overview" onclick="wmdTrack('cr_ln_article')">Myocardial Infarction</a>
         </div>
         <ul>
          <!--ul_nav_for_article pagemode=multipage-->
          <li class="sections-nav-title">
           <div class="nav-title">
            Sections <span class="nav-title-name">Myocardial Infarction</span>
           </div></li>
          <li><a href="javascript:void(0)">Overview</a><!--sub_menu_second_level skip=false-->
           <ul>
            <!--display_second_level_menu sect1-link='overview', sect1-position=1--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=false-->
            <li class="li_1-1 "><a href="155919-overview#a1" onclick="wmdTrack('cr-ln1_1');">Practice Essentials</a></li>
            <li class="li_1-2 "><a href="155919-overview#a2" onclick="wmdTrack('cr-ln1_2');">Background</a></li>
            <li class="li_1-3 "><a href="155919-overview#a9" onclick="wmdTrack('cr-ln1_3');">Definitions</a></li>
            <li class="li_1-4 "><a href="155919-overview#a4" onclick="wmdTrack('cr-ln1_4');">Pathophysiology</a></li>
            <li class="li_1-5 "><a href="155919-overview#a5" onclick="wmdTrack('cr-ln1_5');">Etiology</a></li>
            <li class="li_1-6 "><a href="155919-overview#a6" onclick="wmdTrack('cr-ln1_6');">Epidemiology</a></li>
            <li class="li_1-7 "><a href="155919-overview#a7" onclick="wmdTrack('cr-ln1_7');">Prognosis</a></li>
            <li class="li_1-8 "><a href="155919-overview#a8" onclick="wmdTrack('cr-ln1_8');">Patient Education</a></li>
            <li class="li_showall"><a href="155919-overview#showall" onclick="wmdTrack('cr-ln1_showall');">Show All</a></li>
           </ul></li>
          <li><a href="javascript:void(0)">Presentation</a><!--sub_menu_second_level skip=false-->
           <ul>
            <!--display_second_level_menu sect1-link='clinical', sect1-position=2--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=false-->
            <li class="li_2-1 "><a href="155919-clinical#b1" onclick="wmdTrack('cr-ln2_1');">History</a></li>
            <li class="li_2-2 "><a href="155919-clinical#b3" onclick="wmdTrack('cr-ln2_2');">Physical Examination</a></li>
            <li class="li_showall"><a href="155919-clinical#showall" onclick="wmdTrack('cr-ln2_showall');">Show All</a></li>
           </ul></li>
          <li class="no_subsection"><!--current section name=differential--><a href="155919-differential" onclick="wmdTrack('cr-ln3_0')" style="">DDx</a></li>
          <li><a href="javascript:void(0)">Workup</a><!--sub_menu_second_level skip=false-->
           <ul>
            <!--display_second_level_menu sect1-link='workup', sect1-position=4--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=false-->
            <li class="li_4-1 "><a href="155919-workup#c1" onclick="wmdTrack('cr-ln4_1');">Approach Considerations</a></li>
            <li class="li_4-2 "><a href="155919-workup#c13" onclick="wmdTrack('cr-ln4_2');">Electrocardiography</a></li>
            <li class="li_4-3 "><a href="155919-workup#c8" onclick="wmdTrack('cr-ln4_3');">Cardiac Biomarkers</a></li>
            <li class="li_4-4 "><a href="155919-workup#c9" onclick="wmdTrack('cr-ln4_4');">Cardiac Troponin</a></li>
            <li class="li_4-5 "><a href="155919-workup#c17" onclick="wmdTrack('cr-ln4_5');">B-Type Natriuretic Peptide</a></li>
            <li class="li_4-6 "><a href="155919-workup#c16" onclick="wmdTrack('cr-ln4_6');">Other Laboratory Studies</a></li>
            <li class="li_4-7 "><a href="155919-workup#c14" onclick="wmdTrack('cr-ln4_7');">Cardiac Imaging</a></li>
            <li class="li_showall"><a href="155919-workup#showall" onclick="wmdTrack('cr-ln4_showall');">Show All</a></li>
           </ul></li>
          <li><a href="javascript:void(0)">Treatment</a><!--sub_menu_second_level skip=false-->
           <ul>
            <!--display_second_level_menu sect1-link='treatment', sect1-position=5--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=true-->
            <li class="li_5-1 "><a href="#d1" data-wmdtrack="cr-ln5_1" data-wmdpageview="{hash:'#d1',page:'1'}">Approach Considerations</a></li>
            <li class="li_5-2 "><a href="#d5" data-wmdtrack="cr-ln5_2" data-wmdpageview="{hash:'#d5',page:'2'}">Prehospital Care and Initial Management</a></li>
            <li class="li_5-3 "><a href="#d6" data-wmdtrack="cr-ln5_3" data-wmdpageview="{hash:'#d6',page:'3'}">Emergency Department Care and In-Hospital Management</a></li>
            <li class="li_5-4 "><a href="#d25" data-wmdtrack="cr-ln5_4" data-wmdpageview="{hash:'#d25',page:'4'}">ST-Elevation Myocardial Infarction</a></li>
            <li class="li_5-5 "><a href="#d26" data-wmdtrack="cr-ln5_5" data-wmdpageview="{hash:'#d26',page:'5'}">Non-ST-Elevation (NSTE) ACS</a></li>
            <li class="li_5-6 "><a href="#d7" data-wmdtrack="cr-ln5_6" data-wmdpageview="{hash:'#d7',page:'6'}">Additional Aspects of Management and Late Hospital Care</a></li>
            <li class="li_5-7 "><a href="#d19" data-wmdtrack="cr-ln5_7" data-wmdpageview="{hash:'#d19',page:'7'}">Complications</a></li>
            <li class="li_5-8 "><a href="#d15" data-wmdtrack="cr-ln5_8" data-wmdpageview="{hash:'#d15',page:'8'}">Future and Emerging Therapies</a></li>
            <li class="li_showall"><a href="#showall" data-wmdtrack="cr-ln_all" data-wmdpageview="{hash:'showall', page:'5'}">Show All</a></li>
           </ul></li>
          <li><a href="javascript:void(0)">Guidelines</a><!--sub_menu_second_level skip=false-->
           <ul>
            <!--display_second_level_menu sect1-link='guidelines', sect1-position=6--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=false-->
            <li class="li_6-1 "><a href="155919-guidelines#g1" onclick="wmdTrack('cr-ln6_1');">Guidelines Summary</a></li>
            <li class="li_6-2 "><a href="155919-guidelines#g2" onclick="wmdTrack('cr-ln6_2');">Percutaneous Coronary Intervention</a></li>
            <li class="li_6-3 "><a href="155919-guidelines#g3" onclick="wmdTrack('cr-ln6_3');">Coronary Artery Bypass Grafting</a></li>
            <li class="li_6-4 "><a href="155919-guidelines#g4" onclick="wmdTrack('cr-ln6_4');">Mechanical Circulatory Support</a></li>
            <li class="li_6-5 "><a href="155919-guidelines#g5" onclick="wmdTrack('cr-ln6_5');">Dual Antiplatelet Therapy</a></li>
            <li class="li_showall"><a href="155919-guidelines#showall" onclick="wmdTrack('cr-ln6_showall');">Show All</a></li>
           </ul></li>
          <li><a href="javascript:void(0)">Medication</a><!--sub_menu_second_level skip=false-->
           <ul>
            <!--display_second_level_menu sect1-link='medication', sect1-position=7--><!--display_second_level_menu isMedication=true, isMultiPage=true, current=false-->
            <li class="li_7-1 "><a href="155919-medication#1" onclick="wmdTrack('cr-ln7_1');">Medication Summary</a></li>
            <li class="li_7-2 "><a href="155919-medication#2" onclick="wmdTrack('cr-ln7_2');">Antiplatelet Agents</a></li>
            <li class="li_7-3 "><a href="155919-medication#3" onclick="wmdTrack('cr-ln7_3');">Antithrombotic Agents</a></li>
            <li class="li_7-4 "><a href="155919-medication#4" onclick="wmdTrack('cr-ln7_4');">Glycoprotein IIb/IIIa Inhibitors</a></li>
            <li class="li_7-5 "><a href="155919-medication#5" onclick="wmdTrack('cr-ln7_5');">Vasodilators</a></li>
            <li class="li_7-6 "><a href="155919-medication#6" onclick="wmdTrack('cr-ln7_6');">Beta-adrenergic blockers</a></li>
            <li class="li_7-7 "><a href="155919-medication#7" onclick="wmdTrack('cr-ln7_7');">Angiotensin-Converting Enzyme Inhibitors</a></li>
            <li class="li_7-8 "><a href="155919-medication#8" onclick="wmdTrack('cr-ln7_8');">Angiotensin-Receptor Blockers</a></li>
            <li class="li_7-9 "><a href="155919-medication#9" onclick="wmdTrack('cr-ln7_9');">Thrombolytics</a></li>
            <li class="li_7-10 "><a href="155919-medication#10" onclick="wmdTrack('cr-ln7_10');">Analgesics</a></li>
            <li class="li_7-11 "><a href="155919-medication#11" onclick="wmdTrack('cr-ln7_11');">PCSK9 Inhibitors</a></li>
            <li class="li_showall"><a href="155919-medication#showall" onclick="wmdTrack('cr-ln7_showall');">Show All</a></li>
           </ul></li>
          <li class="multimedia_link no_subsection"><a href="javascript:refImgShow('001');">Media Gallery</a></li>
          <li class="tables_link no_subsection"><a href="javascript:showModal('clinref-table-layer')">Tables</a></li>
          <li class="reference_link no_subsection"><a href="javascript:showModal('references-layer');">References</a></li>
         </ul>
        </div>
       </div>
      </div>
     </div><!--Overview--><!--sectiontitle : Treatment & Management,
			sectiontitlenew : Treatment-->
     <div class="h1title">
      Treatment
     </div><!--sect1-id : treatment--><!--overview_maincontent-->
     <div xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" class="drugdbsectioncontent">
      <!--sect1 @id not labs multipage--><!--sect2-->
      <div id="content_d1">
       <noscript>
        <a name="d1"></a>
       </noscript>
       <h2>Approach Considerations</h2>
       <div class="refsection_content">
        <!--sect2: d1-->
        <p>The first goal for healthcare professionals in management of acute myocardial infarction (MI) is to diagnose the condition in a very rapid manner.</p>
        <p>As a general rule, initial therapy for acute MI is directed toward restoration of perfusion as soon as possible to salvage as much of the jeopardized myocardium as possible. This may be accomplished through medical or mechanical means, such as percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) surgery.</p>
        <div id="ads-pos-1122" class="AdUnit"></div>
        <script>webmd.ads2.defineAd({id:'ads-pos-1122',pos: 1122});</script>
        <p>Although the initial treatment of the different types of acute coronary syndrome (ACS) may appear to be similar, it is very important to distinguish whether the patient is having an ST-elevation MI (STEMI) or a non–STEMI (NSTEMI), because definitive therapies differ between these two types of MI. Particular considerations and differences involve the urgency of therapy and the degree of evidence regarding different pharmacologic options.</p>
        <p>Over the last decade, inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising target to reduce residual cardiovascular disease risk. PCSK9 is a protein that binds to low-density lipoprotein (LDL) receptors (LDLR) to promote their degradation. Monoclonal antibodies inhibit PCSK9 and thus prevent LDLR degradation. This action will increase the number of LDLRs and subsequently increase the clearance of LDL, ultimately lowering LDL-C levels.&nbsp;</p>
        <div class="txtAd520SpcHolder" id="plcHold-520">
         <div id="ads-pos-520" class="AdUnit"></div>
        </div>
        <script>webmd.ads2.defineAd({id:'ads-pos-520',pos: 520});</script>
        <p>In December 2017, the FDA approved the first PCSK9 inhibitor, evolocumab (Repatha), for the prevention of strokes, heart attacks, and coronary revascularizations.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','64')" href="javascript:void(0);">64</a>] </sup>The approval was based on data from the evolocumab cardiovascular outcomes study (FOURIER). In the FOURIER clinical trial, evolocumab demonstrated significant benefits for 27,564 patients with established cardiovascular disease. The study revealed that when used in addition to optimized statin therapy, evolocumab reduced the risk of heart attack by 27%, the risk of stroke by 21%, and the risk of coronary revascularization by 22%. In addition, evolocumab showed a statistically significant 15% reduction in the risk of the primary composite endpoint, which included hospitalization for unstable angina, coronary revascularization, heart attack, stroke, or cardiovascular death.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','65')" href="javascript:void(0);">65</a>] </sup></p>
        <div class="txtAd1520SpcHolder" id="plcHold-1520">
         <div id="ads-pos-1520" class="AdUnit"></div>
        </div>
        <script>webmd.ads2.defineAd({id:'ads-pos-1520',pos: 1520});</script>
        <p>Morbidity and mortality from MI are significantly reduced if patients and bystanders recognize symptoms early, activate the emergency medical service (EMS) system, and thereby shorten the time to definitive treatment. Trained prehospital personnel can provide life-saving interventions if the patient develops cardiac arrest. The key to improved survival is the availability of early defibrillation. Approximately 1 in every 300 patients with chest pain transported to the emergency department by private vehicle goes into cardiac arrest en route.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','66')" href="javascript:void(0);">66</a>] </sup>&nbsp;In the United States, several studies have confirmed that patients with STEMI usually do not call 911, and only about 40% of patients with a confirmed coronary event used EMS.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','67')" href="javascript:void(0);">67</a>] </sup></p>
        <div class="inContentAd"></div>
        <h3>2017 American Heart Association/American College of Cardiology (AHA/ACC) clinical performance and quality measures for adults with STEMI and NSTEMI</h3>
        <p><em>Revised STEMI and NSTEMI measures</em><sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','68')" href="javascript:void(0);">68</a>, <a onclick="showToolTip(this,'references-layer','69')" href="javascript:void(0);">69</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Statin use for patients with AMI (acute myocardial infarction)</p>
        <div class="inContentAd"></div>
        <p>Evaluation of LVEF (left ventricular ejection fraction)</p>
        <div class="inContentAd"></div>
        <p>P2Y<sub>12&nbsp;</sub>receptor (clopidogrel, ticagrelor, prasugret) inhibitor prescribed at discharge. All 3 medications are inhibitors of the P2Y<sub>12</sub>&nbsp;receptor and are recommended in addition to aspirin (as part of a dual antiplatelet regimen) to reduce recurrent ischemic events after AMI.</p>
        <div class="inContentAd"></div>
        <p><em>New STEMI/NSTEMI measures</em><sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','68')" href="javascript:void(0);">68</a>, <a onclick="showToolTip(this,'references-layer','69')" href="javascript:void(0);">69</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Immediate angiography for resuscitated out-of-hospital cardiac arrest in STEMI patients.</p>
        <div class="inContentAd"></div>
        <p>Noninvasive stress testing before discharge in conservatively treated patients to detect inducible ischemia in medically treated STEMI and NSTEMI patients.</p>
        <div class="inContentAd"></div>
        <p>Early cardiac troponin measurement (within 6 hours of arrival).</p>
        <div class="inContentAd"></div>
        <p>Participation in regional or national acute myocardial infarction registry to help track and assess the outcomes, complications, and quality of care for patients with AMI.</p>
        <div class="inContentAd"></div>
        <p>Risk score stratification for NSTEMI patients to dictate the appropriate strategy (invasive versus ischemic-guided) and the timing of the strategy (early versus late invasive) in patients with NSTEMI.</p>
        <div class="inContentAd"></div>
        <p>Early invasive strategy (within 24 hours) in high-risk NSTEMI patients.</p>
        <div class="inContentAd"></div>
        <p>Therapeutic hypothermia for comatose STEMI patients with out-of-hospital cardiac arrest.</p>
        <div class="inContentAd"></div>
        <p>Aldosterone antagonist at discharge.</p>
        <div class="inContentAd"></div>
        <p>Inappropriate in-hospital use of nonsteroidal antiinflammatory drugs (NSAIDs) (caution against the use of these drugs after AMI).</p>
        <div class="inContentAd"></div>
        <p>Inappropriate prescription of prasugrel at discharge in patients with a history of prior stroke or transient ischemic attack (TIA) (caution against the use of prasugrel in patients with prior TIA/stroke, because of net clinical harm in these patients. The FDA also issued a black box warning on this.)</p>
        <div class="inContentAd"></div>
        <p>Inappropriate prescription of high-dose aspirin with ticagrelor at discharge (caution against the use of high-dose aspirin &gt;100 mg among patients receiving ticagrelor. The FDA also issued a black box warning on this.)</p>
        <div class="inContentAd"></div>
       </div>
       <div class="emed-logo">
        <img src="//img.medscapestatic.com/pi/global/logos/emed/logo-emedicine77x17.svg" alt="eMedicine Logo">
       </div><!--output_version : web--><!--page_nav-->
       <div class="back_next_btn">
        <div class="next_btn">
         Next: 
        </div>
        <div class="spacer"></div>
       </div>
       <div class="spacer"></div>
      </div><!--sect2-->
      <div id="content_d5">
       <noscript>
        <a name="d5"></a>
       </noscript>
       <h2>Prehospital Care and Initial Management</h2>
       <div class="refsection_content">
        <!--sect2: d5-->
        <p>All patients being transported for chest pain should be managed as if the pain is ischemic in origin, unless clear evidence to the contrary is established. If available, an advanced cardiac life support (ACLS)–trained unit should transport patients with hemodynamic instability or respiratory difficulty.</p>
        <div class="inContentAd"></div>
        <p>Prehospital notification by emergency medical services (EMS) personnel should alert emergency department staff to the possibility of a patient with myocardial infarction (MI). EMS personnel should receive online medical advice for a patient with high-risk features; this allows for early and prompt delivery of medical treatment and, most importantly, facilitates the transportation of patients to facilities with the appropriate level of care.</p>
        <div class="inContentAd"></div>
        <p>Specific prehospital care includes the following:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           <p>Intravenous access, supplemental oxygen if the oxygen saturation (SaO<sub>2</sub>) is less than 90%, pulse oximetry</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Immediate administration of nonenteric-coated chewable aspirin en route</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Nitroglycerin for active chest pain, given sublingually or by spray</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Telemetry and prehospital electrocardiography (ECG), if available</p>
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <p>Most deaths caused by MI occur early and are attributable to primary ventricular fibrillation (VF). Therefore, initial objectives are immediate ECG monitoring; electric cardioversion in cases of VF; and rapid transfer of the patient to facilitate prompt coronary assessment.</p>
        <div class="inContentAd"></div>
        <p>Prehospital integration of ECG interpretation has been shown to decrease "door-to-balloon time,” allow paramedics to bypass non–percutaneous coronary intervation (PCI)–capable hospitals in favor of PCI-capable facilities, and to expedite care by allowing an emergency department physician to activate the catheterization laboratory before the patient's arrival.</p>
        <div class="inContentAd"></div>
        <p>Additional objectives of prehospital care by paramedical and emergency personnel include adequate analgesia (generally achieved with morphine); pharmacologic reduction of excessive sympathoadrenal and vagal stimulation; treatment of hemodynamically significant or symptomatic ventricular arrhythmias (generally with amiodarone and lidocaine); and support of cardiac output, systemic blood pressure, and respiration.</p>
        <div class="inContentAd"></div>
        <p>Prehospital fibrinolytic therapy by the administration of tissue-type plasminogen activator (t-PA), aspirin, and heparin may be given to patients with bona fide MI by paramedics, as guided by electrocardiographic findings, within 90 minutes of the onset of symptoms. This treatment improves outcomes, as compared with thrombolysis begun after the patient arrives at the hospital.&nbsp;Prehospital fibrinolytic therapy is not used widely in the United States due to the lack of resources to train EMS personnel or the lack of funding for necessary equipment. However, it is more widespread in some regions in Europe and the United Kingdom.</p>
        <div class="inContentAd"></div>
       </div>
       <div class="emed-logo">
        <img src="//img.medscapestatic.com/pi/global/logos/emed/logo-emedicine77x17.svg" alt="eMedicine Logo">
       </div><!--output_version : web--><!--page_nav-->
       <div class="back_next_btn">
        <div class="back_btn">
         Previous
        </div>
        <div class="next_btn">
         Next: 
        </div>
        <div class="spacer"></div>
       </div>
       <div class="spacer"></div>
      </div><!--sect2-->
      <div id="content_d6">
       <noscript>
        <a name="d6"></a>
       </noscript>
       <h2>Emergency Department Care and In-Hospital Management</h2>
       <div class="refsection_content">
        <!--sect2: d6-->
        <h3>Triage and evaluation</h3>
        <p>Because acute coronary syndrome (ACS) is a spectrum of conditions, initial evaluation to establish a working diagnosis is crucial, as this will dictate management owing to some differences in management steps and timelines for each component of the ACS spectrum.</p>
        <div class="inContentAd"></div>
        <p>All patients presenting to the the emergency department with symptoms suggestive of acute myocardial infarction (MI) should be evaluated with a targeted history and focused physical examination (see <a href="https://emedicine.medscape.com/article/155919-clinical#">Presentation</a>). A 12-lead electrocardiogram (ECG) interpreted by an experienced physician should be completed within 10 minutes of arrival, in addition to establishing intravenous (IV) access.</p>
        <div class="inContentAd"></div>
        <h3>Initial management</h3>
        <p>The initial management of the overall management plan for patients with acute MI has the following aims:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           Restoration of the balance between oxygen supply and demand to prevent further ischemia
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           Pain relief
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           Prevention and treatment of complications
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <p><em>Oxygen</em></p>
        <div class="inContentAd"></div>
        <p>Continuous oxygen saturation monitoring by pulse oximetry is needed for all patients.</p>
        <div class="inContentAd"></div>
        <p>Supplemental oxygen by a mask or nasal cannula is indicated only for patients who are breathless, hypoxic (oxygen saturation &lt; 90% or PaO<sub>2</sub>&lt; 60 mm Hg<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','70')" href="javascript:void(0);">70</a>] </sup>), or who present with heart failure. The use of oxygen in patients with acute MI who don’t fall into one of the three above-mentioned categories remains uncertain, with some studies suggesting possible harm in such patients.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','71')" href="javascript:void(0);">71</a>] </sup></p>
        <div class="inContentAd"></div>
        <p><em>Aspirin</em></p>
        <div class="inContentAd"></div>
        <p>All patients presenting with ACS should receive nonenteric-coated chewable aspirin in a dose of at least 162 to 325 mg, unless there is a clear history of aspirin allergy. Patients with aspirin intolerance still should receive aspirin at presentation.</p>
        <div class="inContentAd"></div>
        <p>Chewable aspirin is preferred, as this promotes rapid absorption into the bloodstream to achieve faster therapeutic levels.</p>
        <div class="inContentAd"></div>
        <p><em>Reduction of cardiac pain</em></p>
        <div class="inContentAd"></div>
        <p>Nitrates</p>
        <div class="inContentAd"></div>
        <p>Nitrates are potent vasodilators, and they act mainly to relax the venous system. Systemic venodilation results in reduction of venous blood return to the heart (ie, reducing the ventricular preload); this will lead to reduction of the workload of the heart, less oxygen demand, and reduction in ischemic pain. Nitrates are also the most commonly used agents to reduce cardiac chest pain related to ischemia via coronary vasodilation; however, their use is not associated with reduction in ACS-associated mortality.</p>
        <div class="inContentAd"></div>
        <p>Nitrates are usually given as a 0.4 mg dose in a sublingual tablet, followed by close observation of the effect on chest pain and the hemodynamic response. If the initial dose is well tolerated, further nitrates can be administered.&nbsp;The most common side effect of nitrates are hypotension and headache.</p>
        <div class="inContentAd"></div>
        <p>When chest pain persists or recurs, IV nitrates are indicated, usually started at a dose of 5 to 10 µg/min and gradually increased until relief of chest pain is achieved.</p>
        <div class="inContentAd"></div>
        <p>Nitrates should not be used in patients presenting with marked hypotension or bradycardia, or if there is suspicion of right ventricular infarction.</p>
        <div class="inContentAd"></div>
        <p>Special attention should be made in taking the history of whether concomitant use of phosphodiesterase (PDE) inhibitors (eg, sildenafil) has occurred within the last 24 to 72 hours, because this drug combination may lead to life-threatening hypotension.</p>
        <div class="inContentAd"></div>
        <p>Analgesia</p>
        <div class="inContentAd"></div>
        <p>Refractory or severe pain should be treated symptomatically with IV morphine.</p>
        <div class="inContentAd"></div>
        <p>The initial dose of morphine of 2 to 4 mg as an IV bolus can be given, with increments of 2 to 4 mg repeated every 5 to 10 minutes until the pain is relieved or intolerance is manifested by hypotension, vomiting, or depressed respiration. Should toxicity occur, a morphine antagonist such as naloxone is used for reversal. The patient's blood pressure and pulse must be monitored; the systolic blood pressure must be maintained above 100 mm Hg and, optimally, below 140 mm Hg.</p>
        <div class="inContentAd"></div>
        <p>The use of other analgesic agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided if at all possible, as the use of these agents has been associated with adverse cardiovascular events.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','72')" href="javascript:void(0);">72</a>] </sup></p>
        <div class="inContentAd"></div>
       </div>
       <div class="emed-logo">
        <img src="//img.medscapestatic.com/pi/global/logos/emed/logo-emedicine77x17.svg" alt="eMedicine Logo">
       </div><!--output_version : web--><!--page_nav-->
       <div class="back_next_btn">
        <div class="back_btn">
         Previous
        </div>
        <div class="next_btn">
         Next: 
        </div>
        <div class="spacer"></div>
       </div>
       <div class="spacer"></div>
      </div><!--sect2-->
      <div id="content_d25">
       <noscript>
        <a name="d25"></a>
       </noscript>
       <h2>ST-Elevation Myocardial Infarction</h2>
       <div class="refsection_content">
        <!--sect2: d25-->
        <p>Management of ST-elevation myocardial infarction (MI) (STEMI) relies on two essential and key components: rapid recognition and timely reperfusion. Therefore, systems must be placed and implemented to prevent delay in management of patients who develop STEMI. Minimizing delays has been associated with improved overall outcomes as well as reduced mortality and long-term morbidity.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','73')" href="javascript:void(0);">73</a>, <a onclick="showToolTip(this,'references-layer','74')" href="javascript:void(0);">74</a>] </sup>&nbsp;Current clinical practice guidelines have emphasized adopting institutional quality improvement measures to reduce total ischemic time, which is the principal determinant of outcome,<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','75')" href="javascript:void(0);">75</a>, <a onclick="showToolTip(this,'references-layer','76')" href="javascript:void(0);">76</a>] </sup>&nbsp;greatest emphasis is to be placed on the appropriate and timely use of some form of reperfusion therapy which is likely more important than the choice of therapy.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Some factors that may lead to shortening total ischemic time include the following:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           Prehospital electrocardiography (ECG) to diagnose STEMI to activate the percutaneous coronary intervention (PCI) team while the patient is en route to the hospital
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           Emergency department physicians activate the PCI team
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           A single call to a central page operator who activates the PCI team
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           The goal is set for the PCI team to arrive in the catheterization laboratory within 20 minutes after being paged
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           Timely data feedback and analysis are provided to members of the STEMI care team
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <h3>Reperfusion</h3>
        <p>Early mechanical intervention (primary PCI) or pharmacologic reperfusion should be performed as soon as possible for patients with clinical presentation of STEMI within 12 hours of symptom onset and who have persistent ST-segment elevation or new or presumed new left bundle branch block (LBBB). In addition, it is reasonable to consider an early reperfusion strategy for patients presenting after more than 12 hours, provided there is clinical and/or ECG evidence of ongoing ischemia, with primary PCI being the preferred method in this population.</p>
        <div class="inContentAd"></div>
        <p>In the United States, only a minority of hospitals have the capability of performing primary PCI; therefore, a multifaceted community-wide approach that involves patient education, improvements in emergency medical services (EMS) and emergency department care, establishment of networks of STEMI-referral (non–PCI-capable) and STEMI-receiving (PCI-capable) hospitals, has been implemented to overcome this limitation.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','77')" href="javascript:void(0);">77</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>For patients presenting to a PCI-capable hospital, emergent coronary angiography and primary PCI should be accomplished within 90 minutes. For patients presenting to a non–PCI-capable hospital, if they cannot be transferred to a PCI-capable hospital within 120 minutes, it is very important to rapidly assess the following to reach a decision about administration of fibrinolytic therapy:</p><!--orderedlist-->
        <ol class="bodylist">
         <!--listitem-->
         <li class="topitem">The time from onset of symptoms</li><!--listitem-->
         <li class="topitem">The risk of complications related to STEMI</li><!--listitem-->
         <li class="topitem">The risk of bleeding with fibrinolysis therapy</li><!--listitem-->
         <li class="topitem">The presence of shock or severe heart failure</li><!--listitem-->
         <li class="topitem">The time required for transfer to a PCI-capable hospital</li>
        </ol>
        <div class="inContentAd"></div>
        <p>Even when interhospital transfer times are short, there may be relative advantages to a strategy of immediate fibrinolytic therapy versus any delay to primary PCI for eligible patients who present within the first 1 to 2 hours after symptom onset.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>] </sup></p>
        <div class="inContentAd"></div>
        <p><em>Primary percutaneous intervention</em></p>
        <div class="inContentAd"></div>
        <p>PCI is defined as an emergent percutaneous coronary intervention in the setting of STEMI, without previous fibrinolytic treatment. It is the preferred reperfusion strategy in patients with STEMI, provided it can be performed expeditiously within clinical practice guidelines–mandated times and in high-volume centers with experienced interventional cardiology teams and skilled support staff.</p>
        <div class="inContentAd"></div>
        <p>PCI achieves superior reperfusion outcomes and is associated with less complications, death, and long-term complications of STEMI when compared to fibrinolytic therapy.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>, <a onclick="showToolTip(this,'references-layer','4')" href="javascript:void(0);">4</a>, <a onclick="showToolTip(this,'references-layer','77')" href="javascript:void(0);">77</a>, <a onclick="showToolTip(this,'references-layer','78')" href="javascript:void(0);">78</a>, <a onclick="showToolTip(this,'references-layer','79')" href="javascript:void(0);">79</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Current guidelines strongly recommend performing primary PCI in patients presenting with symptoms of less than 12 hours' duration, or those who present with cardiogenic shock or who develop acute severe heart failure, irrespective of time of delay from onset of symptoms. Guidelines also recommend considering primary PCI for patients who present between 12 and 24 hours after onset of symptoms, provided there is ongoing clinical or ECG evidence of myocardial ischemia.</p>
        <div class="inContentAd"></div>
        <p>PCI of the noninfarct related artery (nonculprit artery) at the time of primary PCI of the culprit lesion is under active investigation. In a meta-analysis of 9 trials comprising 2991 patients with STEMI that compared complete multivessel PCI (revacularization of infarct-related and noninfarct-related arteries) to culprit-infarct-artery-only PCI, Vaidya et al noted their findings suggested complete revascularization is safe in patients with STEMI and multivessel disease.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','80')" href="javascript:void(0);">80</a>] </sup>Although complete vascularization appeared to be associated with lowered rates of major adverse cardiac events, cardiac death, and repeat revascularization in this population, no reduction in all-cause mortality and nonfatal MI was observed.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','80')" href="javascript:void(0);">80</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>This method of reperfusion entails performing emergent coronary angiography, after establishing arterial access, which can be achieved via the radial or femoral artery. After identifying the anatomy of the coronary circulation and determining the culprit vessel, coronary stents are placed to establish reperfusion.</p>
        <div class="inContentAd"></div>
        <p>In patients with STEMI, the evaluation of 70% ST-segment resolution following primary PCI appears to be a 5-year independent predictor of patient-oriented composite endpoint, particularly all-cause death and any revascularization.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','81')" href="javascript:void(0);">81</a>] </sup>The investigators suggested it may be used to identify those at high risk of very long-term cardiovascular events.</p>
        <div class="inContentAd"></div>
        <p>Drug-eluting stents (DES) or bare-metal stents (BMS) are used. However, if there are financial or social barriers that may limit patient compliance, an increased risk of bleeding, or an anticipated invasive or surgical procedure, the use of DES is not recommended.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Placement of coronary stents requires dual antiplatelet therapy for an extended time period (see the subsection "Antiplatelet agents," below). The duration of therapy is dependent of the type of stent used.</p>
        <div class="inContentAd"></div>
        <p>Cardiac rupture is a major lethal complication of primary PCI for treatment of patients with STEMI. In a study comprising 1663 STEMI patients who underwent PCI of whom 33 (1.98%) developed cardiac rupture, investigators noted that the SYNTAX &nbsp;(Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery) Score II (SSII), which is used to assess anatomic and clinical risk in patients with stable coronary artery disease, is an independent predictor for cardiac rupture, which in itself has a poor prognosis.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','82')" href="javascript:void(0);">82</a>] </sup>&nbsp;Increasing SSII tertiles were noted to be associated with a gradual rise in cardiac rupture occurrence.</p>
        <div class="inContentAd"></div>
        <p><em>Fibrinolysis</em></p>
        <div class="inContentAd"></div>
        <p>Fibrinolysis is an important reperfusion strategy, particularly in settings where primary PCI cannot be offered to STEMI patients within the recommended timelines. The benefit of fibrinolytic therapy in patients with STEMI is well established, with the largest benefit seen when administered early (within 12 hours after symptomatic onset) and in patients with the highest cardiovascular risk, including patients older than 75 years.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','83')" href="javascript:void(0);">83</a>, <a onclick="showToolTip(this,'references-layer','84')" href="javascript:void(0);">84</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Fibrinolytic therapy may not be beneficial in patients who present more than 12 hours after symptom onset, although current practice guidelines recommend consideration of fibrinolysis in symptomatic patients with a large area of myocardium at risk (based on ECG or cardiovascular imaging) or hemodynamic instability if PCI is unavailable.&nbsp;See absolute and relative contraindications to fibrinolytic therapy in table 1, below.</p>
        <div class="inContentAd"></div><!--table--><!--inline_table-->
        <p>Table 1.&nbsp;Absolute and Relative Contraindications to Fibrinolytic Therapy in Patients with STEMI<a href="javascript:showModal('clinref-table-layer','td0b69fcde')" onclick="wmdPageLink('cr-tbl_1')"> (Open Table in a new window)</a></p><!--inline_table_body BNR-->
        <div class="inlinetable">
         <table id="td0b69fcde" class="datatable">
          <tbody>
           <tr>
            <td><strong>Absolute Contraindications</strong></td>
            <td><strong>Relative Contraindications</strong></td>
           </tr>
           <tr>
            <td><!--itemizedlist-->
             <ul class="topbullet-para">
              <!--listitem-->
              <li>
               <div>
                Any prior intracranial hemorrhage
               </div></li><!--listitem-->
              <li>
               <div>
                Known structural cerebral vascular lesion
               </div></li><!--listitem-->
              <li>
               <div>
                Known intracranial neoplasm (primary or metastatic)
               </div></li><!--listitem-->
              <li>
               <div>
                Ischemic stroke within the past 3 months (except for acute stroke within 4.5 hours)
               </div></li><!--listitem-->
              <li>
               <div>
                Suspected aortic dissection
               </div></li><!--listitem-->
              <li>
               <div>
                Active bleeding or bleeding diathesis (excluding menses)
               </div></li><!--listitem-->
              <li>
               <div>
                Significant closed-head or facial trauma within 3 months
               </div></li><!--listitem-->
              <li>
               <div>
                Intracranial or intraspinal surgery within 2 months
               </div></li><!--listitem-->
              <li>
               <div>
                Severe uncontrolled hypertension (unresponsive to emergency therapy)
               </div></li><!--listitem-->
              <li>
               <div>
                For streptokinase (no longer marketed in the US): Prior treatment within previous 6 months
               </div></li>
             </ul></td>
            <td><!--itemizedlist-->
             <ul class="topbullet-para">
              <!--listitem-->
              <li>
               <div>
                History of chronic, severe, poorly controlled hypertension
               </div></li><!--listitem-->
              <li>
               <div>
                Systolic pressure &gt;180 mm Hg or diastolic pressure &gt;110 mm Hg
               </div></li><!--listitem-->
              <li>
               <div>
                History of prior ischemic stroke &gt;3 months
               </div></li><!--listitem-->
              <li>
               <div>
                Dementia
               </div></li><!--listitem-->
              <li>
               <div>
                Known intracranial pathology not covered in absolute contraindications
               </div></li><!--listitem-->
              <li>
               <div>
                Traumatic or prolonged CPR (&gt;10 minutes)
               </div></li><!--listitem-->
              <li>
               <div>
                Recent (within 2-4 weeks) internal bleeding
               </div></li><!--listitem-->
              <li>
               <div>
                Noncompressible vascular punctures
               </div></li><!--listitem-->
              <li>
               <div>
                Pregnancy
               </div></li><!--listitem-->
              <li>
               <div>
                Active peptic ulcer disease
               </div></li><!--listitem-->
              <li>
               <div>
                Current use of anticoagulants: The higher the INR, the higher the risk of bleeding
               </div></li><!--listitem-->
              <li>
               <div>
                For streptokinase (no longer marketed in the US): Prior exposure (&gt;5 days previously) or prior allergic reaction to these agents
               </div></li>
             </ul></td>
           </tr>
           <tr>
            <td colspan="2"><p>CPR = cardiopulmonary resuscitation; INR = international normalized ratio;&nbsp;STEMI =&nbsp;ST-elevation myocardial infarction; US = United States of America.</p><p>&nbsp;</p><p>Table modified from 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>] </sup></p></td>
           </tr>
          </tbody>
         </table>
        </div>
        <div class="inContentAd"></div><!--/table-->
        <p>Fibrinolytic therapy is associated with an&nbsp;excess of strokes, mainly due to cerebral hemorrhage, which is more commonly seen in patients with advanced age, lower weight, female sex, prior cerebrovascular disease, and hypertension on admission.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','85')" href="javascript:void(0);">85</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Different fibrinolytic agents are available, and table 2, below, lists different fibrinolytic agents with some of their key characteristics. In general, fibrin-specific agents are preferred when available.<strong>&nbsp;Note:</strong>&nbsp;Streptokinase is no longer marketed in the United States.</p>
        <div class="inContentAd"></div><!--table--><!--inline_table-->
        <p>Table 2.&nbsp;Fibrinolytic Agents Used in Management of STEMI.<a href="javascript:showModal('clinref-table-layer','t2074863fc')" onclick="wmdPageLink('cr-tbl_1')"> (Open Table in a new window)</a></p><!--inline_table_body BNR-->
        <div class="inlinetable">
         <table id="t2074863fc" class="datatable">
          <tbody>
           <tr>
            <td><p><strong>Fibrinolytic Agent</strong></p></td>
            <td><p><strong>Dose</strong></p></td>
            <td><p><strong>Fibrin Specificity</strong></p></td>
            <td><p><strong>Antigenic</strong></p></td>
            <td><p><strong>Patency Rate</strong></p></td>
           </tr>
           <tr>
            <td><p><strong>Non-fibrin specific</strong></p></td>
            <td>&nbsp;</td>
            <td><p>&nbsp;</p></td>
            <td><p>&nbsp;</p></td>
            <td><p>&nbsp;</p></td>
           </tr>
           <tr>
            <td><p>Streptokinase (no longer marketed in the US)</p></td>
            <td><p>1.5 million units IV given over 30–60 min</p></td>
            <td><p>No</p></td>
            <td><p>Yes</p></td>
            <td><p>60%–68%</p></td>
           </tr>
           <tr>
            <td><p><strong>Fibrin specific</strong></p></td>
            <td>&nbsp;</td>
            <td><p>&nbsp;</p></td>
            <td><p>&nbsp;</p></td>
            <td><p>&nbsp;</p></td>
           </tr>
           <tr>
            <td><p>Tenecteplase</p><p>(TNK-tPA)</p></td>
            <td><p>30 mg for weight &lt; 60 kg</p><p>35 mg for 60–69 kg</p><p>40 mg for 70–79 kg</p><p>45 mg for 80–89 kg</p><p>50 mg for &gt;90 kg</p></td>
            <td><p>++++</p></td>
            <td><p>No</p></td>
            <td><p>85%</p></td>
           </tr>
           <tr>
            <td><p>Reteplase (rPA)</p></td>
            <td><p>10-U IV boluses given 30 min apart</p></td>
            <td><p>++</p></td>
            <td><p>No</p></td>
            <td><p>84%</p></td>
           </tr>
           <tr>
            <td><p>Alteplase (tPA)</p></td>
            <td><p>Bolus 15 mg followed by infusion 0.75 mg/kg for 30 min (maximum 50 mg), then 0.5 mg/kg (maximum 35 mg) over the next 60 min; total dose not to exceed 100 mg.</p></td>
            <td><p>++</p></td>
            <td><p>No</p></td>
            <td><p>73%-84%</p></td>
           </tr>
           <tr>
            <td colspan="5"><p>IV = intravenous; rPA = recombinant human tissue plasminogen activator; STEMI =&nbsp;ST-elevation myocardial infarction;&nbsp;tPA = tissue plasminogen activator; US = United States of America.</p><p>&nbsp;</p><p>Table modified from 2013 ACCF/AHA guidelines for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>] </sup></p></td>
           </tr>
          </tbody>
         </table>
        </div>
        <div class="inContentAd"></div><!--/table-->
        <p>&nbsp;</p>
        <div class="inContentAd"></div>
        <p><em>Coronary artery bypass grafting (CABG)</em></p>
        <div class="inContentAd"></div>
        <p>Despite great improvement of intraoperative myocardial preservation, CABG has a limited role in the acute management of STEMI. However, CABG remains indicated for cardiogenic shock, failed PCI, high-risk anatomy, surgical repair of a mechanical complication of STEMI (eg, ventricular septal rupture, free-wall rupture, or severe mitral regurgitation from papillary muscle dysfunction or rupture). CABG is also the&nbsp;preferred revascularization strategy for patients with unprotected left main disease, but PCI with DES is a reasonable alternative treatment option in those with favorable anatomy and high surgical risk.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','86')" href="javascript:void(0);">86</a>] </sup></p>
        <div class="inContentAd"></div>
        <h3>Anticoagulation</h3>
        <p>Anticoagulant agents are an important adjunctive therapy for reperfusion therapy regardless of the strategy chosen (ie, whether it is primary PCI or fibrinolysis therapy).&nbsp;Different anticoagulation agents are available; the utility of each agent depends on the clinical context, taking into account the method of reperfusion.</p>
        <div class="inContentAd"></div>
        <p>For primary PCI, unfractionated heparin (UFH), bivalirudin,<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>, <a onclick="showToolTip(this,'references-layer','4')" href="javascript:void(0);">4</a>] </sup>&nbsp;and low molecular weight heparin (LMWH) (eg, enoxaparin<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','4')" href="javascript:void(0);">4</a>] </sup>)&nbsp;are the available options. Fondaparinux is not used in this setting because of the increased risk of catheter thrombosis.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','87')" href="javascript:void(0);">87</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>In patients receiving fibrinolytic therapy, anticoagulation should be given until revascularization is performed; if reperfusion is not feasible anticoagulants should be given for at least 48 hours or for the duration of hospital stay up to 8 days.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','4')" href="javascript:void(0);">4</a>] </sup>&nbsp;UFH or LMWH may be used, with LMWH (enoxaparin) being preferred.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','88')" href="javascript:void(0);">88</a>, <a onclick="showToolTip(this,'references-layer','89')" href="javascript:void(0);">89</a>, <a onclick="showToolTip(this,'references-layer','90')" href="javascript:void(0);">90</a>] </sup>&nbsp;Use caution with the administration of enoxaparin in patients older than 75 years as well as those with impaired renal function, because the use of enoxaparin is associated with a higher risk of intracranial bleeding. Bivalirudin may be used for patients who develop or have a history of heparin-induced thrombocytopenia (HIT) and require anticoagulation.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','91')" href="javascript:void(0);">91</a>] </sup></p>
        <div class="inContentAd"></div>
        <h3>Antiplatelet agents</h3>
        <p>All patients with STEMI should receive an empiric loading dose of aspirin (150.5 to 325 mg) as early as possible and prior to reperfusion, regardless of the reperfusion method. A lifelong maintenance dose of (75 to 81 mg) daily should be prescribed to all patients after STEMI.</p>
        <div class="inContentAd"></div>
        <p>Other antiplatelet agents used for dual antiplatelet therapy are the P2Y<sub>12</sub> receptor inhibitors (eg, clopidogrel, ticagrelor, prasugrel); a loading dose of these agents is given before or at the time of reperfusion and an extended duration maintenance dose is administered thereafter, depending on the method of reperfusion.</p>
        <div class="inContentAd"></div>
        <p>For patients undergoing primary PCI, a loading dose of 600 mg of clopidogrel, 180 mg of ticagrelor, or 60 mg of prasugrel should be given as early as possible or at the time of primary PCI. A maintenance dose of P2Y<sub>12</sub> receptor inhibitors should be continued for at least 1 year for patients who receive a stent, either a BMS or a DES. A daily dose of 75 mg clopidogrel, 90 mg ticagrelor (twice daily), or 10 mg prasugrel is recommended. It is reasonable to discontinue P2Y<sub>12</sub> receptor inhibitor agents prior to 1 year for patients who receive a BMS if there is evidence of increased bleeding.</p>
        <div class="inContentAd"></div>
        <p>Introducing ticagrelor after myocardial infarction in patients with previous ischemic stroke is associated with lower rates of recurrent ischemic stroke, without an increase in intracranial bleeding.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','92')" href="javascript:void(0);">92</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>The use of prasugrel is not recommended for patients with a history of stroke or transient ischemic attack (TIA).<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','93')" href="javascript:void(0);">93</a>, <a onclick="showToolTip(this,'references-layer','94')" href="javascript:void(0);">94</a>, <a onclick="showToolTip(this,'references-layer','95')" href="javascript:void(0);">95</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>For patients who receive fibrinolytic therapy, a loading dose of clopidogrel 300 mg followed by a daily maintenance dose of 75 mg should be given, preferably for 1 year or a minimum of 14 days. The use of other P2Y<sub>12</sub> receptor inhibitor agents in patients treated with fibrinolysis has not been prospectively studied.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Other antiplatelet agents that may be used in STEMI management are the intravenous (IV) glycoprotein (GP) II<sub>b</sub>/III<sub>a</sub> receptor antagonists. The adjunctive use of GP II<sub>b</sub>/III<sub>a</sub> agents at the time of PCI can be considered on an individual basis for a large thrombus burden&nbsp;or inadequate P2Y<sub>12</sub> receptor antagonist loading. For patients receiving bivalirudin as the primary anticoagulant, routine adjunctive use of GP II<sub>b</sub>/III<sub>a</sub> inhibitors is not recommended but may be considered in selected cases.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>, <a onclick="showToolTip(this,'references-layer','4')" href="javascript:void(0);">4</a>] </sup></p>
        <div class="inContentAd"></div>
       </div>
       <div class="emed-logo">
        <img src="//img.medscapestatic.com/pi/global/logos/emed/logo-emedicine77x17.svg" alt="eMedicine Logo">
       </div><!--output_version : web--><!--page_nav-->
       <div class="back_next_btn">
        <div class="back_btn">
         Previous
        </div>
        <div class="next_btn">
         Next: 
        </div>
        <div class="spacer"></div>
       </div>
       <div class="spacer"></div>
      </div><!--sect2-->
      <div id="content_d26">
       <noscript>
        <a name="d26"></a>
       </noscript>
       <h2>Non-ST-Elevation (NSTE) ACS</h2>
       <div class="refsection_content">
        <!--sect2: d26-->
        <p>Key points in the management of patients with non–ST-elevation&nbsp;acute coronary syndrome (NSTE-ACS) (unstable angina and non-STE myocardial infarction [NSTEMI]) is early evaluation and assessment of hemodynamic and electrical stability, estimatation of the overall risk in these patients, and guidance of therapy.</p>
        <div class="inContentAd"></div>
        <p>There are two alternative management strategies, either an early invasive strategy with angiography, with intent for revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), or a conservative strategy with initial medical therapy and noninvasive cardiovascular imaging. Regardless of the strategy, both entail aggressive utility of medications such as anticoagulants, antiplatelet agents, beta blockers, statins, and possible use of angiotensin-converting enzyme (ACE) inhibitors for appropriate patient populations.</p>
        <div class="inContentAd"></div>
        <p>Patients with refractory angina, clinical evidence of heart failure, or hemodynamic or electrical instability who do not have serious comorbidities or contraindications to angiography/PCI should undergo an early invasive strategy.</p>
        <div class="inContentAd"></div>
        <p>An immediate early invasive strategy is also recommended for patient who are stable but at a high risk for clinical events.&nbsp;It is reasonable to consider an early invasive strategy within 24 hours of admission in patients with intermediate/high risk. For patients who fall outside this category, a delayed invasive strategy within 25 to 72 hours of admission versus a conservative (ischemia-guided) strategy may be considered.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','1')" href="javascript:void(0);">1</a>] </sup></p>
        <div class="inContentAd"></div>
        <h3>Beta blockers</h3>
        <p>Beta blockers work by reduction of oxygen consumption of the myocardium by lowering the heart rate, blood pressure, and myocardial contractility. They also play an important role in reduction of reinfarction and complex ventricular arrhythmias.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','31')" href="javascript:void(0);">31</a>, <a onclick="showToolTip(this,'references-layer','96')" href="javascript:void(0);">96</a>] </sup>These agents are recommended to be given orally within the first 24 hours, preferably using one of the three drugs proven to reduce mortality in heart failure patients: metoprolol, carvedilol, or bisoprolol.</p>
        <div class="inContentAd"></div>
        <p>Beta blockers should not be given intravenously in patients with evidence of low cardiac output state (heart rate &gt;110 beats/min or systolic blood pressure &lt; 100 mmHg), and used with caution in elderly patients or in individuals with an unknown left ventricular ejection fraction.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','96')" href="javascript:void(0);">96</a>] </sup>&nbsp;These agents should also not be given to patients who have a contraindication to beta blockers (eg, first-degree heart block with a PR interval &gt;240 ms, second- or third-degree heart block without a cardiac pacemaker, recent cocaine use, severe/advanced active reactive airway disease).</p>
        <div class="inContentAd"></div>
        <p>In patients with chronic obstructive lung disease or chronic asthma, beta-1 selective beta blockers are preferred and should be initiated at low doses.</p>
        <div class="inContentAd"></div>
        <h3>Calcium channel blockers</h3>
        <p>Non-dihydropyridine calcium channel blockers (eg, verapamil or diltiazem) should be given for recurrent myocardial ischemia only if there are contraindications to using beta blockers.&nbsp;Similar to beta blockers, use of non-dihydropyridine calcium channel blockers can also increase the likelihood of developing cardiogenic shock, thus, similar caution should be used when considering the use of these drugs.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','96')" href="javascript:void(0);">96</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Avoid short-acting nifedipine in patients who are not receiving beta blockers, as this may result in increased mortality in patients with ACS.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','96')" href="javascript:void(0);">96</a>] </sup></p>
        <div class="inContentAd"></div>
        <h3>Antiplatelet agents</h3>
        <p><em>Aspirin</em></p>
        <div class="inContentAd"></div>
        <p>Nonenteric-coated chewable aspirin 150 to 325 mg should be given to all patients with NSTE-ACS as soon as possible after presentation.</p>
        <div class="inContentAd"></div>
        <p>A maintenance dose of aspirin 75-100 mg daily should be continued indefinitely.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','1')" href="javascript:void(0);">1</a>, <a onclick="showToolTip(this,'references-layer','3')" href="javascript:void(0);">3</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Some clinical data suggest that maintenance dose of aspirin higher than 160 mg daily is associated with increased risk of bleeding with no clear improvement in outcomes.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','97')" href="javascript:void(0);">97</a>, <a onclick="showToolTip(this,'references-layer','98')" href="javascript:void(0);">98</a>] </sup></p>
        <div class="inContentAd"></div>
        <p><em>P2Y<sub>12</sub> receptor inhibitors</em></p>
        <div class="inContentAd"></div>
        <p>The use of P2Y<sub>12</sub>&nbsp;receptor inhibitors in addition to aspirin has resulted in better outcomes, with a reduction of the incidence of cardiovascular death, MI, and stroke.&nbsp;The three P2Y<sub>12</sub>&nbsp;receptor inhibitors&nbsp;most commonly used&nbsp;in the treatment of NSTE-ACS are described in this section, as follows:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           Clopidogrel
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           Ticagrelor
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           Prasugrel
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <p>All three agents are given with an initial loading dose, followed by a daily maintenance dose up to 12 months for all patients treated for NSTE ACS with either early invasive or conservative strategies.</p>
        <div class="inContentAd"></div>
        <p>With the wider use of new generation drug-eluting stents (DES), a shorter duration of P2Y<sub>12</sub> receptor inhibitors of 3-6 months can be considered in patients who are at high bleeding risk.</p>
        <div class="inContentAd"></div>
        <p>Clopidogrel</p>
        <div class="inContentAd"></div>
        <p>A oading dose of clopidogrel 300-600 mg is recommended, followed by a maintenance dose of 75 mg daily.</p>
        <div class="inContentAd"></div>
        <p>Extrapolated results from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial demonstrated that clopidogrel can be used in patients with NSTE-ACS who are intolerant to aspirin.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','99')" href="javascript:void(0);">99</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Ticagrelor</p>
        <div class="inContentAd"></div>
        <p>Ticagrelor&nbsp;is a reversible inhibitor of the P2Y<sub>12 </sub>receptor that has a more rapid onset of action and a shorter half-life than clopidogrel; therefore, it is administered twice daily for maintenance.&nbsp;A loading dose of ticagrelor 180 mg is recommended, followed by a maintenance dose of 90 mg twice daily.&nbsp;</p>
        <div class="inContentAd"></div>
        <p>The Platelet Inhibition and Patient Outcomes (PLATO) trial compared clopidogrel to ticagrelor in patients with NSTE-ACS and concluded that patients receiving ticagrelor had lower events of MI, stroke, and overall mortality.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','100')" href="javascript:void(0);">100</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>A unique side effect observed in patients taking ticagrelor is dyspnea, but this is rarely severe enough to cause termination of treatment.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','101')" href="javascript:void(0);">101</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Ticagrelor should not be used concomitantly with higher doses of aspirin (&gt;100 mg daily).</p>
        <div class="inContentAd"></div>
        <p>Prasugrel</p>
        <div class="inContentAd"></div>
        <p>A loading dose of prasugrel 60 mg is recommended, followed by a maintenance dose of 10 mg daily.</p>
        <div class="inContentAd"></div>
        <p>Because of the unique metabolic conversion pathways of prasugrel, it has a more rapid and more consistent platelet inhibition than clopidogrel, which was demonstrated in the Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38 trial. However, there was a concern of an increased bleeding risk in individuals treated with prasugrel.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','93')" href="javascript:void(0);">93</a>, <a onclick="showToolTip(this,'references-layer','94')" href="javascript:void(0);">94</a>, <a onclick="showToolTip(this,'references-layer','95')" href="javascript:void(0);">95</a>] </sup>Therefore, major contraindication to the use of prasugrel are a previous history of stroke or transient ischemic attack (TIA), age over 75 years, and low body weight (&lt; 60 kg).<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','93')" href="javascript:void(0);">93</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Current clinical practice guidelines have different recommendations with regard to the use of prasugrel upfront in patients with NSTE-ACS. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines do not recommend the use of prasugrel in this setting; however, its use can be considered for those undergoing PCI.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','96')" href="javascript:void(0);">96</a>] </sup>&nbsp;The ESC guidelines, however, recommend the use of prasugrel upfront in patients treated for NSTE-ACS—provided there is no contraindication to its use.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','3')" href="javascript:void(0);">3</a>] </sup></p>
        <div class="inContentAd"></div>
        <p><em>Glycoprotein (GP) II<sub>b</sub>/III<sub>a</sub> receptor inhibitors</em></p>
        <div class="inContentAd"></div>
        <p>The&nbsp;Platelet&nbsp;Glycoprotein&nbsp;IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy&nbsp;(PURSUIT) trial<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','102')" href="javascript:void(0);">102</a>] </sup>and the Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trial<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','103')" href="javascript:void(0);">103</a>] </sup>demonstrated the efficacy of these agents in the treatment of NSTE-ACS.</p>
        <div class="inContentAd"></div>
        <p>The preferred GP II<sub>b</sub>/III<sub>a</sub> receptor inhibitors are eptifibatide or tirofiban.&nbsp;Patients undergoing an early invasive strategy who received dual antiplatelet therapy with high-risk features are considered candidates to receive either of these two agents.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','1')" href="javascript:void(0);">1</a>, <a onclick="showToolTip(this,'references-layer','3')" href="javascript:void(0);">3</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>However, GP II<sub>b</sub>/III<sub>a</sub> agents are associated with an increased risk of bleeding complications, and most of the clinical trials studying these drugs were completed prior to the release of the P2Y<sub>12</sub> receptor inhibitors. Thus, their use in NSTE-ACS is limited currently.</p>
        <div class="inContentAd"></div>
        <h3>Anticoagulant therapy</h3>
        <p>Anticoagulant agents are recommended to be given to all patients with NSTE-ACS, regardless of the initial treatment strategy, in addition to antiplatelet therapy.&nbsp;The following agents may be considered as treatment options from this group of medications.</p>
        <div class="inContentAd"></div>
        <p><em>Unfractionated heparin (UH)</em></p>
        <div class="inContentAd"></div>
        <p>An initial loading dose of 60 IU/kg (maximum 4,000 IU) with an initial infusion of 12 IU/kg per hour (maximum 1,000 IU/h) adjusted per activated partial thromboplastin time (PTT) is recommended to maintain therapeutic anticoagulation according to the specific hospital protocol. This regimen is continued for 48 hours or until PCI is performed.</p>
        <div class="inContentAd"></div>
        <p>A major disadvantage of the use of unfractionated heparin is the large interindividual variability and narrow therapeutic window.</p>
        <div class="inContentAd"></div>
        <p><em>Low molecular weight heparin (LMWH)</em></p>
        <div class="inContentAd"></div>
        <p>Enoxaparin is given at a dose of 1 mg/kg subcutaneously (SC) every 12 hours.&nbsp;It should be continued for the duration of hospitalization or until PCI is performed.&nbsp;A dose reduction is required for patients with impaired kidney function.</p>
        <div class="inContentAd"></div>
        <p>Enoxaparin results in a more predictable and efficient anticoagulation compared to unfractionated heparin, leading to reduction in recurrent MI events<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','104')" href="javascript:void(0);">104</a>, <a onclick="showToolTip(this,'references-layer','105')" href="javascript:void(0);">105</a>] </sup>; however, there is possibly a higher bleeding risk in patients undergoing PCI.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','106')" href="javascript:void(0);">106</a>] </sup>These findings were demonstrated in the Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q wave Coronary Events (ESSENCE) trial.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','104')" href="javascript:void(0);">104</a>, <a onclick="showToolTip(this,'references-layer','105')" href="javascript:void(0);">105</a>, <a onclick="showToolTip(this,'references-layer','106')" href="javascript:void(0);">106</a>] </sup></p>
        <div class="inContentAd"></div>
        <p><em>Bivalirudin</em></p>
        <div class="inContentAd"></div>
        <p>Bivalirudin is direct thrombin inhibitor that is given as 0.1 mg/kg loading dose, followed by 0.25 mg/kg per hour only in patients managed with an early invasive strategy. This regimen is continued until diagnostic angiography or PCI.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','107')" href="javascript:void(0);">107</a>] </sup>In the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial, the efficacy of bivalirudin was noninferior to the use of heparin plus GP II<sub>b</sub>/III<sub>a</sub>.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','108')" href="javascript:void(0);">108</a>] </sup></p>
        <div class="inContentAd"></div>
        <p><em>Fondaparinux</em></p>
        <div class="inContentAd"></div>
        <p>Fondaparinux is a selective factor X inhibitor. This agent is given as a once-daily SC injection of 2.5 mg, which is continued for the duration of hospitalization or until PCI is performed.</p>
        <div class="inContentAd"></div>
        <p>Note that fondarparinux&nbsp;is contraindicated in patients with impaired kidney function. In addition, in patients undergoing PCI, administer another anticoagulant agent (eg, unfractionated heparin or bivalirudin), as fondaparinux is associated with a higher risk of catheter thrombosis; this was demonstrated in the Fifth Organization to Assess Strategies in Ischemic Syndromes (OASIS-5) trial.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','87')" href="javascript:void(0);">87</a>, <a onclick="showToolTip(this,'references-layer','109')" href="javascript:void(0);">109</a>, <a onclick="showToolTip(this,'references-layer','110')" href="javascript:void(0);">110</a>] </sup></p>
        <div class="inContentAd"></div>
       </div>
       <div class="emed-logo">
        <img src="//img.medscapestatic.com/pi/global/logos/emed/logo-emedicine77x17.svg" alt="eMedicine Logo">
       </div><!--output_version : web--><!--page_nav-->
       <div class="back_next_btn">
        <div class="back_btn">
         Previous
        </div>
        <div class="next_btn">
         Next: 
        </div>
        <div class="spacer"></div>
       </div>
       <div class="spacer"></div>
      </div><!--sect2-->
      <div id="content_d7">
       <noscript>
        <a name="d7"></a>
       </noscript>
       <h2>Additional Aspects of Management and Late Hospital Care</h2>
       <div class="refsection_content">
        <!--sect2: d7-->
        <p>After the initial management and stabilization of the patient in the early and critical phase of acute myocardial infarction (MI), the goals of care for these patients is to restore normal activities, prevent long-term complications, as well as aggressively modify lifestyle and risk factors.&nbsp;This multifaceted goal is achieved with the implementation of important key elements, including the use of cardioprotective medications and cardiac rehabilitation, as well as physical activity, diet, and patient education.</p>
        <div class="inContentAd"></div>
        <h3>Cardioprotective medications</h3>
        <p><em>Inhibitors of the renin-angiotensin-aldosterone (RAA) system</em></p>
        <div class="inContentAd"></div>
        <p>Initiate angiotensin-converting enzyme (ACE) inhibitors and continue administration indefinitely in all patients with a left ventricular ejection fraction that is less than 40% and in those with hypertension, diabetes mellitus, or stable chronic kidney disease, unless contraindicated.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','111')" href="javascript:void(0);">111</a>, <a onclick="showToolTip(this,'references-layer','112')" href="javascript:void(0);">112</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Angiotensin-receptor blockers (ARBs) are recommended in patients who are intolerant of ACE inhibitors.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','113')" href="javascript:void(0);">113</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Aldosterone blockers are recommended&nbsp;in addition to beta blockers and ACE inhibitors&nbsp;in patient who have had an MI with a reduced left ventricular ejection fraction of less than 40%, provided they have no renal impairment and have normal blood potassium levels (&lt; 5 mEq/L). This was emphasized in the Eplerenone Post-acute myocardial infarction Heart failure Efficacy and Survival Study (EPHESUS).<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','114')" href="javascript:void(0);">114</a>] </sup>&nbsp;</p>
        <div class="inContentAd"></div>
        <p><em>Beta blockers</em></p>
        <div class="inContentAd"></div>
        <p>After an MI, all patients should be maintained on a beta blocker. Current clinical practice guidelines recommend use of one of three beta blocker agents proven to reduce mortality in patients with heart failure: metoprolol, carvedilol, or bisoprolol.</p>
        <div class="inContentAd"></div>
        <p>See the discussion on beta blockers in the previous section, <a href="https://emedicine.medscape.com/article/155919-treatment#d26">Non-ST-Elevation (NSTE) ACS</a>.</p>
        <div class="inContentAd"></div>
        <p><em>Statins</em></p>
        <div class="inContentAd"></div>
        <p>All patients with an acute MI should be started on high-potency statin therapy and continued indefinitely.</p>
        <div class="inContentAd"></div>
        <p>Current clinical practice guidelines, high potency statins such as atorvastatin 40 mg or 80 mg, or rosuvastatin 20 mg are recommended.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','1')" href="javascript:void(0);">1</a>, <a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>, <a onclick="showToolTip(this,'references-layer','115')" href="javascript:void(0);">115</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>The Effects of Atorvastatin on Early Recurrent Ischemic Events In Acute Coronary Syndromes (MIRACL) trial<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','116')" href="javascript:void(0);">116</a>] </sup>and the Atorvastatin for Reduction of Myocardial Damage During Angioplasty-Acute Coronary Syndromes (ARMYDA-ACS) trial<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','117')" href="javascript:void(0);">117</a>] </sup>demonstrated a reduction in mortality rates in patients who received high-potency statins after acute MI as compared to placebo.</p>
        <div class="inContentAd"></div>
        <h3>Lifestyle modifications and cardiac rehabilitation</h3>
        <p>Much emphasis has been placed on postdischarge care for patients after MI.</p>
        <div class="inContentAd"></div>
        <p>Several lifestyle modifications have been strongly linked to a reduction in recurrent MI and prevention of further progression of cardiovascular disease. These modification include dietary changes that adopt a low-fat and low-salt diet with dietary counseling, smoking cessation, up-to-date vaccination, and an increase in physical activity and exercise.</p>
        <div class="inContentAd"></div>
        <p>Referral to a well-structured cardiac rehabilitation program after MI should be considered for all patients, as this will promote patient compliance with the medical regimen and enhance lifestyle changes. In addition, aerobic exercise training within a cardiac rehabilitation program should be offered to patients after MI, with the need for an evaluation of both exercise capacity and exercise-associated risk.</p>
        <div class="inContentAd"></div>
        <p>The recommended frequency of regular exercise training is three or more times a week, for at least 30 minutes per session.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','1')" href="javascript:void(0);">1</a>, <a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>, <a onclick="showToolTip(this,'references-layer','118')" href="javascript:void(0);">118</a>] </sup></p>
        <div class="inContentAd"></div>
        <p><em>2019 ACC/AHA primary CVD prevention recommendations</em></p>
        <div class="inContentAd"></div>
        <p>The American College of Cardiology (ACC) and the American Heart Association (AHA) published recommendations on the primary prevention of cardiovascular disease (CVD) in March 2019.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','119')" href="javascript:void(0);">119</a>, <a onclick="showToolTip(this,'references-layer','120')" href="javascript:void(0);">120</a>] </sup>Ten key messages and a few recommendations from the guidelines are summarized below, including an emphasis on lifestyle choices/modifications and a major shift away from the broad use of aspirin in primary prevention.</p>
        <div class="inContentAd"></div>
        <p>◊ Key messages</p>
        <div class="inContentAd"></div>
        <p>A healthy lifestyle over a lifetime is the most important way to prevent atherosclerotic vascular disease, heart failure, and atrial fibrillation.</p>
        <div class="inContentAd"></div>
        <p>A team-based care approach is an effective strategy for CVD prevention. Clinicians should evaluate the social determinants of health that affect individuals to inform treatment decisions.</p>
        <div class="inContentAd"></div>
        <p>Adults aged 40-75 years being evaluated for CVD prevention should undergo 10-year atherosclerotic CVD (ASCVD) risk estimation and have a clinician–patient risk discussion before being started on pharmacotherapy (eg, antihypertensive therapy, a statin, or aspirin). The presence or absence of additional risk factors and/or the use of coronary artery calcium (CAC) scanning can help guide decisions about preventive interventions in select individuals.</p>
        <div class="inContentAd"></div>
        <p>All adults should consume a healthy diet that emphasizes consumption of vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish, and minimizes the intake of trans fats, processed meats, refined carbohydrates, and sweetened beverages. In the setting of overweight and obesity, counseling and caloric restriction are recommended to achieve and maintain weight loss.</p>
        <div class="inContentAd"></div>
        <p>Adults, including those with type 2 diabetes mellitus (T2DM), should engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or 75 minutes per week of vigorous-intensity physical activity.</p>
        <div class="inContentAd"></div>
        <p>For adults with T2DM, lifestyle changes (eg, improving dietary habits, achieving exercise recommendations) are crucial. If medication is indicated, metformin is first-line therapy, followed by consideration of a sodium-glucose cotransporter 2 inhibitor (SGLT2) or a glucagon-like peptide-1 receptor agonist (GLP-1).</p>
        <div class="inContentAd"></div>
        <p>At every healthcare visit, assess all adults for tobacco use. Assist tobacco users and strongly advise them to quit.</p>
        <div class="inContentAd"></div>
        <p>Aspirin should be used infrequently in the routine primary prevention of ASCVD because of a lack of net benefit.</p>
        <div class="inContentAd"></div>
        <p>Statin therapy is first-line treatment for the primary prevention of ASCVD in patients with elevated low-density lipoprotein cholesterol (LDL-C) levels (≥190 mg/dL), those with diabetes mellitus who are aged 40-75 years, and those determined to be at sufficient ASCVD risk after a clinician-patient risk discussion.</p>
        <div class="inContentAd"></div>
        <p>Nonpharmacologic interventions are recommended for all adults with elevated blood pressure or hypertension. When pharmacologic therapy is required, target the blood pressure to generally be below 130/80 mmHg.</p>
        <div class="inContentAd"></div>
        <p>◊ Select recommendations</p>
        <div class="inContentAd"></div>
        <p>For adults aged 40-75 years, routinely assess traditional CV risk factors and calculate their 10-year ASCVD risk with the pooled cohort equations (PCE). For those aged 20-39 years, it is reasonable to assess traditional ASCVD risk factors at least every 4-6 years.</p>
        <div class="inContentAd"></div>
        <p>In adults at borderline risk (5% to &lt; 7.5% 10-year ASCVD risk) or intermediate risk (≥7.5% to &lt; 20% 10-year ASCVD risk), using additional risk-enhancing factors is reasonable to guide decisions about preventive interventions (eg, statin therapy).</p>
        <div class="inContentAd"></div>
        <p>In adults at intermediate risk (≥7.5% to &lt; 20% 10-year ASCVD risk) or selected adults at borderline risk (5% to &lt; 7.5% 10-year ASCVD risk), if risk-based decisions for preventive interventions (eg, statin therapy) remain uncertain, measuring a CAC score to guide the clinician-patient risk discussion is reasonable, as follows:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           <p>CAC = 0: Withholding statin therapy is reasonable; reassess in 5-10 years if higher risk conditions are absent (eg, diabetes, family history of premature coronary heart disease, tobacco use).</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>CAC = 1-99: Initiating statin therapy is reasonable for those aged 55 years or older.</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>CAC is ≥100, or is in ≥75th percentile: Initiating statin therapy is reasonable.</p>
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <p>For adults aged 20-39 years and for those aged 40-59 years whose 10-year ASCVD risk is below 7.5%, consider estimating their lifetime or 30-year ASCVD risk.</p>
        <div class="inContentAd"></div>
        <p>In adults at intermediate risk (≥7.5% to &lt; 20% 10-year ASCVD risk):</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           <p>If statin therapy is decided upon, use a moderate-intensity agent.</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Reduce LDL-C levels by ≥30%; for optimal ASCVD risk reduction, particularly in high-risk patients (≥20% 10-year ASCVD risk), reduce LDL-C levels by ≥50%.</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>In the setting of risk-enhancing factors, initiating or intensifying statin therapy is favored.</p>
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <p>In diabetic adults aged 40-75 years, regardless of the estimated 10-year ASCVD risk, moderate-intensity statin therapy is indicated. High-intensity statin therapy is reasonable for diabetic adults with multiple ASCVD risk factors to reduce LDL-C levels by 50% or more.</p>
        <div class="inContentAd"></div>
        <p>The maximally tolerated statin therapy is recommended in patients aged 20-75 years with LDL-C levels of 190 mg/dL (≥4.9 mmol/L) or higher.</p>
        <div class="inContentAd"></div>
        <p>Blood pressure (BP)-lowering agents are recommended for the following patients:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           <p>Adults with an estimated 10-year ASCVD risk of ≥10% and an average BP of ≥130/80 mmHg (for primary CVD prevention)</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Adults with an estimated 10-year ASCVD risk &lt; 10% and a BP of ≥140/90 mmHg</p>
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <p>Low-dose aspirin (75-100 mg orally daily) guidance includes the following:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           <p>Consider for primary ASCVD prevention in select adults aged 40-70 years who have higher ASCVD risk but not an increased bleeding risk.</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Do&nbsp;<em>not</em>&nbsp;routinely administer for primary ASCVD prevention in adults &gt;70 years as well as in adults of any age who have a higher bleeding risk.</p>
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <h3>Special considerations for elderly patients</h3>
        <p>Elderly patients should be treated aggressively. However, this patient population&nbsp;with MI is at an increased risk for developing complications, such as&nbsp;a greater risk of bleeding with thrombolytic therapy, but they also have the most to gain from this treatment.&nbsp;</p>
        <div class="inContentAd"></div>
        <p>Very elderly patients should undergo primary angioplasty if available, but they should receive thrombolytic agents if excessive delay is anticipated before angioplasty can be performed.</p>
        <div class="inContentAd"></div>
       </div>
       <div class="emed-logo">
        <img src="//img.medscapestatic.com/pi/global/logos/emed/logo-emedicine77x17.svg" alt="eMedicine Logo">
       </div><!--output_version : web--><!--page_nav-->
       <div class="back_next_btn">
        <div class="back_btn">
         Previous
        </div>
        <div class="next_btn">
         Next: 
        </div>
        <div class="spacer"></div>
       </div>
       <div class="spacer"></div>
      </div><!--sect2-->
      <div id="content_d19">
       <noscript>
        <a name="d19"></a>
       </noscript>
       <h2>Complications</h2>
       <div class="refsection_content">
        <!--sect2: d19-->
        <p>Complications of myocardial infarction (MI) include arrhythmic complications, mechanical complications, left ventricular aneurysm formation, ventricular septal rupture, associated right ventricular infarction, ventricular pseudoaneurysm, and other issues. See&nbsp;<a href="https://emedicine.medscape.com/article/155919-overview">Complications of Myocardial Infarction</a>.</p>
        <div class="inContentAd"></div>
        <h3>Arrhythmic complications</h3>
        <p>Cardiac arrhythmias are not uncommon during and immediately after an acute MI.&nbsp;The incidence increases with ST-elevation MI STEMI and decreases with non-STEMI (NSTEMI).&nbsp;Of all patients who have an acute MI, about 90% develop some form of cardiac arrhythmias. In 25% of patients, such rhythm abnormalities occur within the first 24 hours. The risk of serious arrhythmias, such as ventricular fibrillation (VF), is greatest in the first hour and then declines thereafter.&nbsp;</p>
        <div class="inContentAd"></div>
        <p>Most peri-infarction arrhythmias are benign and self-limited. However, aggressively monitor and treat arrhythmias that result in hypotension, increase myocardial oxygen requirements, and/or predispose the patient to malignant ventricular arrhythmias.</p>
        <div class="inContentAd"></div>
        <h3>Mechanical complications</h3>
        <p>The three major mechanical complications of MI, each of which can cause cardiogenic shock, are as follows:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           <p>Ventricular free wall rupture</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p><a href="https://emedicine.medscape.com/article/428240-overview">Ventricular septal defect</a></p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Papillary muscle rupture with severe <a href="https://emedicine.medscape.com/article/155618-overview">mitral regurgitation</a></p>
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <h3>Left ventricular aneurysm formation</h3>
        <p>Left ventricular aneurysm is defined as a localized area of myocardium with abnormal outward bulging and deformation during systole and diastole. The rate of left ventricular aneurysm formation after acute MI is approximately 3-15%. Risk factors for these aneurysms after acute MI include the following:</p><!--itemizedlist-->
        <ul>
         <!--listitem-->
         <li>
          <div class="topbullet">
           <p>Female sex</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Total occlusion of the left anterior descending (LAD) coronary artery</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Single-vessel coronary artery disease (CAD)</p>
          </div></li><!--listitem-->
         <li>
          <div class="topbullet">
           <p>Absence of previous angina pectoris</p>
          </div></li>
        </ul>
        <div class="inContentAd"></div>
        <p>Clinically, ventricular aneurysms may be recognized late, with symptoms and signs of heart failure, recurrent ventricular arrhythmias, or recurrent embolization.</p>
        <div class="inContentAd"></div>
        <h3>Ventricular septal defect</h3>
        <p>Ventricular septal rupture (acute ventricular septal defect) is a rare but critical complication of MI. It occurs 2-8 days after an infarction and often precipitates <a href="https://emedicine.medscape.com/article/152191-overview">cardiogenic shock</a>. The differential diagnosis of postinfarction cardiogenic shock should exclude free ventricular wall rupture and rupture of the papillary muscles.</p>
        <div class="inContentAd"></div>
        <p>Ventricular rupture is more common in patients with anterior MI, individuals with hypertension, and those receiving nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids.</p>
        <div class="inContentAd"></div>
        <p>To avoid the high morbidity and mortality associated with ventricular septal rupture, patients should undergo emergent surgery.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','121')" href="javascript:void(0);">121</a>, <a onclick="showToolTip(this,'references-layer','122')" href="javascript:void(0);">122</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Concomitant coronary artery bypass grafting (CABG) may be required. Developments in myocardial protection and improved prosthetic materials have contributed greatly to successful management of ventricular septal rupture.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','123')" href="javascript:void(0);">123</a>] </sup>Long-term survival can be achieved in patients who undergo prompt surgery.</p>
        <div class="inContentAd"></div>
        <p>Ventricular rupture occurs in the interventricular septum or the left ventricular free wall. Rupture in either location is a catastrophic event, with a greater than 90% mortality. Prompt recognition, stabilization, and surgical repair are crucial for patient survival. An echocardiogram can usually define the abnormality, and a right heart catheterization can show an oxygen saturation step-up in the case of a septal rupture.</p>
        <div class="inContentAd"></div>
        <h3>Associated right ventricular infarction</h3>
        <p>Approximately one third of patients with inferior MI develop right ventricular infarction, which presents a special challenge because the adjunctive therapy, other than reperfusion, is somewhat different.</p>
        <div class="inContentAd"></div>
        <p>A right-sided electrocardiogram (ECG) with a more than 1-mm ST elevation in lead V<sub>3</sub> R or V<sub>4</sub> R describes a right ventricular infarction. An echocardiogram may be helpful in confirming the diagnosis.</p>
        <div class="inContentAd"></div>
        <p>On physical examination, signs of right-sided heart failure&nbsp;may be present,&nbsp;such as elevated jugular venous pulsation, right-sided S<sub>3</sub>, Kussmaul sign, or hypotension, but the patient may have clear lung fields.</p>
        <div class="inContentAd"></div>
        <p>The patient becomes volume dependent to maintain adequate left and right ventricular filling. Occasionally, dobutamine may be needed, or even an intraaortic balloon pump for hemodynamic support.</p>
        <div class="inContentAd"></div>
        <p>Avoid nitrates or any medications that lower preload in this setting. A pulmonary artery catheter can be helpful in guiding therapy.</p>
        <div class="inContentAd"></div>
        <p>For more information, see <a href="https://emedicine.medscape.com/article/157961-overview">Right Ventricular Infarction</a>.</p>
        <div class="inContentAd"></div>
        <h3>Ventricular pseudoaneurysm</h3>
        <p>Complications of MI, such as ventricular pseudoaneurysms, are confirmed by means of echocardiography,magnetic resonance imaging (MRI), or contrast-enhanced computed tomography (CT) scanning. Imaging of a pseudoaneurysm typically shows a relatively narrow neck and a complete absence of muscle in the wall of the pseudoaneurysm—unlike a true aneurysm, which has a rim of myocardial wall that may be identified on angiography by the presence of mural vessels.</p>
        <div class="inContentAd"></div>
        <h3>Miscellaneous complications</h3>
        <p><em>Left ventricular mural thrombus&nbsp;</em></p>
        <div class="inContentAd"></div>
        <p>Left ventricular mural thrombus Is a well-known complication of acute anterior MI and frequently develops after left anterior wall infarction. The incidence of left ventricular mural thrombus as a complication of acute MI ranges from 20% to 40% but may reach 60% in patients with large, anterior-wall acute MIs who are not treated with anticoagulant therapy.</p>
        <div class="inContentAd"></div>
        <p>Left ventricular mural thrombus is associated with high risk of systemic embolization. Anticoagulant therapy may substantially decrease the rate of embolic events by 33% compared with no anticoagulation.</p>
        <div class="inContentAd"></div>
        <p><em>Pericarditis</em></p>
        <div class="inContentAd"></div>
        <p>The incidence of early pericarditis after MI is approximately 10%, and this complication usually develops within 24-96 hours after MI. Pericarditis is caused by inflammation of pericardial tissue overlying the infarcted myocardium. The clinical presentation may include severe chest pain, usually pleuritic, and pericardial friction rub.</p>
        <div class="inContentAd"></div>
        <p>Before the era of reperfusion, the incidence of post-MI pericarditis (Dressler syndrome) ranged from 1% to 5% after acute MI, but this rate has dramatically declined with the advent of thrombolysis and percutaneous coronary intervention (PCI).</p>
        <div class="inContentAd"></div>
       </div>
       <div class="emed-logo">
        <img src="//img.medscapestatic.com/pi/global/logos/emed/logo-emedicine77x17.svg" alt="eMedicine Logo">
       </div><!--output_version : web--><!--page_nav-->
       <div class="back_next_btn">
        <div class="back_btn">
         Previous
        </div>
        <div class="next_btn">
         Next: 
        </div>
        <div class="spacer"></div>
       </div>
       <div class="spacer"></div>
      </div><!--sect2-->
      <div id="content_d15">
       <noscript>
        <a name="d15"></a>
       </noscript>
       <h2>Future and Emerging Therapies</h2>
       <div class="refsection_content">
        <!--sect2: d15-->
        <p>Local injection of progenitor cells, growth factors, or stem cells may stimulate vascular development. Stem cell therapies for acute myocardial infarction (MI) remain a major target of research, with some data showing modest results.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','124')" href="javascript:void(0);">124</a>] </sup>Investigators in the Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) study examined 204 patients with acute ST-elevation MI (STEMI) and reported greater improvement in left ventricular ejection fraction (LVEF) among patients who received intracoronary progenitor cell infusion than among those given placebo.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','125')" href="javascript:void(0);">125</a>] </sup></p>
        <div class="inContentAd"></div>
        <p>Several smaller clinical trials have suggested that intracoronary delivery of autologous bone marrow mononuclear cells (BMCs) have improved left ventricular function when administered within the first week following MI. However, results from the LateTIME Randomized Trial that evaluated whether intracoronary delivery of autologous BMCs delivered 2-3 weeks following first MI&nbsp;improved global and regional left ventricular function when compared with placebo suggested&nbsp;little improvement with this strategy&nbsp;in patients with MI and left ventricular dysfunction following reperfusion with percutaenous coronary intervention (PCI).<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','126')" href="javascript:void(0);">126</a>] </sup></p>
        <div class="inContentAd"></div>
       </div>
       <div class="emed-logo">
        <img src="//img.medscapestatic.com/pi/global/logos/emed/logo-emedicine77x17.svg" alt="eMedicine Logo">
       </div><!--output_version : web--><!--page_nav-->
       <div class="back_next_btn">
        <div class="back_btn">
         Previous
        </div>
        <div class="spacer"></div>
       </div>
       <div class="next_section_btn">
        <a href="155919-guidelines" onclick="wmdTrack('cr-sn_next');">Guidelines</a>
       </div>
       <div class="spacer">
        &nbsp;
       </div>
      </div>
     </div>
     <div xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" class="spacer">
      &nbsp;
     </div><!--Reference Layer-->
     <div id="references-layer" class="modal-layer inactive">
      <div class="modal-header">
       <div class="close-modal">
        <span><a href="javascript:showModal('inactive');"></a></span>
       </div>
       <h6>References</h6>
      </div><!--refgrp template-->
      <div class="modal-content">
       <ol>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <em>Circulation</em>. 2014 Dec 23. 130 (25):e344-426. <a href="https://www.qxmd.com/r/25249585">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/130/25/e344.long" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] O'Gara PT, Kushner FG, Ascheim DD, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <em>Circulation</em>. 2013 Jan 29. 127 (4):e362-425. <a href="https://www.qxmd.com/r/23247304">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/127/4/e362.long" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <em>Eur Heart J</em>. 2016 Jan 14. 37 (3):267-315. <a href="https://www.qxmd.com/r/26320110">[QxMD MEDLINE Link]</a>. <a href="https://eurheartj.oxfordjournals.org/content/37/3/267.long" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <em>Eur Heart J</em>. 2012 Oct. 33 (20):2569-619. <a href="https://www.qxmd.com/r/22922416">[QxMD MEDLINE Link]</a>. <a href="https://eurheartj.oxfordjournals.org/content/33/20/2569" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Costa e Silva R, Pellanda L, Portal V, Maciel P, Furquim A, Schaan B. Transdisciplinary approach to the follow-up of patients after myocardial infarction. <em>Clinics (Sao Paulo)</em>. 2008 Aug. 63 (4):489-96. <a href="https://www.qxmd.com/r/18719760">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Schulman KA, Solomon AJ. The role of reperfusion therapy in paced patients with acute myocardial infarction. <em>Am Heart J</em>. 2001 Sep. 142(3):516-9. <a href="https://www.qxmd.com/r/11526367">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Jaffe AS. Third universal definition of myocardial infarction. <em>Clin Biochem</em>. 2013 Jan. 46 (1-2):1-4. <a href="https://www.qxmd.com/r/23127386">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Bonaca MP, Wiviott SD, Braunwald E, et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). <em>Circulation</em>. 2012 Jan 31. 125(4):577-83. <a href="https://www.qxmd.com/r/22199016">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. <em>J Am Coll Cardiol</em>. 2012 Oct 16. 60 (16):1581-98. <a href="https://www.qxmd.com/r/22958960">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Fujita M, Nakae I, Kihara Y, et al. Determinants of collateral development in patients with acute myocardial infarction. <em>Clin Cardiol</em>. 1999 Sep. 22 (9):595-9. <a href="https://www.qxmd.com/r/10486700">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. <em>Circulation</em>. 2013 Jul 23. 128 (4):388-400. <a href="https://www.qxmd.com/r/23877061">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. <em>N Engl J Med</em>. 2007 Sep 13. 357 (11):1121-35. <a href="https://www.qxmd.com/r/17855673">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Marban E. Myocardial stunning and hibernation. The physiology behind the colloquialisms. <em>Circulation</em>. 1991 Feb. 83 (2):681-8. <a href="https://www.qxmd.com/r/1991384">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. <em>Arterioscler Thromb Vasc Biol</em>. 2000 Aug. 20 (8):1998-2004. <a href="https://www.qxmd.com/r/10938023">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Kolodgie FD, Virmani R, Burke AP, et al. Pathologic assessment of the vulnerable human coronary plaque. <em>Heart</em>. 2004 Dec. 90 (12):1385-91. <a href="https://www.qxmd.com/r/15547008">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Soares AAS, Tavoni TM, de Faria EC, Remalay AT, Maranhao RC, Sposito AC, et al. HDL acceptor capacities for cholesterol efflux from macrophages and lipid transfer are both acutely reduced after myocardial infarction. <em>Clin Chim Acta</em>. 2018 Mar. 478:51-6. <a href="https://www.qxmd.com/r/29274325">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Holmes MV, Millwood IY, Kartsonaki C, et al, for the China Kadoorie Biobank Collaborative Group. Lipids, lipoproteins, and metabolites and&nbsp;risk of myocardial infarction and&nbsp;stroke. <em>J Am Coll Cardiol</em>. 2018 Feb 13. 71 (6):620-32. <a href="https://www.qxmd.com/r/29420958">[QxMD MEDLINE Link]</a>. <a href="https://www.sciencedirect.com/science/article/pii/S0735109717418687" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. <em>J Am Coll Cardiol</em>. 2007 Jun 26. 49(25):2379-93. <a href="https://www.qxmd.com/r/17599600">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. <em>Circulation</em>. 2004 Jul 20. 110(3):278-84. <a href="https://www.qxmd.com/r/15249505">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Falk E, Shah PK, Fuster V. Coronary plaque disruption. <em>Circulation</em>. 1995 Aug 1. 92(3):657-71. <a href="https://www.qxmd.com/r/7634481">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">McDaniel MC, Willis P, Walker B, et al. Plaque necrotic core content is greater immediately distal to bifurcations compared to bifurcations in the proximal lad of patients with CAD. <em>Am J Cardiol</em>. 2008. 102(8):242i. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Yusuf S, Hawken S, Ounpuu S, et al, for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. <em>Lancet</em>. 2004 Sep 11-17. 364 (9438):937-52. <a href="https://www.qxmd.com/r/15364185">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Macintyre CR, Heywood AE, Kovoor P, et al. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study. <em>Heart</em>. 2013 Dec. 99 (24):1843-8. <a href="https://www.qxmd.com/r/23966030">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. <em>N Engl J Med</em>. 2018 Jan 25. 378 (4):345-53. <a href="https://www.qxmd.com/r/29365305">[QxMD MEDLINE Link]</a>. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841753/" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Concheiro-Guisan A, Sousa-Rouco C, Fernandez-Santamarina I, Gonzalez-Carrero J. Intrauterine myocardial infarction: unsuspected diagnosis in the delivery room. <em>Fetal Pediatr Pathol</em>. 2006 Jul-Aug. 25(4):179-84. <a href="https://www.qxmd.com/r/17162524">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Rogers WJ, Frederick PD, Stoehr E, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. <em>Am Heart J</em>. 2008 Dec. 156 (6):1026-34. <a href="https://www.qxmd.com/r/19032996">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Lloyd-Jones D, Adams RJ, Brown TM, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. <em>Circulation</em>. 2010 Feb 23. 121 (7):948-54. <a href="https://www.qxmd.com/r/20177011">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. <em>Heart</em>. 2002 Aug. 88 (2):119-24. <a href="https://www.qxmd.com/r/12117828">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. <em>Circulation</em>. 2004 Sep 7. 110 (10):1236-44. <a href="https://www.qxmd.com/r/15337690">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Reddy KS. Cardiovascular disease in non-Western countries. <em>N Engl J Med</em>. 2004 Jun 10. 350 (24):2438-40. <a href="https://www.qxmd.com/r/15190135">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. <em>Am Heart J</em>. 2004 Jul. 148 (1):7-15. <a href="https://www.qxmd.com/r/15215786">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Ezzati M. How can cross-country research on health risks strengthen interventions? Lessons from INTERHEART. <em>Lancet</em>. 2004 Sep 11-17. 364 (9438):912-4. <a href="https://www.qxmd.com/r/15364171">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. <em>JAMA</em>. 2000 Aug 16. 284(7):835-42. <a href="https://www.qxmd.com/r/10938172">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Jaber WA, Prior DL, Marso SP, Houghtaling PL, Menon V, Harrington RA. CHF on presentation is associated with markedly worse outcomes among patients with acute coronary syndromes: PURSUIT trial findings. Circulation 1999:100(suppl I):I-433 . </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. <em>Am J Cardiol</em>. 1967 Oct. 20(4):457-64. <a href="https://www.qxmd.com/r/6059183">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. <em>Circulation</em>. 2003 Jul 22. 108 (3):275-81. <a href="https://www.qxmd.com/r/12847065">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. <em>N Engl J Med</em>. 2001 Oct 4. 345 (14):1014-21. <a href="https://www.qxmd.com/r/11586953">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Haaf P, Reichlin T, Corson N, et al. B-type natriuretic peptide in the early diagnosis and risk stratification of acute chest pain. <em>Am J Med</em>. 2011 May. 124 (5):444-52. <a href="https://www.qxmd.com/r/21531234">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. <em>J Am Coll Cardiol</em>. 1998 Jun. 31 (7):1460-5. <a href="https://www.qxmd.com/r/9626820">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Boggs W. Worse Prognosis for Myocardial Infarction Patients With ST-Deviation in AVR. <em>Medscape</em>. Jul 11 2013. <a href="https://www.medscape.com/viewarticle/807686">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Alherbish A, Westerhout CM, Fu Y, et al. The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?. <em>Am Heart J</em>. Jul 3 2013. <a href="https://www.ahjonline.com/article/S0002-8703(13)00366-9/abstract" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-I investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. <em>Circulation</em>. 1995 Mar 15. 91 (6):1659-68. <a href="https://www.qxmd.com/r/7882472">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Smith SC Jr, Allen J, Blair SN, et al,. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. <em>Circulation</em>. 2006 May 16. 113 (19):2363-72. <a href="https://www.qxmd.com/r/16702489">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/113/19/2363.full" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. <em>Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine</em>. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Wijnbergen I, Van't Veer M, Pijls NH, Tijssen J. Circadian and weekly variation and the influence of environmental variables in acute myocardial infarction. <em>Neth Heart J</em>. 2012 Sep. 20 (9):354-9. <a href="https://www.qxmd.com/r/22733558">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Kundi H, Kiziltunc E, Korkmaz A, Cicek G, Ornek E, Ileri M. A novel risk scoring system to predict cardiovascular death in patients with acute myocardial infarction: CHA2DS2-VASc-CF score. <em>Clin Appl Thromb Hemost</em>. 2018 Mar. 24 (2):273-8. <a href="https://www.qxmd.com/r/28627231">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Kacprzak M, Kidawa M, Zielińska M. Fever in myocardial infarction: is it still common, is it still predictive?. <em>Cardiol J</em>. 2012. 19 (4):369-73. <a href="https://www.qxmd.com/r/22825897">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Risøe C, Kirkeby OJ, Grøttum P, Sederholm M, Kjekshus JK. Fever after acute myocardial infarction in patients treated with intravenous timolol or placebo. <em>Br Heart J</em>. 1987 Jan. 57 (1):28-31. <a href="https://www.qxmd.com/r/3541997">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). <em>Am J Cardiol</em>. 2005 Mar 1. 95 (5):614-8. <a href="https://www.qxmd.com/r/15721102">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Lee-Lewandrowski E, Januzzi JL Jr, Grisson R, Mohammed AA, Lewandrowski G, Lewandrowski K. Evaluation of first-draw whole blood, point-of-care cardiac markers in the context of the universal definition of myocardial infarction: a comparison of a multimarker panel to troponin alone and to testing in the central laboratory. <em>Arch Pathol Lab Med</em>. 2011 Apr. 135 (4):459-63. <a href="https://www.qxmd.com/r/21466362">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. <em>Clin Chem</em>. 2009 Jul. 55 (7):1303-6. <a href="https://www.qxmd.com/r/19478023">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Diercks DB, Peacock WF 4th, Hollander JE, et al. Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain. <em>Am Heart J</em>. 2012 Jan. 163 (1):74-80.e4. <a href="https://www.qxmd.com/r/22172439">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Takakuwa KM, Ou FS, Peterson ED, et al. The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. <em>Clin Cardiol</em>. 2009 Sep. 32 (9):498-505. <a href="https://www.qxmd.com/r/19743496">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Mueller C. Biomarkers and acute coronary syndromes: an update. <em>Eur Heart J</em>. 2014 Mar. 35 (9):552-6. <a href="https://www.qxmd.com/r/24357507">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Anderson JL, Adams CD, Antman EM, et al, for the ACC, AHA Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the management of patients with unstable angina/NSTEMI, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interv... <em>Circulation</em>. 2007 Aug 14. 116 (7):e148-304. <a href="https://www.qxmd.com/r/17679616">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. <em>Circulation</em>. 2011 Jul 12. 124(2):136-45. <a href="https://www.qxmd.com/r/21709058">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Storrow AB, Nowak RM, Diercks DB, et al. Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trial. <em>Clin Biochem</em>. 2015 Mar. 48 (4-5):260-7. <a href="https://www.qxmd.com/r/25261587">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Storrow AB, Christenson RH, Nowak RM, et al. Diagnostic performance of cardiac troponin I for early rule-in and rule-out of acute myocardial infarction: Results of a prospective multicenter trial. <em>Clin Biochem</em>. 2015 Mar. 48 (4-5):254-9. <a href="https://www.qxmd.com/r/25195101">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Cullen L, Parsonage WA, Greenslade J, et al. Delta troponin for the early diagnosis of AMI in emergency patients with chest pain. <em>Int J Cardiol</em>. 2013 Oct 3. 168 (3):2602-8. <a href="https://www.qxmd.com/r/23582689">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Thygesen K, Mair J, Mueller C, et al, for the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. <em>Eur Heart J</em>. 2012 Aug. 33 (16):2001-6. <a href="https://www.qxmd.com/r/21292681">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Goldstein JA, Chinnaiyan KM, Abidov A, et al, for the CT-STAT Investigators. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. <em>J Am Coll Cardiol</em>. 2011 Sep 27. 58 (14):1414-22. <a href="https://www.qxmd.com/r/21939822">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Samad Z, Hakeem A, Mahmood SS, et al. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. <em>J Nucl Cardiol</em>. 2012 Apr. 19 (2):364-76. <a href="https://www.qxmd.com/r/22322526">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Cremer PC, Khalaf S, Agarwal S, et al. Myocardial perfusion imaging in emergency department patients with negative cardiac biomarkers: yield for detecting ischemia, short-term events, and impact of downstream revascularization on mortality. <em>Circ Cardiovasc Imaging</em>. 2014 Nov. 7 (6):912-9. <a href="https://www.qxmd.com/r/25273569">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Amgen Inc. FDA approves Amgen's Repatha (evolocumab) to prevent heart attack and stroke [press release]. Available at <a href="https://www.amgen.com/media/news-releases/2017/12/fda-approves-amgens-repatha-evolocumab-to-prevent-heart-attack-and-stroke/" target="_blank">https://www.amgen.com/media/news-releases/2017/12/fda-approves-amgens-repatha-evolocumab-to-prevent-heart-attack-and-stroke/</a>. December 1, 2017; Accessed: December 7, 2017.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Sabatine MS, Giugliano RP, Keech AC, et al, for the FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. <em>N Engl J Med</em>. 2017 May 4. 376 (18):1713-22. <a href="https://www.qxmd.com/r/28304224">[QxMD MEDLINE Link]</a>. <a href="https://www.nejm.org/doi/10.1056/NEJMoa1615664?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest during self-transport for chest pain. <em>Ann Emerg Med</em>. 1996 Dec. 28 (6):612-6. <a href="https://www.qxmd.com/r/8953948">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Mathews R, Peterson ED, Li S, et al. Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The Guidelines. <em>Circulation</em>. 2011 Jul 12. 124 (2):154-63. <a href="https://www.qxmd.com/r/21690494">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Jneid H, Addison D, Bhatt DL, et al. 2017 AHA/ACC clinical performance and quality measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <em>J Am Coll Cardiol</em>. 2017 Oct 17. 70 (16):2048-90. <a href="https://www.qxmd.com/r/28943066">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Wendling P. AHA/ACC issue new performance, quality measures for MI. Medscape Medical News. Available at <a href="https://www.medscape.com/viewarticle/886075">https://www.medscape.com/viewarticle/886075</a>. September 22, 2017; Accessed: March 26, 2018.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Ibanez B, James S, Agewall S, et al, for the ESC Scientific Document Group . 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). <em>Eur Heart J</em>. 2018 Jan 7. 39 (2):119-77. <a href="https://www.qxmd.com/r/28886621">[QxMD MEDLINE Link]</a>. <a href="https://academic.oup.com/eurheartj/article/39/2/119/4095042" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. <em>Cochrane Database Syst Rev</em>. 2013 Aug 21. 8:CD007160. <a href="https://www.qxmd.com/r/23963794">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. <em>Circulation</em>. 2006 Jun 27. 113 (25):2906-13. <a href="https://www.qxmd.com/r/16785336">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. <em>JAMA</em>. 2000 Jul 5. 284 (1):60-7. <a href="https://www.qxmd.com/r/10872014">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. <em>Circulation</em>. 2004 Mar 16. 109 (10):1223-5. <a href="https://www.qxmd.com/r/15007008">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. <em>Circulation</em>. 2009 Mar 10. 119 (9):1293-303. <a href="https://www.qxmd.com/r/19273730">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Bates ER, Nallamothu BK. Commentary: the role of percutaneous coronary intervention in ST-segment-elevation myocardial infarction. <em>Circulation</em>. 2008 Jul 29. 118 (5):567-73. <a href="https://www.qxmd.com/r/18663104">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Ellis SG, Armstrong P, Betriu A, et al, for the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. <em>Am Heart J</em>. 2004 Apr. 147 (4):E16. <a href="https://www.qxmd.com/r/15077099">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Andersen HR, Nielsen TT, Rasmussen K, et al, for the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. <em>N Engl J Med</em>. 2003 Aug 21. 349 (8):733-42. <a href="https://www.qxmd.com/r/12930925">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Widimsky P, Budesínsky T, Vorac D, et al, for the 'PRAGUE' Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. <em>Eur Heart J</em>. 2003 Jan. 24 (1):94-104. <a href="https://www.qxmd.com/r/12559941">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Vaidya SR, Qamar A, Arora S, Devarapally SR, Kondur A, Kaul P. Culprit versus multivessel coronary intervention in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. <em>Coron Artery Dis</em>. 2018 Mar. 29 (2):151-60. <a href="https://www.qxmd.com/r/29120880">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Spitaleri G, Brugaletta S, Scalone G, et al. Role of ST-segment resolution in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention (from the 5-year outcomes of the EXAMINATION Trial) [in press]. <em>Am J Cardiol</em>. 7 Feb 2018. <a href="https://www.ajconline.org/article/S0002-9149(18)30157-7/abstract" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Rencuzogullari I, Cagdas M, Karabag Y, et al. Association of the SYNTAX Score II with cardiac rupture in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. <em>Coron Artery Dis</em>. 2018 Mar. 29 (2):97-103. <a href="https://www.qxmd.com/r/29028739">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. <em>Lancet</em>. 1994 Feb 5. 343 (8893):311-22. <a href="https://www.qxmd.com/r/7905143">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">White HD. Thrombolytic therapy in the elderly. <em>Lancet</em>. 2000 Dec 16. 356 (9247):2028-30. <a href="https://www.qxmd.com/r/11145486">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Van de Werf F, Barron HV, Armstrong PW, et al, for the ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. <em>Eur Heart J</em>. 2001 Dec. 22 (24):2253-61. <a href="https://www.qxmd.com/r/11728145">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Kodumuri V, Balasubramanian S, Vig A, et al. A meta-analysis comparing percutaneous coronary intervention with drug eluting stents versus coronary artery bypass grafting in unprotected left main disease [in press]. <em>Am J Cardiol</em>. 5 Feb 2018. <a href="https://www.ajconline.org/article/S0002-9149(18)30092-4/abstract" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Yusuf S, Mehta SR, Chrolavicius S, et al, for the OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. <em>JAMA</em>. 2006 Apr 5. 295 (13):1519-30. <a href="https://www.qxmd.com/r/16537725">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Giraldez RR, Nicolau JC, Corbalan R, et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. <em>Eur Heart J</em>. 2007 Jul. 28 (13):1566-73. <a href="https://www.qxmd.com/r/17562672">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. <em>Circulation</em>. 2003 Jul 15. 108 (2):135-42. <a href="https://www.qxmd.com/r/12847070">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. <em>Lancet</em>. 2001 Aug 25. 358 (9282):605-13. <a href="https://www.qxmd.com/r/11530146">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. <em>Lancet</em>. 2001 Dec 1. 358 (9296):1855-63. <a href="https://www.qxmd.com/r/11741625">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Henriksson R, Bjorklund F, Mooe T. The introduction of ticagrelor is associated with lower rates of recurrent ischemic stroke after myocardial infarction. <em>PLoS One</em>. 2019. 14 (5):e0216404. <a href="https://www.qxmd.com/r/31059535">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Wiviott SD, Braunwald E, McCabe CH, et al, for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. <em>N Engl J Med</em>. 2007 Nov 15. 357 (20):2001-15. <a href="https://www.qxmd.com/r/17982182">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Tcheng JE, Mackay SM. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. <em>Am J Cardiovasc Drugs</em>. 2012 Apr 1. 12 (2):83-91. <a href="https://www.qxmd.com/r/22316323">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Schnapf AJ. Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome. <em>J Cardiovasc Nurs</em>. 2013 Sep-Oct. 28 (5):483-94. <a href="https://www.qxmd.com/r/22990232">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Ryan TJ. Percutaneous coronary intervention in st-elevation myocardial infarction. <em>Curr Cardiol Rep</em>. 2001 Jul. 3(4):273-9. <a href="https://www.qxmd.com/r/11406084">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Berger JS, Sallum RH, Katona B, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. <em>Am Heart J</em>. 2012 Aug. 164 (2):153-162.e5. <a href="https://www.qxmd.com/r/22877800">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. <em>N Engl J Med</em>. 2010 Sep 2. 363 (10):930-42. <a href="https://www.qxmd.com/r/20818903">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. <em>Lancet</em>. 1996 Nov 16. 348 (9038):1329-39. <a href="https://www.qxmd.com/r/8918275">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Wallentin L, Becker RC, Budaj A,et al, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <em>N Engl J Med</em>. 2009 Sep 10. 361 (11):1045-57. <a href="https://www.qxmd.com/r/19717846">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. <em>Eur Heart J</em>. 2011 Dec. 32 (23):2945-53. <a href="https://www.qxmd.com/r/21804104">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. <em>N Engl J Med</em>. 1998 Aug 13. 339 (7):436-43. <a href="https://www.qxmd.com/r/9705684">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Gibson CM, Goel M, Cohen DJ, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. <em>J Am Coll Cardiol</em>. 1998 Jul. 32 (1):28-34. <a href="https://www.qxmd.com/r/9669245">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. <em>J Am Coll Cardiol</em>. 2000 Sep. 36 (3):693-8. <a href="https://www.qxmd.com/r/10987586">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. <em>JAMA</em>. 2004 Jul 7. 292 (1):89-96. <a href="https://www.qxmd.com/r/15238596">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. <em>Am Heart J</em>. 2006 Dec. 152 (6):1042-50. <a href="https://www.qxmd.com/r/17161049">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Stone GW, McLaurin BT, Cox DA, et al, for the ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. <em>N Engl J Med</em>. 2006 Nov 23. 355 (21):2203-16. <a href="https://www.qxmd.com/r/17124018">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Goto K, Lansky AJ, Fahy M, et al. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. <em>Circulation</em>. 2010 Feb 23. 121 (7):853-62. <a href="https://www.qxmd.com/r/20142447">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">FUTURA/OASIS-8 Trial Group, Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. <em>JAMA</em>. 2010 Sep 22. 304 (12):1339-49. <a href="https://www.qxmd.com/r/20805623">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Jolly SS, Faxon DP, Fox KA, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. <em>J Am Coll Cardiol</em>. 2009 Jul 28. 54 (5):468-76. <a href="https://www.qxmd.com/r/19628124">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. <em>JAMA</em>. 1995 May 10. 273 (18):1450-6. <a href="https://www.qxmd.com/r/7654275">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. <em>N Engl J Med</em>. 2000 Jan 20. 342 (3):145-53. <a href="https://www.qxmd.com/r/10639539">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. <em>N Engl J Med</em>. 2008 Apr 10. 358 (15):1547-59. <a href="https://www.qxmd.com/r/18378520">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. <em>N Engl J Med</em>. 2003 Apr 3. 348 (14):1309-21. <a href="https://www.qxmd.com/r/12668699">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Lopez-Jimenez F, Simha V, Thomas RJ, et al. A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. <em>Mayo Clin Proc</em>. 2014 Sep. 89 (9):1257-78. <a href="https://www.qxmd.com/r/25131697">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. <em>JAMA</em>. 2001 Apr 4. 285(13):1711-8. <a href="https://www.qxmd.com/r/11277825">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Patti G, Barczi G, Orlic D, et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. <em>J Am Coll Cardiol</em>. 2011 Oct 4. 58 (15):1592-9. <a href="https://www.qxmd.com/r/21958886">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Eckel RH, Jakicic JM, Ard JD, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <em>Circulation</em>. 2014 Jun 24. 129 (25 Suppl 2):S76-99. <a href="https://www.qxmd.com/r/24222015">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/129/25_suppl_2/S76" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. <em>Circulation</em>. 2019 Mar 17. CIR0000000000000678. <a href="https://www.qxmd.com/r/30879355">[QxMD MEDLINE Link]</a>. <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000678" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Jeffrey S. New AHA/ACC CVD primary prevention guideline. Medscape Medical News. Available at <a href="https://www.medscape.com/viewarticle/910513">https://www.medscape.com/viewarticle/910513</a>. March 17, 2019; Accessed: March 24, 2019.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">David TE. Operative management of postinfarction ventricular septal defect. <em>Semin Thorac Cardiovasc Surg</em>. 1995 Oct. 7(4):208-13. <a href="https://www.qxmd.com/r/8590745">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Gaudiani VA, Miller DG, Stinson EB, Oyer PE, Reitz BA, Moreno-Cabral RJ, et al. Postinfarction ventricular septal defect: an argument for early operation. <em>Surgery</em>. 1981 Jan. 89(1):48-55. <a href="https://www.qxmd.com/r/7466611">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Daggett WM, Buckley MJ, Akins CW, Leinbach RC, Gold HK, Block PC, et al. Improved results of surgical management of postinfarction ventricular septal rupture. <em>Ann Surg</em>. 1982 Sep. 196(3):269-77. <a href="https://www.qxmd.com/r/7114934">[QxMD MEDLINE Link]</a>. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1352596/" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Fish KM, Ishikawa K, Hajjar RJ. Stem cell therapy for acute myocardial infarction: on the horizon or still a dream?. <em>Coron Artery Dis</em>. 2018 Mar. 29 (2):89-91. <a href="https://www.qxmd.com/r/29140809">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Schachinger V, Erbs S, Elsasser A, et al, for the REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. <em>N Engl J Med</em>. 2006 Sep 21. 355 (12):1210-21. <a href="https://www.qxmd.com/r/16990384">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. <em>JAMA</em>. 2011 Nov 16. 306(19):2110-9. <a href="https://www.qxmd.com/r/22084195">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <em>Eur Heart J</em>. 2014 Oct 1. 35 (37):2541-619. <a href="https://www.qxmd.com/r/25173339">[QxMD MEDLINE Link]</a>. <a href="https://eurheartj.oxfordjournals.org/content/early/2014/09/10/eurheartj.ehu278" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <em>Circulation</em>. 2016 Mar 15. 133 (11):1135-47. <a href="https://www.qxmd.com/r/26490017">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/133/11/1135" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <em>Circulation</em>. 2011 Dec 6. 124 (23):e574-651. <a href="https://www.qxmd.com/r/22064601">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/124/23/e574.long" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <em>Circulation</em>. 2011 Dec 6. 124 (23):e652-735. <a href="https://www.qxmd.com/r/22064599">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/124/23/e652.long" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Kulik A, Ruel M, Jneid H, et al, for the American Heart Association Council on Cardiovascular Surgery and Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. <em>Circulation</em>. 2015 Mar 10. 131 (10):927-64. <a href="https://www.qxmd.com/r/25679302">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/131/10/927.full" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention. <em>J Am Coll Cardiol</em>. 2015 May 19. 65 (19):e7-e26. <a href="https://www.qxmd.com/r/25861963">[QxMD MEDLINE Link]</a>. <a href="https://www.onlinejacc.org/content/65/19/2140" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. <em>J Heart Lung Transplant</em>. 2013 Feb. 32 (2):157-87. <a href="https://www.qxmd.com/r/23352391">[QxMD MEDLINE Link]</a>. <a href="https://www.jhltonline.org/article/S1053-2498(12)01294-6/pdf" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable isc... <em>Circulation</em>. 2016 Sep 6. 134 (10):e123-55. <a href="https://www.qxmd.com/r/27026020">[QxMD MEDLINE Link]</a>. <a href="https://circ.ahajournals.org/content/early/2016/03/28/CIR.0000000000000404.long" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Sanofi-Aventis. FDA approves Praluent (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization [press release]. Available at <a href="https://www.news.sanofi.us/2019-04-26-FDA-approves-Praluent-R-alirocumab-to-prevent-heart-attack-stroke-and-unstable-angina-requiring-hospitalization" target="_blank">https://www.news.sanofi.us/2019-04-26-FDA-approves-Praluent-R-alirocumab-to-prevent-heart-attack-stroke-and-unstable-angina-requiring-hospitalization</a>. April 26, 2019; Accessed: April 30,2019.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Szarek M, White HD, Schwartz GG, et al, for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab reduces total nonfatal cardiovascular and fatal events: The ODYSSEY OUTCOMES Trial. <em>J Am Coll Cardiol</em>. 2019 Feb 5. 73 (4):387-96. <a href="https://www.qxmd.com/r/30428396">[QxMD MEDLINE Link]</a>. <a href="https://www.sciencedirect.com/science/article/pii/S0735109718389617?via%3Dihub" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Modi KA, Nylk TM, Sheridan FM. Medical management of acute ST elevation myocardial infarction. <em>J La State Med Soc</em>. 2001 Jun. 153(6):284-90. <a href="https://www.qxmd.com/r/11480378">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. <em>Chest</em>. 2001 Jan. 119(1 Suppl):253S-277S. <a href="https://www.qxmd.com/r/11157653">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Chou R, for the High Value Care Task Force of the American College of Physicians. Cardiac screening with electrocardiography, stress echocardiography, or myocardial perfusion imaging: advice for high-value care from the American College of Physicians. <em>Ann Intern Med</em>. 2015 Mar 17. 162 (6):438-47. <a href="https://www.qxmd.com/r/25775317">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Ferencik M. High-risk coronary plaque predicts acute coronary syndrome independently of &gt;50% coronary stenosis and cardiovascular risk factors in patients with acute chest pain: results from ROMICAT II trial (abstract 109). Presented at: Society of Cardiovascular Computed Tomography 2014 Annual Scientific Meeting; July 11, 2014; San Diego, California. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Busko M. High-risk plaque predicts ACS in ER patients with chest pain. <em>Heartwire</em>. July 18, 2014. <a href="https://www.medscape.com/viewarticle/828520">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Diaz-Zamudio M. Quantitative plaque burden from coronary CT angiography noninvasively predict lesion-specific ischemia in intermediate coronary lesions (abstract 231). Presented at: Society of Cardiovascular Computed Tomography 2014 Annual Scientific Meeting; July 12, 2014; San Diego, California. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Than M, Cullen L, Reid CM, Lim SH, et al. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. <em>Lancet</em>. 2011 Mar 26. 377 (9771):1077-84. <a href="https://www.qxmd.com/r/21435709">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Innocenti F, Lazzeretti D, Conti A, Zanobetti M, Vicidomini S, Pini R. Stress echocardiography in the ED: diagnostic performance in high-risk subgroups. <em>Am J Emerg Med</em>. 2013 Jul 1. <a href="https://www.qxmd.com/r/23827088">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Boggs W. Stress Echo Rules out Myocardial Ischemia in the ED. Medscape [serial online]. Available at <a href="https://www.medscape.com/viewarticle/808919">https://www.medscape.com/viewarticle/808919</a>. Accessed: August 12, 2013.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Terkelsen CJ, Sorensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. <em>JAMA</em>. 2010 Aug 18. 304 (7):763-71. <a href="https://www.qxmd.com/r/20716739">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Jeffrey S. AVOID Oxygen? Evidence of Harm in MI. <em>Medscape</em>. Nov 21 2014. <a href="https://www.medscape.com/viewarticle/835297">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Nainggolan L. New US STEMI Guidelines Are More User Friendly. Medscape News Dec 18, 2012. Available at <a href="https://www.medscape.com/viewarticle/776325">https://www.medscape.com/viewarticle/776325</a>. Accessed: February 6, 2013.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Niccoli G, Rigattieri S, De Vita MR, et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). <em>JACC Cardiovasc Interv</em>. 2013 Jun. 6 (6):580-9. <a href="https://www.qxmd.com/r/23683738">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. <em>Lancet</em>. 2011 Aug 20. 378(9792):693-703. <a href="https://www.qxmd.com/r/21856483">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. <em>Lancet</em>. 2011 Jun 25. 377(9784):2193-204. <a href="https://www.qxmd.com/r/21665265">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. <em>BMJ</em>. 2011 May 11. 342:d2690. <a href="https://www.qxmd.com/r/21562004">[QxMD MEDLINE Link]</a>. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092520/" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">AstraZeneca. US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack [news release]. Available at <a href="https://www.astrazeneca.com/Media/Press-releases/Article/20150903" target="_blank">https://www.astrazeneca.com/Media/Press-releases/Article/20150903</a>. September 3, 2015; Accessed: September 15, 2015.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. <em>N Engl J Med</em>. 2015 May 7. 372 (19):1791-800. <a href="https://www.qxmd.com/r/25773268">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. <em>Ann Oncol</em>. 2014 Aug 5. <a href="https://www.qxmd.com/r/25096604">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Bankhead C. Benefits add up for regular aspirin use. <em>MedPage Today</em>. August 5, 2014. <a href="https://www.medpagetoday.com/HematologyOncology/ColonCancer/47079" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Stiles S. L-Carnitine Retakes Spotlight, Hints at Survival Benefit in Acute MI: Meta-analysis. Medscape Medical News. Available at <a href="https://www.medscape.com/viewarticle/782488">https://www.medscape.com/viewarticle/782488</a>. Accessed: May 2, 2013.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. <em>Mayo Clin Proc</em>. 2013 Jun. 88 (6):544-51. <a href="https://www.qxmd.com/r/23597877">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Reuters Health Information. Prophylactic Lidocaine for Out-of-Hospital Cardiac Arrest Seen Helpful. Medscape [serial online]. Available at <a href="https://www.medscape.com/viewarticle/805805">https://www.medscape.com/viewarticle/805805</a>. Accessed: June 30, 2013.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Kudenchuk PJ, Newell C, White L, Fahrenbruch C, Rea T, Eisenberg M. Prophylactic lidocaine for post resuscitation care of patients with out-of-hospital ventricular fibrillation cardiac arrest. <em>Resuscitation</em>. 2013 Jun 3. <a href="https://www.qxmd.com/r/23743237">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Boggs W. Aspiration thrombectomy may improve angioplasty after acute MI. <em>Medscape Medical News</em>. May 13, 2013. <a href="https://www.medscape.com/viewarticle/804021">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Kumbhani DJ, Bavry AA, Desai MY, Bangalore S, Bhatt DL. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: An updated meta-analysis of randomized trials. <em>J Am Coll Cardiol</em>. 2013 May 8. <a href="https://www.qxmd.com/r/23665372">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Zaman S, Narayan A, Thiagalingam A, et al. Long-term arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia post myocardial infarction. <em>Circulation</em>. 2013 Dec 31. <a href="https://www.qxmd.com/r/24381209">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">O'Riordan M. Positive EP test helps ID post-MI patients for ICDs. <em>Heartwire</em>. January 2, 2014. <a href="https://www.medscape.com/viewarticle/818627">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Wood S. FDA Review Finds No Increased Risk of MI With Dabigatran (Pradaxa). Medscape Medical News. Available at <a href="https://www.medscape.com/viewarticle/825080">https://www.medscape.com/viewarticle/825080</a>. Accessed: May 27, 2014.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">FDA. FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at <a href="https://www.fda.gov/Drugs/DrugSafety/ucm396470.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm396470.htm</a>. Accessed: May 27, 2014.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">O'Riordan M. A shot in arm, a boost for the heart: flu vaccination reduces AMI risk. <em>Medscape Medical News</em>. August 26, 2013. <a href="https://www.medscape.com/viewarticle/810007">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Rao KK, Enriquez JR, de Lemos JA, Alexander KP, Chen AY, McGuire DK, et al. Use of aldosterone antagonists at discharge after myocardial infarction: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG). <em>Am Heart J</em>. 2013 Oct. 166(4):709-715. <a href="https://www.qxmd.com/r/24093851">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Stiles, S. Even With CKD, Warfarin Safely Cuts Events in AF After MI, Study Finds. Medscape Medical News. Available at <a href="https://www.medscape.com/viewarticle/821444">https://www.medscape.com/viewarticle/821444</a>. Accessed: March 12, 2014.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. <em>JAMA</em>. 2014 Mar 5. 311(9):919-28. <a href="https://www.qxmd.com/r/24595776">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients. US Food and Drug Administration. Available at <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm396585.htm" target="_blank">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm396585.htm</a>. Accessed: May 12, 2014.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. <em>PLoS One</em>. 2014. 9(1):e85805. <a href="https://www.qxmd.com/r/24489673">[QxMD MEDLINE Link]</a>. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905977/" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. <em>JAMA Intern Med</em>. 2013 Mar 4. 1-9. <a href="https://www.qxmd.com/r/23459863">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">O'Riordan M. Another study links testosterone therapy to MI risk. <em>Heartwire</em>. January 30, 2014. <a href="https://www.medscape.com/viewarticle/819968">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Quinn T, Johnsen S, Gale CP, Snooks H, McLean S, Woollard M, et al. Effects of prehospital 12-lead ECG on processes of care and mortality in acute coronary syndrome: a linked cohort study from the Myocardial Ischaemia National Audit Project. <em>Heart</em>. 2014 Apr 14. <a href="https://www.qxmd.com/r/24732676">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Stiles S. Prehospital ECG Cuts Mortality in STEMI and NSTEMI: UK Study. Medscape Medical News. Available at <a href="https://www.medscape.com/viewarticle/823754">https://www.medscape.com/viewarticle/823754</a>. Accessed: April 19, 2014.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Chughtai H, Ratner D, Pozo M, et al. Prehospital delay and its impact on time to treatment in ST-elevation myocardial infarction. <em>Am J Emerg Med</em>. 2011 May. 29 (4):396-400. <a href="https://www.qxmd.com/r/20825810">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Xiang L, Zhong A, You T, Chen J, Xu W, Shi M. Prognostic significance of right bundle branch block for patients with acute myocardial infarction: a systematic review and meta-analysis. <em>Med Sci Monit</em>. 2016 Mar 27. 22:998-1004. <a href="https://www.qxmd.com/r/27017617">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Kim KH, Jeon KN, Kang MG, et al. Prognostic value of computed tomographic coronary angiography and exercise electrocardiography for cardiovascular events. <em>Korean J Intern Med</em>. 2016 Mar 25. <a href="https://www.qxmd.com/r/27017387">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Hussain MA, Bin-Ayeed SA, Saeed OQ, Verma S, Al-Omran M. Impact of diabetes on carotid artery revascularization. <em>J Vasc Surg</em>. 2016 Apr. 63 (4):1099-1107.e4. <a href="https://www.qxmd.com/r/27016859">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Stetler J, Karatasakis A, Christakopoulos GE, et al. Impact of crossing technique on the incidence of periprocedural myocardial infarction during chronic total occlusion percutaneous coronary intervention. <em>Catheter Cardiovasc Interv</em>. 2016 Jul. 88 (1):1-6. <a href="https://www.qxmd.com/r/27014962">[QxMD MEDLINE Link]</a>. </p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Mizuno S, Kunisawa S, Sasaki N, Fushimi K, Imanaka Y. Effects of night-time and weekend admissions on in-hospital mortality in acute myocardial infarction patients in Japan. <em>PLoS One</em>. 2018. 13 (1):e0191460. <a href="https://www.qxmd.com/r/29351557">[QxMD MEDLINE Link]</a>. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774760/" target="_blank">[Full Text]</a>.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Brooks M. FDA approves evolocumab (Repatha) to prevent CV events. Medscape Medical News. Available at <a href="https://www.medscape.com/viewarticle/889513">https://www.medscape.com/viewarticle/889513</a>. December 1, 2017; Accessed: December 7., 2017.</p></li>
        <li><p xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">[Guideline] Wong GC, Welsford M, Ainsworth C, et al, for members of the Secondary Panel. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology guidelines on the acute management of ST-elevation myocardial infarction: focused update on regionalization and reperfusion. <em>Can J Cardiol</em>. 2019 Feb. 35 (2):107-32. <a href="https://www.qxmd.com/r/30760415">[QxMD MEDLINE Link]</a>. <a href="https://www.onlinecjc.ca/article/S0828-282X(18)31321-7/fulltext" target="_blank">[Full Text]</a>.</p></li>
       </ol>
      </div>
     </div><!--PPE-81698: media_gallery_layer-->
     <div xmlns:xs="https://www.w3.org/2001/XMLSchema" id="imageGallery" class="inactive">
      <div class="gallery_header">
       Media Gallery<span class="close_gallery"></span>
      </div>
      <div class="gallery-content">
       <div class="enlargeThisImage"></div>
       <div class="imagelayer_rtcol">
        <div id="carousel">
         <ul>
          <!--TODO BNReddy need to change graphic[1]/@format=('IMAGE','VIDEO')--><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/17/34917.jpg-->
          <li id="reimageid1">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/17/34917.jpg"></div>
           <div class="captionWrapper">
            Acute anterior myocardial infarction. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/18/34918.jpg-->
          <li id="reimageid2">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/18/34918.jpg"></div>
           <div class="captionWrapper">
            Acute inferior myocardial infarction. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/19/34919.jpg-->
          <li id="reimageid3">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/19/34919.jpg"></div>
           <div class="captionWrapper">
            Acute posterolateral myocardial infarction. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/20/34920.jpg-->
          <li id="reimageid4">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/20/34920.jpg"></div>
           <div class="captionWrapper">
            A 53-year-old patient who had experienced 3 hours of chest pain had a 12-lead electrocardiogram performed, and the results are as shown. He was given sublingual nitroglycerin and developed severe symptomatic hypotension. His blood pressure normalized with volume resuscitation. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/21/34921.jpg-->
          <li id="reimageid5">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/21/34921.jpg"></div>
           <div class="captionWrapper">
            The right-sided leads indicate ST-segment elevations in RV&lt;inf&gt;3&lt;/inf&gt; to RV&lt;inf&gt;5&lt;/inf&gt;, which are consistent with a right ventricular infarct. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/22/34922.png-->
          <li id="reimageid6">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/22/34922.png"></div>
           <div class="captionWrapper">
            Timing of release of various cardiac biomarker peaks after the onset of myocardial infarction
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/23/34923.jpg-->
          <li id="reimageid7">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/23/34923.jpg"></div>
           <div class="captionWrapper">
            Modified 2-dimensional (top) echocardiogram and color flow Doppler image (bottom). Apical 4-chamber views show a breach in the interventricular septum and free communication between ventricles through a large apical septum ventricular septal defect in a patient who recently had an anterior myocardial infarction. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/24/34924.jpg-->
          <li id="reimageid8">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/24/34924.jpg"></div>
           <div class="captionWrapper">
            Apical 2-chamber view depicts a large left ventricular apical thrombus with mobile extensions. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/25/34925.jpg-->
          <li id="reimageid9">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/25/34925.jpg"></div>
           <div class="captionWrapper">
            Parasternal long-axis view of the left ventricle demonstrates a large inferobasal aneurysm. Note the wide neck and base of the aneurysm. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/26/34926.jpg-->
          <li id="reimageid10">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/26/34926.jpg"></div>
           <div class="captionWrapper">
            Acute myocardial infarct. At 3 days, there is a zone of yellow necrosis surrounded by darker hyperemic borders. The arrow points to a transmural infarct in the posterior wall of the left ventricle, in this short axis slice through the left and right ventricular chambers. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/27/34927.jpg-->
          <li id="reimageid11">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/27/34927.jpg"></div>
           <div class="captionWrapper">
            Acute myocardial infarction, reperfusion type. In this case, the infarct is diffusely hemorrhagic. There is a rupture track through the center of this posterior left ventricular transmural infarct. The mechanism of death was hemopericardium. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/28/34928.jpg-->
          <li id="reimageid12">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/28/34928.jpg"></div>
           <div class="captionWrapper">
            Healing myocardial infarction, lateral left ventricle. In this heart, there is a variegated or mottled appearance to the lateral left ventricle (left). This infarct began 19 days prior to death. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/29/34929.jpg-->
          <li id="reimageid13">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/29/34929.jpg"></div>
           <div class="captionWrapper">
            Early healed myocardial infarction, anterior septum. There is a glistening gelatinous appearance to this infarction, which occurred 6 weeks prior to death, from embolization during valve surgery. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/30/34930.jpg-->
          <li id="reimageid14">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/30/34930.jpg"></div>
           <div class="captionWrapper">
            Healed myocardial infarction, anterior left ventricle. There is diffuse scarring (white) with marked thinning of the ventricle (aneurysm). 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/31/34931.jpg-->
          <li id="reimageid15">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/31/34931.jpg"></div>
           <div class="captionWrapper">
            Acute myocardial infarct. The earliest change is hypereosinophilia (above) with an intense pink cytoplasm. There is no inflammation at border between the necrotic myocardium and the viable myocardium (left and below), indicating that the necrosis is about 12-24 hours in age. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/32/34932.jpg-->
          <li id="reimageid16">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/32/34932.jpg"></div>
           <div class="captionWrapper">
            Acute myocardial infarct. After 24 hours, there is a neutrophilic infiltrate at the border of the infarct. Viable myocardium is at the left, and neutrophils with apoptosis (karyorrhexis) are seen infiltrating the necrotic muscle. This patient experienced abdominal pain 35 hours prior to death. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/33/34933.jpg-->
          <li id="reimageid17">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/33/34933.jpg"></div>
           <div class="captionWrapper">
            Healing myocardial infarct. This patient died 8 days after experiencing sudden chest pain at rest. There is a large area of necrosis with hypereosinophilia of myocytes, with a rim of viable myocardium at the very bottom. At the border, there is chronic inflammation with early granulation tissue, with ingrowth of endothelial cells. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/34/34934.jpg-->
          <li id="reimageid18">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/34/34934.jpg"></div>
           <div class="captionWrapper">
            Healing myocardial infarct. At 10 days to 2 weeks, there is chronic inflammation, hemosiderin-laden macrophages, and early fibroblasts without significant collagen deposition. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/35/34935.jpg-->
          <li id="reimageid19">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/35/34935.jpg"></div>
           <div class="captionWrapper">
            Healed myocardial infarct. At 3 months, there is dense scar, which is blue on this Masson trichrome stain. This infarct was subendocardial, in the posterior left ventricle near the ventricular septum. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/36/34936.jpg-->
          <li id="reimageid20">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/36/34936.jpg"></div>
           <div class="captionWrapper">
            This is a posteroanterior view of a right ventricular endocardial activation map during ventricular tachycardia in a patient with a previous septal myocardial infarction. Earliest activation is recorded in red; late activation shows as blue to magenta. Fragmented low-amplitude diastolic local electrocardiograms were recorded adjacent to the earliest (red) breakout area, and local ablation in this scarred zone (red dots) resulted in termination and noninducibility of this previously incessant arrhythmia. 
           </div></li><!--BNReddy: imagesWidgets xslt figure:carousel:full-url: //img.medscapestatic.com/pi/meds/ckb/37/34937.jpg-->
          <li id="reimageid21">
           <div class="imgWrapper" data-rel="//img.medscapestatic.com/pi/meds/ckb/37/34937.jpg"></div>
           <div class="captionWrapper">
            A color-enhanced angiogram of the heart left shows a plaque-induced obstruction (top center) in a major artery, which can lead to myocardial infarction (MI). MIs can precipitate heart failure. 
           </div></li>
         </ul>
        </div>
       </div>
       <div class="imageLayer_ad">
        <div id="adtagrightcol_imglayer"></div>
       </div>
      </div>
      <div id="overlayLayer2">
       <div class="gallery_counter2">
        <div id="prevImgbtn"></div>
        <div id="nextImgbtn"></div>
        <div class="gallery-item-num">
         <span id="currentImg"></span> of <span id="totalImg">21</span>
        </div>
       </div>
      </div>
     </div><!--Table layer -->
     <div xmlns:xs="https://www.w3.org/2001/XMLSchema" id="clinref-table-layer" class="modal-layer inactive">
      <div class="modal-header">
       <div class="close-modal"></div>
       <h6>Tables</h6>
      </div>
      <div class="modal-content">
       <div id="tablelayer_right">
        <div id="adtagrightcol_tablelayer"></div>
       </div>
       <div id="tablelayer_left">
        <div id="tablelist_layer" class="active">
         <div class="tablelist">
          <ul>
           <li><a href="javascript:showModal('clinref-table-layer', 'td0b69fcde');" onclick="wmdPageLink('cr-tbl_1');">Table 1.&nbsp;Absolute and Relative Contraindications to Fibrinolytic Therapy in Patients with STEMI</a></li>
           <li><a href="javascript:showModal('clinref-table-layer', 't2074863fc');" onclick="wmdPageLink('cr-tbl_1');">Table 2.&nbsp;Fibrinolytic Agents Used in Management of STEMI.</a></li>
          </ul>
         </div>
        </div>
        <div id="tablecontent_layer" class="inactive">
         <div id="td0b69fcde" class="tablelayer_content">
          <div class="table_title">
           Table 1.&nbsp;Absolute and Relative Contraindications to Fibrinolytic Therapy in Patients with STEMI
          </div>
          <div class="table_scrolllayer">
           <table id="table-td0b69fcde" class="datatable">
            <tbody xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">
             <tr>
              <td><strong>Absolute Contraindications</strong></td>
              <td><strong>Relative Contraindications</strong></td>
             </tr>
             <tr>
              <td><!--itemizedlist-->
               <ul class="topbullet-para">
                <!--listitem-->
                <li>
                 <div>
                  Any prior intracranial hemorrhage
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Known structural cerebral vascular lesion
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Known intracranial neoplasm (primary or metastatic)
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Ischemic stroke within the past 3 months (except for acute stroke within 4.5 hours)
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Suspected aortic dissection
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Active bleeding or bleeding diathesis (excluding menses)
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Significant closed-head or facial trauma within 3 months
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Intracranial or intraspinal surgery within 2 months
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Severe uncontrolled hypertension (unresponsive to emergency therapy)
                 </div></li><!--listitem-->
                <li>
                 <div>
                  For streptokinase (no longer marketed in the US): Prior treatment within previous 6 months
                 </div></li>
               </ul></td>
              <td><!--itemizedlist-->
               <ul class="topbullet-para">
                <!--listitem-->
                <li>
                 <div>
                  History of chronic, severe, poorly controlled hypertension
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Systolic pressure &gt;180 mm Hg or diastolic pressure &gt;110 mm Hg
                 </div></li><!--listitem-->
                <li>
                 <div>
                  History of prior ischemic stroke &gt;3 months
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Dementia
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Known intracranial pathology not covered in absolute contraindications
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Traumatic or prolonged CPR (&gt;10 minutes)
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Recent (within 2-4 weeks) internal bleeding
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Noncompressible vascular punctures
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Pregnancy
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Active peptic ulcer disease
                 </div></li><!--listitem-->
                <li>
                 <div>
                  Current use of anticoagulants: The higher the INR, the higher the risk of bleeding
                 </div></li><!--listitem-->
                <li>
                 <div>
                  For streptokinase (no longer marketed in the US): Prior exposure (&gt;5 days previously) or prior allergic reaction to these agents
                 </div></li>
               </ul></td>
             </tr>
             <tr>
              <td colspan="2"><p>CPR = cardiopulmonary resuscitation; INR = international normalized ratio;&nbsp;STEMI =&nbsp;ST-elevation myocardial infarction; US = United States of America.</p><p>&nbsp;</p><p>Table modified from 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>] </sup></p></td>
             </tr>
            </tbody>
           </table>
          </div>
         </div>
         <div id="t2074863fc" class="tablelayer_content">
          <div class="table_title">
           Table 2.&nbsp;Fibrinolytic Agents Used in Management of STEMI.
          </div>
          <div class="table_scrolllayer">
           <table id="table-t2074863fc" class="datatable">
            <tbody xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">
             <tr>
              <td><p><strong>Fibrinolytic Agent</strong></p></td>
              <td><p><strong>Dose</strong></p></td>
              <td><p><strong>Fibrin Specificity</strong></p></td>
              <td><p><strong>Antigenic</strong></p></td>
              <td><p><strong>Patency Rate</strong></p></td>
             </tr>
             <tr>
              <td><p><strong>Non-fibrin specific</strong></p></td>
              <td>&nbsp;</td>
              <td><p>&nbsp;</p></td>
              <td><p>&nbsp;</p></td>
              <td><p>&nbsp;</p></td>
             </tr>
             <tr>
              <td><p>Streptokinase (no longer marketed in the US)</p></td>
              <td><p>1.5 million units IV given over 30–60 min</p></td>
              <td><p>No</p></td>
              <td><p>Yes</p></td>
              <td><p>60%–68%</p></td>
             </tr>
             <tr>
              <td><p><strong>Fibrin specific</strong></p></td>
              <td>&nbsp;</td>
              <td><p>&nbsp;</p></td>
              <td><p>&nbsp;</p></td>
              <td><p>&nbsp;</p></td>
             </tr>
             <tr>
              <td><p>Tenecteplase</p><p>(TNK-tPA)</p></td>
              <td><p>30 mg for weight &lt; 60 kg</p><p>35 mg for 60–69 kg</p><p>40 mg for 70–79 kg</p><p>45 mg for 80–89 kg</p><p>50 mg for &gt;90 kg</p></td>
              <td><p>++++</p></td>
              <td><p>No</p></td>
              <td><p>85%</p></td>
             </tr>
             <tr>
              <td><p>Reteplase (rPA)</p></td>
              <td><p>10-U IV boluses given 30 min apart</p></td>
              <td><p>++</p></td>
              <td><p>No</p></td>
              <td><p>84%</p></td>
             </tr>
             <tr>
              <td><p>Alteplase (tPA)</p></td>
              <td><p>Bolus 15 mg followed by infusion 0.75 mg/kg for 30 min (maximum 50 mg), then 0.5 mg/kg (maximum 35 mg) over the next 60 min; total dose not to exceed 100 mg.</p></td>
              <td><p>++</p></td>
              <td><p>No</p></td>
              <td><p>73%-84%</p></td>
             </tr>
             <tr>
              <td colspan="5"><p>IV = intravenous; rPA = recombinant human tissue plasminogen activator; STEMI =&nbsp;ST-elevation myocardial infarction;&nbsp;tPA = tissue plasminogen activator; US = United States of America.</p><p>&nbsp;</p><p>Table modified from 2013 ACCF/AHA guidelines for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.<sup><!--reference_ids_tool_tip reference_ids--> [<a onclick="showToolTip(this,'references-layer','2')" href="javascript:void(0);">2</a>] </sup></p></td>
             </tr>
            </tbody>
           </table>
          </div>
         </div>
         <div class="table_layer_bar">
          <div id="prevtablebtn">
           <a><img border="0" src="https://img.medscape.com/pi/reference/slide_btn.png" alt="Previous"></a>
          </div>
          <div id="nexttablebtn">
           <a><img border="0" src="https://img.medscape.com/pi/reference/slide_btn.png" alt="Next"></a>
          </div>
          <div id="reftable_num"></div>
         </div>
         <div id="link_tablelist">
          <a href="javascript:void(0)">Back to List</a>
         </div>
        </div>
       </div>
      </div>
     </div>
     <noscript xmlns:xs="https://www.w3.org/2001/XMLSchema">
      <style>#author-disclosures{display:block}#author-disclosures.modal-layer{position:relative}#author-disclosures .modal-content{max-height:none}#author-disclosures .close-modal{display:none}</style>
     </noscript><!--Authors Layer--><!--Output version : web-->
     <div xmlns:xs="https://www.w3.org/2001/XMLSchema" id="author-disclosures" class="modal-layer inactive">
      <div class="modal-header">
       <div class="close-modal">
        <span><a href="javascript:showModal('inactive');"></a></span>
       </div>
       <h6>Contributor Information and Disclosures </h6>
      </div>
      <div class="modal-content" id="authorinfo">
       <!--author layer --><!--author_block-->
       <div class="layer_title2">
        Author
       </div>
       <p><strong>A Maziar Zafari, MD, PhD, FACC, FAHA</strong> Professor of Medicine, Emory University School of Medicine; Chief of Cardiology, Atlanta Veterans Affairs Health Care System; Adjunct Professor of Medicine, Morehouse School of Medicine<br><br><!--Output version : web-->A Maziar Zafari, MD, PhD, FACC, FAHA is a member of the following medical societies: <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.cardiosource.org" target="_blank">American College of Cardiology</a>, <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.heart.org" target="_blank">American Heart Association</a><br><br>Disclosure: Nothing to disclose.</p><!--author_block-->
       <div class="layer_title2">
        Coauthor(s)
       </div>
       <p><strong>Mahmoud H Abdou, MD</strong> Fellow, Division of Cardiology, Emory University School of Medicine <br><br><!--Output version : web-->Mahmoud H Abdou, MD is a member of the following medical societies: <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.cardiosource.org" target="_blank">American College of Cardiology</a>, <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.acponline.org" target="_blank">American College of Physicians</a>, Libyan Medical Association<br><br>Disclosure: Nothing to disclose.</p>
       <div class="layer_title2">
        Specialty Editor Board
       </div><!--author_block-->
       <p><strong>Francisco Talavera, PharmD, PhD</strong> Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference<br><br>Disclosure: Received salary from Medscape for employment. for: Medscape.</p><!--author_block-->
       <p><strong>Yasmine S Ali, MD, MSCI, FACC, FACP</strong> Assistant Clinical Professor of Medicine, Vanderbilt University School of Medicine; President, LastSky Writing, LLC<br><br><!--Output version : web-->Yasmine S Ali, MD, MSCI, FACC, FACP is a member of the following medical societies: <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.cardiosource.org" target="_blank">American College of Cardiology</a>, <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.acponline.org" target="_blank">American College of Physicians</a>, <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.heart.org" target="_blank">American Heart Association</a>, <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://ama-assn.org" target="_blank">American Medical Association</a>, <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.amwa.org" target="_blank">American Medical Writers Association</a>, <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.lipid.org" target="_blank">National Lipid Association</a>, <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.tnmed.org" target="_blank">Tennessee Medical Association</a><br><br>Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: LastSky Writing, LLC;Philips Healthcare;M Health; AKH, Inc.; PeerView Institute; LearnRoll, LLC; Kaplan; RxCe.com; M3 USA; ChesterPA511&lt;br/&gt;Serve(d) as a speaker or a member of a speakers bureau for: RxCe.com.</p><!--author_block-->
       <div class="layer_title2">
        Chief Editor
       </div>
       <p><strong>Eric H Yang, MD</strong> Associate Professor of Medicine, Director of Cardiac Catherization Laboratory and Interventional Cardiology, Mayo Clinic ArizonA<br><br><!--Output version : web-->Eric H Yang, MD is a member of the following medical societies: <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.alphaomegaalpha.org/" target="_blank">Alpha Omega Alpha</a><br><br>Disclosure: Nothing to disclose.</p><!--author_block-->
       <div class="layer_title2">
        Additional Contributors
       </div>
       <p><strong>Samer M Garas, MD, FACC, FSCAI</strong> Interventional Cardiologist, President, St Vincent's Health System Cardiovascular Council<br><br><!--Output version : web-->Samer M Garas, MD, FACC, FSCAI is a member of the following medical societies: <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.cardiosource.org" target="_blank">American College of Cardiology</a><br><br>Disclosure: Nothing to disclose.</p>
       <p><strong>Ahmad M Jeroudi, MD</strong> Fellow in Cardiovascular Disease, Division of Cardiology, Emory University School of Medicine<br><br>Disclosure: Nothing to disclose.</p>
       <p><strong>Shilpa V Reddy, MD</strong> Fellow in Cardiovascular Disease, Division of Cardiology, Emory University School of Medicine<br><br><!--Output version : web-->Shilpa V Reddy, MD is a member of the following medical societies: <a xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com" href="https://www.cardiosource.org" target="_blank">American College of Cardiology</a><br><br>Disclosure: Nothing to disclose.</p>
       <div class="layer_title2">
        Acknowledgements
       </div>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com"><strong>David FM Brown, MD</strong> Associate Professor, Division of Emergency Medicine, Harvard Medical School; Vice Chair, Department of Emergency Medicine, Massachusetts General Hospital</p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">David FM Brown, MD is a member of the following medical societies: <a href="https://www.acep.org/" target="_blank">American College of Emergency Physicians</a> and <a href="https://www.saem.org/" target="_blank">Society for Academic Emergency Medicine</a></p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Disclosure: Nothing to disclose. </p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com"><strong>Drew Evan Fenton, MD, FAAEM</strong> Private Practice </p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Disclosure: Nothing to disclose.</p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com"><strong>Gary Setnik, MD</strong> Chair, Department of Emergency Medicine, Mount Auburn Hospital; Assistant Professor, Division of Emergency Medicine, Harvard Medical School</p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Gary Setnik, MD is a member of the following medical societies: <a href="https://www.acep.org/" target="_blank">American College of Emergency Physicians</a>, <a href="https://www.naemsp.org/" target="_blank">National Association of EMS Physicians</a>, and <a href="https://www.saem.org/" target="_blank">Society for Academic Emergency Medicine</a></p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Disclosure: SironaHealth Salary Management position; South Middlesex EMS Consortium Salary Management position; ProceduresConsult.com Royalty Other </p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com"><strong>Francisco Talavera, PharmD, PhD</strong> Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference</p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Disclosure: Medscape Salary Employment </p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com"><strong>Eric Vanderbush, MD, FACC</strong> Chief, Department of Internal Medicine, Division of Cardiology, Harlem Hospital Center; Clinical Assistant Professor of Cardiology, Columbia University College of Physicians and Surgeons</p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Eric Vanderbush, MD, FACC is a member of the following medical societies: <a href="https://www.acc.org/" target="_blank">American College of Cardiology</a> and <a href="https://www.americanheart.org/presenter.jhtml?identifier=1200000" target="_blank">American Heart Association</a></p>
       <p xmlns:fn="https://www.w3.org/2005/xpath-functions" xmlns:qnafn="https://www.webmd.com">Disclosure: Nothing to disclose. </p>
      </div>
     </div><!--BNR: Print Option Layer--><!--contentId: 155919--><!--printURL: https://emedicine.medscape.com/article/155919-print-->
     <div xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" id="ref_print_options" class="modal-layer inactive">
      <div class="modal-header">
       <div class="close-modal">
        <span><a href="javascript:showModal('inactive');">Close</a></span>
       </div>
       <h6>What would you like to print?</h6>
      </div>
      <div class="modal-content">
       <span class="print_text"><b>What would you like to print?</b></span>
       <ul>
        <li id="printsection"><a href="javascript:ClinRefPrint1();">Print this section<span id="print_secttionname"></span></a></li>
        <li id="printall"><a href="javascript:ClinRefPrint2();">Print the entire contents of <span id="print_h1name"></span></a></li>
        <li id="printallsections"><a href="https://emedicine.medscape.com/article/155919-print" target="Figure" onclick="hideModal('ref_print_options'); resizeWin('Figure',400,520);">Print the entire contents of article</a></li>
       </ul>
      </div>
     </div><!--BAR: /Print Option Layer-->
     <div class="ads-container">
      <div id="ads-pos-904" class="AdUnit"></div>
      <script>
					webmd.ads2.defineAd({
					id: 'ads-pos-904',
					pos: 904
					});
				</script>
      <div id="ads-pos-906" class="AdUnit"></div>
      <script>
					webmd.ads2.defineAd({
					id: 'ads-pos-906',
					pos: 906
					});
				</script>
      <div id="ads-pos-907" class="AdUnit"></div>
      <script>
					webmd.ads2.defineAd({
					id: 'ads-pos-907',
					pos: 907
					});
				</script>
     </div>
     <div id="rel-links-container"></div>
    </div><!--multilevel menu for leftnav, Inside article-content, after	articledbmain-->
    <div xmlns:xs="https://www.w3.org/2001/XMLSchema" xmlns:fn="https://www.w3.org/2005/xpath-functions" class="sections-nav" style="">
     <ul>
      <!--ul_nav_for_article pagemode=multipage-->
      <li class="sections-nav-title">
       <div class="nav-title">
        Sections <span class="nav-title-name">Myocardial Infarction</span>
       </div></li>
      <li><a href="javascript:void(0)">Overview</a><!--sub_menu_second_level skip=false-->
       <ul>
        <!--display_second_level_menu sect1-link='overview', sect1-position=1--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=false-->
        <li class="li_1-1 "><a href="155919-overview#a1" onclick="wmdTrack('cr-ln1_1');">Practice Essentials</a></li>
        <li class="li_1-2 "><a href="155919-overview#a2" onclick="wmdTrack('cr-ln1_2');">Background</a></li>
        <li class="li_1-3 "><a href="155919-overview#a9" onclick="wmdTrack('cr-ln1_3');">Definitions</a></li>
        <li class="li_1-4 "><a href="155919-overview#a4" onclick="wmdTrack('cr-ln1_4');">Pathophysiology</a></li>
        <li class="li_1-5 "><a href="155919-overview#a5" onclick="wmdTrack('cr-ln1_5');">Etiology</a></li>
        <li class="li_1-6 "><a href="155919-overview#a6" onclick="wmdTrack('cr-ln1_6');">Epidemiology</a></li>
        <li class="li_1-7 "><a href="155919-overview#a7" onclick="wmdTrack('cr-ln1_7');">Prognosis</a></li>
        <li class="li_1-8 "><a href="155919-overview#a8" onclick="wmdTrack('cr-ln1_8');">Patient Education</a></li>
        <li class="li_showall"><a href="155919-overview#showall" onclick="wmdTrack('cr-ln1_showall');">Show All</a></li>
       </ul></li>
      <li><a href="javascript:void(0)">Presentation</a><!--sub_menu_second_level skip=false-->
       <ul>
        <!--display_second_level_menu sect1-link='clinical', sect1-position=2--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=false-->
        <li class="li_2-1 "><a href="155919-clinical#b1" onclick="wmdTrack('cr-ln2_1');">History</a></li>
        <li class="li_2-2 "><a href="155919-clinical#b3" onclick="wmdTrack('cr-ln2_2');">Physical Examination</a></li>
        <li class="li_showall"><a href="155919-clinical#showall" onclick="wmdTrack('cr-ln2_showall');">Show All</a></li>
       </ul></li>
      <li class="no_subsection"><!--current section name=differential--><a href="155919-differential" onclick="wmdTrack('cr-ln3_0')" style="">DDx</a></li>
      <li><a href="javascript:void(0)">Workup</a><!--sub_menu_second_level skip=false-->
       <ul>
        <!--display_second_level_menu sect1-link='workup', sect1-position=4--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=false-->
        <li class="li_4-1 "><a href="155919-workup#c1" onclick="wmdTrack('cr-ln4_1');">Approach Considerations</a></li>
        <li class="li_4-2 "><a href="155919-workup#c13" onclick="wmdTrack('cr-ln4_2');">Electrocardiography</a></li>
        <li class="li_4-3 "><a href="155919-workup#c8" onclick="wmdTrack('cr-ln4_3');">Cardiac Biomarkers</a></li>
        <li class="li_4-4 "><a href="155919-workup#c9" onclick="wmdTrack('cr-ln4_4');">Cardiac Troponin</a></li>
        <li class="li_4-5 "><a href="155919-workup#c17" onclick="wmdTrack('cr-ln4_5');">B-Type Natriuretic Peptide</a></li>
        <li class="li_4-6 "><a href="155919-workup#c16" onclick="wmdTrack('cr-ln4_6');">Other Laboratory Studies</a></li>
        <li class="li_4-7 "><a href="155919-workup#c14" onclick="wmdTrack('cr-ln4_7');">Cardiac Imaging</a></li>
        <li class="li_showall"><a href="155919-workup#showall" onclick="wmdTrack('cr-ln4_showall');">Show All</a></li>
       </ul></li>
      <li><a href="javascript:void(0)">Treatment</a><!--sub_menu_second_level skip=false-->
       <ul>
        <!--display_second_level_menu sect1-link='treatment', sect1-position=5--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=true-->
        <li class="li_5-1 "><a href="#d1" data-wmdtrack="cr-ln5_1" data-wmdpageview="{hash:'#d1',page:'1'}">Approach Considerations</a></li>
        <li class="li_5-2 "><a href="#d5" data-wmdtrack="cr-ln5_2" data-wmdpageview="{hash:'#d5',page:'2'}">Prehospital Care and Initial Management</a></li>
        <li class="li_5-3 "><a href="#d6" data-wmdtrack="cr-ln5_3" data-wmdpageview="{hash:'#d6',page:'3'}">Emergency Department Care and In-Hospital Management</a></li>
        <li class="li_5-4 "><a href="#d25" data-wmdtrack="cr-ln5_4" data-wmdpageview="{hash:'#d25',page:'4'}">ST-Elevation Myocardial Infarction</a></li>
        <li class="li_5-5 "><a href="#d26" data-wmdtrack="cr-ln5_5" data-wmdpageview="{hash:'#d26',page:'5'}">Non-ST-Elevation (NSTE) ACS</a></li>
        <li class="li_5-6 "><a href="#d7" data-wmdtrack="cr-ln5_6" data-wmdpageview="{hash:'#d7',page:'6'}">Additional Aspects of Management and Late Hospital Care</a></li>
        <li class="li_5-7 "><a href="#d19" data-wmdtrack="cr-ln5_7" data-wmdpageview="{hash:'#d19',page:'7'}">Complications</a></li>
        <li class="li_5-8 "><a href="#d15" data-wmdtrack="cr-ln5_8" data-wmdpageview="{hash:'#d15',page:'8'}">Future and Emerging Therapies</a></li>
        <li class="li_showall"><a href="#showall" data-wmdtrack="cr-ln_all" data-wmdpageview="{hash:'showall', page:'5'}">Show All</a></li>
       </ul></li>
      <li><a href="javascript:void(0)">Guidelines</a><!--sub_menu_second_level skip=false-->
       <ul>
        <!--display_second_level_menu sect1-link='guidelines', sect1-position=6--><!--display_second_level_menu isMedication=false, isMultiPage=true, current=false-->
        <li class="li_6-1 "><a href="155919-guidelines#g1" onclick="wmdTrack('cr-ln6_1');">Guidelines Summary</a></li>
        <li class="li_6-2 "><a href="155919-guidelines#g2" onclick="wmdTrack('cr-ln6_2');">Percutaneous Coronary Intervention</a></li>
        <li class="li_6-3 "><a href="155919-guidelines#g3" onclick="wmdTrack('cr-ln6_3');">Coronary Artery Bypass Grafting</a></li>
        <li class="li_6-4 "><a href="155919-guidelines#g4" onclick="wmdTrack('cr-ln6_4');">Mechanical Circulatory Support</a></li>
        <li class="li_6-5 "><a href="155919-guidelines#g5" onclick="wmdTrack('cr-ln6_5');">Dual Antiplatelet Therapy</a></li>
        <li class="li_showall"><a href="155919-guidelines#showall" onclick="wmdTrack('cr-ln6_showall');">Show All</a></li>
       </ul></li>
      <li><a href="javascript:void(0)">Medication</a><!--sub_menu_second_level skip=false-->
       <ul>
        <!--display_second_level_menu sect1-link='medication', sect1-position=7--><!--display_second_level_menu isMedication=true, isMultiPage=true, current=false-->
        <li class="li_7-1 "><a href="155919-medication#1" onclick="wmdTrack('cr-ln7_1');">Medication Summary</a></li>
        <li class="li_7-2 "><a href="155919-medication#2" onclick="wmdTrack('cr-ln7_2');">Antiplatelet Agents</a></li>
        <li class="li_7-3 "><a href="155919-medication#3" onclick="wmdTrack('cr-ln7_3');">Antithrombotic Agents</a></li>
        <li class="li_7-4 "><a href="155919-medication#4" onclick="wmdTrack('cr-ln7_4');">Glycoprotein IIb/IIIa Inhibitors</a></li>
        <li class="li_7-5 "><a href="155919-medication#5" onclick="wmdTrack('cr-ln7_5');">Vasodilators</a></li>
        <li class="li_7-6 "><a href="155919-medication#6" onclick="wmdTrack('cr-ln7_6');">Beta-adrenergic blockers</a></li>
        <li class="li_7-7 "><a href="155919-medication#7" onclick="wmdTrack('cr-ln7_7');">Angiotensin-Converting Enzyme Inhibitors</a></li>
        <li class="li_7-8 "><a href="155919-medication#8" onclick="wmdTrack('cr-ln7_8');">Angiotensin-Receptor Blockers</a></li>
        <li class="li_7-9 "><a href="155919-medication#9" onclick="wmdTrack('cr-ln7_9');">Thrombolytics</a></li>
        <li class="li_7-10 "><a href="155919-medication#10" onclick="wmdTrack('cr-ln7_10');">Analgesics</a></li>
        <li class="li_7-11 "><a href="155919-medication#11" onclick="wmdTrack('cr-ln7_11');">PCSK9 Inhibitors</a></li>
        <li class="li_showall"><a href="155919-medication#showall" onclick="wmdTrack('cr-ln7_showall');">Show All</a></li>
       </ul></li>
      <li class="multimedia_link no_subsection"><a href="javascript:refImgShow('001');">Media Gallery</a></li>
      <li class="tables_link no_subsection"><a href="javascript:showModal('clinref-table-layer')">Tables</a></li>
      <li class="reference_link no_subsection"><a href="javascript:showModal('references-layer');">References</a></li>
     </ul>
    </div>
   </div>
  </div>
 </div>
 <div id="rightcol" class="column column-right">
  <div id="related-pos1"></div>
  <div id="adcontainer_rightcol">
   <div id="adtagrightcol">
    <div id="ads-pos-122" class="AdUnit"></div>
    <script>
						webmd.ads2.defineAd({
						id: 'ads-pos-122',
						pos: 122
						});
					</script>
   </div>
   <div id="adspace918">
    <div id="ads-pos-918" class="AdUnit"></div>
    <script>
						webmd.ads2.defineAd({ id: 'ads-pos-918', pos: 918 });
					</script>
   </div>
   <div id="related-pos2"></div>
   <div id="adtagrightcol_bottom"></div>
   <div id="adspace910">
    <div id="ads-pos-910" class="AdUnit"></div>
    <script>
						webmd.ads2.defineAd({
						id: 'ads-pos-910',
						pos: 910
						});
					</script>
   </div>
   <div id="related-pos3"></div>
  </div>
 </div>
</div>


    <!-- tiles:insert name="footer" /-->
    <div id="whiteoutlayer"></div>

    <link rel="stylesheet"
          href="//img.medscapestatic.com/medscape-core/reference/css/clinref/clinref_print.css"
          type="text/css" media="print"/>
    
    
    
    <link rel="stylesheet"
          href="//img.medscapestatic.com/medscape-core/reference/css/article/dd-article-common.css"
          type="text/css" media="screen"/>
    <script type="text/javascript" src="//img.medscapestatic.com/medscape-core/reference/js/article/dd-article.js"></script>
    
    

    <!-- FOOTER TAG STARTS HERE -->
    </div>


<div id="footercontents">
<div class="adhesive-footer-wrapper">
	<div class="adhesive-footer_content">
	<div id="ads-af-pos-145" class="AdUnit"></div>
		<script>
			var adId = document.querySelector('.adhesive-footer_content .AdUnit').id;
			webmd.ads2.defineAd({
				id: adId,
				pos: 145
			});
		</script>
	</div>
</div>

<div class="mobile_adlabelleft">
		<div id="ads-pos-1005" class="AdUnit"></div>
			<script>
				webmd.ads2.defineAd({
				id: 'ads-pos-1005',
				pos: 1005
				});
			</script>
		</div>
	<!-- FOOTER -->


<div class="page-footer">

	<div class="footer-global resp-container">

		<div class="footer-logo">
			<img class="footer-logo-image" src="//img.medscapestatic.com/pi/logos/mscp-logo.png" alt="Medscape Logo" width="127" height="28" />
		</div>
	</div>

	<div class="footer-global resp-container">

		<div class="footer-social">
			<div class="footer-heading">Find Us On</div>
			<a href="https://facebook.com/medscape" target="_top" id="footer_fb" onclick="wmdPageLink('ft-sm_fb', this);" aria-label="Facebook">
				<svg title="Facebook" width="32" height="32" viewBox="0 0 32 32" xmlns="https://www.w3.org/2000/svg">
  <g fill="none" fill-rule="evenodd">
    <rect fill="#064aa7" width="32" height="32" rx="3"/>
    <path d="M13.99 23.77h2.38v-8.33h2.61l.274-2.38H16.37v-1.525c0-.586.886-.855 1.16-.855h1.22V8.238l-1.96-.01c-2.576 0-2.8 1.92-2.8 3.15v1.682H12.8v2.38h1.19v8.33" fill="#FFF"/>
  </g>
</svg>
</a>
	        <a href="https://twitter.com/medscape" target="_top" id="footer_twit" onclick="wmdPageLink('ft-sm_twit', this);" aria-label="Twitter">
	        	<svg width="32" height="32" viewBox="0 0 32 32" xmlns="https://www.w3.org/2000/svg">
	<g fill="none" fill-rule="evenodd">
		<rect fill="#064aa7" width="32" height="32" rx="3" />
		<svg width="32" height="32" viewBox="-6 0 30 18" fill="none" xmlns="https://www.w3.org/2000/svg">
			<g clip-path="url(#clip0_17_1372)">
				<path d="M10.1486 7.925L15.2457 2H14.0378L9.612 7.14459L6.07709 2H2L7.34547 9.77954L2 15.9928H3.20793L7.88172 10.5599L11.6148 15.9928H15.6919L10.1483 7.925H10.1486ZM8.49414 9.84808L7.95253 9.07341L3.64316 2.90931H5.49846L8.97618 7.88394L9.51778 8.6586L14.0384 15.1249H12.1831L8.49414 9.84837V9.84808Z" fill="white"/>
			</g>
			<defs>
				<clipPath id="clip0_17_1372">
					<rect width="20" height="20" fill="white" />
				</clipPath>
			</defs>
		</svg>
	</g>
</svg>
</a>
	        <a href="https://www.linkedin.com/company/24356" target="_top" id="footer_li" onclick="wmdPageLink('ft-sm_li', this);" aria-label="Linkedin">
	        	<svg title="Linkedin" width="32" height="32" viewBox="0 0 32 32" xmlns="https://www.w3.org/2000/svg" xmlns:xlink="https://www.w3.org/1999/xlink">
  <defs>
    <path id="a" d="M3.607.007H0V3.26h3.607V.007z"/>
  </defs>
  <g fill="none" fill-rule="evenodd">
    <rect fill="#064aa7" width="32" height="32" rx="3"/>
    <g transform="translate(9 9.035)">
      <mask id="b" fill="#fff">
        <use xlink:href="#a"/>
      </mask>
      <path d="M0 1.42C.065 1.155.137.896.31.676c.397-.503.942-.682 1.567-.67.55.012 1.032.187 1.38.623.668.835.405 2.308-1.02 2.58-.594.115-1.164.043-1.655-.344-.307-.243-.486-.562-.555-.94C.022 1.897.01 1.87 0 1.845V1.42" fill="#FFF" mask="url(#b)"/>
    </g>
    <path d="M14.18 22.98v-9.396h3.196v1.307c.05-.06.08-.09.1-.122.678-.97 1.624-1.423 2.818-1.41.694.008 1.35.147 1.95.505.61.366 1.03.888 1.308 1.525.304.697.405 1.433.406 2.184.005 1.768.002 3.535.002 5.302 0 .033-.004.065-.007.107H20.75v-.168c0-1.682 0-3.363-.007-5.045-.002-.387-.065-.767-.235-1.122-.26-.544-.766-.842-1.384-.82-.8.03-1.453.5-1.665 1.242-.07.242-.076.507-.077.762-.006 1.657-.003 3.315-.003 4.973v.177h-3.2zM9.2 13.584h3.186v9.398c-.05.003-.093.008-.136.008-.968 0-1.937-.002-2.905.003-.122 0-.156-.033-.156-.15.002-3.04.002-6.08.002-9.12 0-.042.004-.084.007-.14" fill="#FFF"/>
  </g>
</svg>
</a>
	        <a href="https://www.youtube.com/user/medscape/" target="_top" id="footer_tube" onclick="wmdPageLink('ft-sm_tube', this);" aria-label="Youtube">
	        	<svg title="Youtube" width="32px" height="32px" viewBox="0 0 32 32" xmlns="https://www.w3.org/2000/svg" xmlns:xlink="https://www.w3.org/1999/xlink">

  <defs>
    <path id="x" d="M19.773 21.548v23.91H0V.024h19.773v21.525H0v23.91h19.773V21.55z"/>
  </defs>
  <g fill="none" fill-rule="evenodd">
    <rect fill="#064aa7" width="32" height="32" rx="3"/>
    <g transform="translate(7 7.007)">
      <mask id="y" fill="#fff">
        <use xlink:href="#x"/>
      </mask>
      <path d="M10.486 13.837c0-.46.003-.922-.003-1.383-.002-.112.02-.192.132-.23.118-.04.234-.105.355-.12.156-.016.244.073.27.233.01.072.012.148.012.222V15.235c-.014.34-.196.454-.512.32-.245-.106-.254-.12-.254-.38v-1.34M14.56 13.284c0-.295-.015-.582.003-.866.014-.218.17-.325.403-.318.234.006.368.118.377.345.01.276.002.552.002.84h-.786z" fill="#FFF" mask="url(#y)"/>
      <path d="M1.72 9.645v.67c0 .2 0 .2.2.2h.88v5.825h1.172v-.185c0-1.824.002-3.647-.003-5.47 0-.14.04-.178.172-.173.275.01.55 0 .824.004.103.002.14-.033.136-.137-.007-.19-.01-.378 0-.565.01-.143-.044-.173-.174-.173-1.01.005-2.022.003-3.033.003H1.72zm12.852 4.362h1.718c.078 0 .146.004.145-.11-.005-.48.012-.963-.01-1.442-.023-.486-.262-.84-.72-1.03-.39-.162-.795-.16-1.2-.09-.625.108-.994.515-1.02 1.155-.025.58-.018 1.16-.018 1.738 0 .337-.01.676.02 1.01.045.466.253.835.703 1.033.288.127.587.15.893.135.313-.015.61-.082.874-.27.467-.33.55-.944.452-1.535h-1.06v.165c-.006.174-.003.348-.02.52-.02.2-.17.32-.376.32-.236-.003-.372-.103-.38-.324-.01-.413-.002-.83-.002-1.273zM8.225 16.35c.006-.036.012-.055.012-.074 0-1.605 0-3.21.002-4.816 0-.1-.046-.115-.127-.114-.25.003-.5 0-.75 0-.216.002-.216.002-.216.216 0 1.234 0 2.468-.002 3.702 0 .058-.013.142-.05.17-.09.065-.194.12-.3.15-.252.074-.388-.03-.405-.293-.005-.063-.005-.127-.005-.192v-3.553c0-.197 0-.197-.188-.198-.24 0-.48.008-.72-.003-.14-.006-.184.033-.183.18.006 1.055.002 2.11.003 3.166 0 .282-.002.565.006.847.01.306.06.598.367.757.326.168.654.157.97-.025.172-.1.333-.22.507-.334.025.117.044.225.074.33.01.032.052.08.08.08.306.005.614.003.925.003zm2.257-6.705c-.316 0-.615.006-.913-.003-.132-.003-.175.03-.175.172.005 2.12.003 4.24.003 6.36v.164h1.098v-.433c.172.125.325.25.49.355.487.313 1.318.154 1.336-.63.002-.063.012-.127.012-.192.002-1 .004-2 .003-3 0-.14-.014-.278-.02-.416-.025-.575-.527-.765-.908-.72-.303.033-.538.2-.765.385-.046.038-.093.074-.163.13V9.644zM0 11.295c.036-.153.067-.308.108-.46.307-1.145 1.028-1.908 2.134-2.28.33-.11.693-.154 1.042-.155 3.954-.01 7.91-.007 11.864-.003 1.04 0 1.91.395 2.573 1.213.35.43.566.924.66 1.47.013.073.035.143.052.215v3.508c-.018.076-.04.15-.055.228-.062.344-.166.675-.34.976-.634 1.095-1.582 1.677-2.837 1.68-3.99.01-7.98.002-11.968.005-1.5.003-2.813-1.033-3.142-2.5L0 14.803v-3.508z" fill="#FFF" mask="url(#y)"/>
    </g>
    <path d="M22.04 14.403c-.34 0-.664.004-.987-.004-.04-.002-.097-.058-.11-.1-.036-.11-.05-.23-.077-.355-.203.134-.39.267-.585.385-.37.225-.915.185-1.202-.112-.106-.11-.178-.275-.21-.427-.043-.215-.046-.442-.046-.664-.004-1.343 0-2.685-.006-4.028 0-.148.034-.2.187-.192.284.012.57.01.854 0 .123-.003.157.04.156.16-.004 1.324-.002 2.647-.002 3.97 0 .08 0 .158.008.237.022.236.143.35.373.305.154-.03.3-.114.44-.19.03-.02.036-.106.036-.16.002-1.374.002-2.746.002-4.118v-.19h1.172v5.483zM10.118 7.03c.444 0 .87-.002 1.297.004.033 0 .086.057.096.097.198.787.39 1.575.582 2.363l.07.296c.016 0 .032 0 .048.003.037-.164.072-.328.112-.49.177-.726.355-1.45.538-2.175.01-.038.065-.093.1-.093.412-.007.823-.005 1.257-.005-.052.164-.096.314-.145.46-.364 1.11-.717 2.22-1.102 3.32-.137.39-.175.776-.17 1.18.01.737.002 1.475.002 2.213v.19h-1.27v-.175c0-.723-.02-1.447.006-2.17.02-.51-.085-.985-.248-1.462-.39-1.14-.76-2.288-1.14-3.433-.01-.032-.016-.065-.032-.123M16.372 11.67v-.09c-.005-.493 0-.988-.017-1.482-.007-.236-.177-.367-.43-.37-.214-.006-.372.126-.406.345-.015.088-.02.177-.02.266v2.64c0 .09.005.18.022.266.045.24.196.354.44.343.234-.01.375-.147.398-.39.008-.08.01-.16.01-.238.002-.43.002-.86.002-1.292m1.177-.014c0 .48.008.96-.003 1.44-.018.743-.436 1.242-1.188 1.343-.437.057-.87.055-1.286-.126-.476-.207-.683-.6-.742-1.09-.02-.163-.02-.327-.02-.49-.003-.758-.012-1.516.004-2.273.005-.262.04-.535.12-.785.124-.38.415-.62.794-.73.544-.16 1.09-.156 1.61.08.45.204.67.593.694 1.072.027.518.006 1.04.006 1.56h.01" fill="#FFF"/>
  </g>
</svg>
</a>
	        <a href="https://www.instagram.com/medscape/" target="_top" id="footer_insta" onclick="wmdPageLink('ft-sm_insta', this);" aria-label="Instagram">
	        	<svg title="Instagram" width="32px" height="32px" viewBox="0 0 32 32" xmlns="https://www.w3.org/2000/svg" xmlns:xlink="https://www.w3.org/1999/xlink">

  <defs>
    <path id="a" d="M8 16H0V0h16v16z"/>
  </defs>
  <g fill="none" fill-rule="evenodd">
    <rect fill="#064aa7" width="32" height="32" rx="3"/>
    <g transform="translate(8 8)">
      <mask id="b" fill="#fff">
        <use xlink:href="#a"/>
      </mask>
      <path d="M7.953 14.487v-.003c1.186 0 2.373.027 3.558-.01.878-.025 1.675-.303 2.27-1.006.488-.577.692-1.267.698-1.997.022-2.29.045-4.584 0-6.875-.037-1.92-1.14-3.018-3.058-3.077-1.958-.06-3.918-.062-5.877-.06-.597.002-1.205.048-1.787.17-1.35.28-2.2 1.33-2.23 2.838-.044 2.33-.05 4.664-.002 6.995.04 1.865 1.165 2.956 3.03 3.02 1.133.04 2.266.007 3.4.007M0 11.2V4.8c.025-.183.064-.364.074-.548C.196 2.187 1.507.626 3.508.192 3.932.103 4.368.063 4.8 0h6.4c.182.026.363.064.546.075 2.038.12 3.557 1.373 4.032 3.36.113.473.15.963.222 1.445v6.16c-.027.235-.066.47-.08.706-.116 2.03-1.372 3.56-3.35 4.03-.5.117-1.02.15-1.53.224H4.88c-.21-.027-.417-.067-.627-.08C2.18 15.803.6 14.466.183 12.456.1 12.04.06 11.618 0 11.2" fill="#FFF" mask="url(#c)"/>
    </g>
    <path d="M15.984 18.65c1.49.005 2.665-1.163 2.666-2.648 0-1.472-1.157-2.646-2.618-2.655-1.496-.01-2.678 1.146-2.685 2.627-.008 1.492 1.155 2.672 2.637 2.676m-4.09-2.67c.015-2.294 1.844-4.102 4.133-4.085 2.29.017 4.097 1.853 4.073 4.142-.023 2.277-1.838 4.07-4.11 4.063-2.293-.007-4.11-1.834-4.095-4.12M21.22 11.714c.008.536-.41.974-.94.983-.516.01-.972-.432-.984-.952-.012-.522.42-.96.955-.968.552-.007.965.39.97.937" fill="#FFF"/>
  </g>
</svg>
</a>
		</div>

		<div class="footer-sections">

			<div class="footer-col footer-about">
				<div class="footer-heading">About</div>
				<a href="https://www.medscape.com/public/about" onclick="wmdTrack('ft-lk_about', this)">About Medscape</a>
				<a href="https://www.medscape.com/public/privacy" target="Figure" onclick="wmdTrack('ft-lk_privacy', this); resizeWin('Figure',400,520)">Privacy Policy</a>
				<a href="https://www.medscape.com/public/editorialpolicies" onclick="wmdTrack('ft-lk_editor', this)">Editorial Policy</a>
				<a href="https://www.medscape.com/public/cookies" target="Figure" onclick="wmdTrack('ft-lk_cookies', this); resizeWin('Figure',400,520)">Cookies</a>
				<style>a#ot-sdk-btn.ot-sdk-show-settings { display: none; border: none; padding: 0 !important; color: #222 !important; font-size: .875rem !important; margin: 0 0 14px 0 !important; } a#ot-sdk-btn.ot-sdk-show-settings:hover { color: #005b81; background-color: transparent; } a#ot-sdk-btn.ot-sdk-show-settings.active { display: inline-block !important; } a#ot-sdk-btn.ot-sdk-show-settings.ib-your-choices { background: url(//icons.internetbrands.com/ccpa/privacyoptions29x14.png) no-repeat 98% 50%; padding-right: 37px !important; }</style>
				<a id="ot-sdk-btn" class="ot-sdk-show-settings" onclick="OneTrust.ToggleInfoDisplay(); wmdPageLink('ft-lk_nosell', this);" href="javascript:void(0);">Manage Preferences</a>
				<script>if (document.getElementById('ot-stub') != null) { document.getElementById('ot-sdk-btn').classList.add('active'); if (!userInEU) { document.getElementById('ot-sdk-btn').classList.add('ib-your-choices'); } }</script>
				<a href="https://www.medscape.com/public/termsofuse" target="Figure" onclick="wmdTrack('ft-lk_terms', this); resizeWin('Figure',400,520)">Terms of Use</a>
				<a href="https://www.medscape.com/public/adpolicy" target="Figure" onclick="wmdTrack('ft-lk_adpol', this); resizeWin('Figure',400,520)">Advertising Policy</a>
				<a onclick="wmdTrack('ft-lk_help', this);" href="https://help.medscape.com/">Help Center</a>
			</div>


			<div class="footer-col footer-membership">
				<div class="footer-heading">Membership</div>
				<a onclick="wmdTrack('ft-lk_mem', this);" href="https://profreg.medscape.com/px/registration.do?lang=en">Become a Member</a></li>
				<a onclick="wmdTrack('ft-lk_abt', this);" href="https://www.medscape.com/profile">About You</a>
				<a onclick="wmdTrack('ft-lk_prof', this);" href="https://www.medscape.com/profile/professional">Professional Information</a>
				<a onclick="wmdTrack('ft-lk_nlsub', this);" href="https://www.medscape.com/newsletters">Newsletters &amp; Alerts</a>
				<a id="mktg-advertise" style="display: none;" onclick="wmdTrack('ft-lk_mktg-advertise', this);" href="https://www.medscape.com/advertise">Advertise</a>
				<script>if (typeof PageMetadata != 'undefined' && typeof PageMetadata.reqHeaders != 'undefined' && typeof PageMetadata.reqHeaders.geoc != 'undefined' && PageMetadata.reqHeaders.geoc == 'US') { document.getElementById('mktg-advertise').style.display = 'block'; }</script>
				<a onclick="wmdTrack('ft-lk_mktg', this);" href="https://www.medscape.com/marketresearch">Market Research</a>
			</div>


			<div class="footer-col footer-apps">
				<div class="footer-heading"><a href="https://www.medscape.com/public/applanding">App</a></div>
				<a onclick="wmdPageLink('ft-lk_medapp', this);" href="https://medscape.onelink.me/U6kk?pid=Medscape_footer&af_web_dp=https%3A%2F%2Fwww.medscape.com%2Fpublic%2Fmedscapeapp&c=FooterIcon&af_dp=medscape%3A%2F%2Fhost">Medscape</a>
			</div>


			<div class="footer-col footer-edition">
				<div class="footer-heading">Editions</div>
				<a onclick="wmdTrack('ft-lk_en', this);" href="https://www.medscape.com" target="_parent">English</a>
				<a onclick="wmdTrack('ft-lk_de', this);" href="https://deutsch.medscape.com" target="_parent">Deutsch</a>
				<a onclick="wmdTrack('ft-lk_es', this);" href="https://espanol.medscape.com" target="_parent">Español</a>
				<a onclick="wmdTrack('ft-lk_fr', this);" href="https://francais.medscape.com" target="_parent">Français</a>
				<a onclick="wmdTrack('ft-lk_pt', this);" href="https://portugues.medscape.com" target="_parent">Português</a>
			</div>

		</div>
	</div>

	<div class="footer_legal-text resp-container">
		All material on this website is protected by copyright, Copyright &copy; 1994-2025 by WebMD LLC.  This website also contains material copyrighted by 3rd parties.
	</div>


<!-- Hidden Iframe -->
<div id="idetailiframewrapper" class="inactive">
	<div id="idetailwinbg">
		<div id="layerbtns">
			<button type="button" id="closepres" name="closepres" value="Close" onclick="removeidetailiframe();">Close</button>
		</div>

		<iframe id="idetailiframe" marginwidth="0" marginheight="0" frameborder="0" style="margin: 0; padding: 0;" scrolling="auto" allowtransparency="true" bordercolor="#FFFFFF" src=""></iframe>
	</div>
</div>
<!-- /Hidden Iframe -->
<script async type="text/javascript" src="//img.medscapestatic.com/medscape-core/shared-all/js/vendor/medscape-vt.js" defer></script>

	<!-- User Notification Start -->

<!-- Build Ad Tag -->
	<script type="text/javascript" src="//img.medscapestatic.com/pi/scripts/ads/build-ad-tag.js" defer></script>
<!-- /Build Ad Tag -->
<!-- Communications Platform  -->
<script type="text/javascript" src="//img.medscapestatic.com/medscape-core/shared-all/js/cp/cp.js"></script>
<!-- /Communications Platform  -->


<!-- begin fc-multisite -->
<link rel="stylesheet" href="//img.medscapestatic.com/medscape-core/common/css/global/global-common.css" type="text/css"  media="all" />
<script>
window.webmd = window.webmd || {};
window.webmd.domainName = 'emedicine.medscape.com';
window.webmd.dmainCategory = 'emedicine';
</script>
<!-- multisite include -->
<script type="text/javascript">var isMscpApp = false;</script>
<script type="text/javascript" src="//img.medscapestatic.com/medscape-core/shared-all/js/medscape/medscape-site.js"></script>
<!-- /multisite include -->

<script language="javascript1.2" type="text/javascript"><!-- 
	var s_user_origin = "Undefined"
	var s_user_specialty = "Undefined"
	var s_account = "webmdcom"
	var s_user_group = "Anonymous"
	var s_auth_channel_id = "100-0"

//-->
</script>
<script language="javascript1.2" type="text/javascript"
src="https://img.medscapestatic.com/pi/scripts/omniture/bi_medscape.js?d=05/15/2025"></script>

</div>
</div>

    <!-- /FOOTER TAG ENDS HERE -->

        
    <div class="inactive">
        









    <div id="ads-pos-1918" class="AdUnit"></div>
    <script>
        webmd.ads2.defineAd({id: 'ads-pos-1918', pos: 1918});
    </script>

<!-- related links -->
<div id="rel-links">
    <script>
        var leadConcept = "Myocardial Infarction";
        var leadSpecialities = "Cardiology";
    </script>
    <span style="display:none">encoded search term (Myocardial Infarction) and Myocardial Infarction </span>


    <div class="rel-links-title-h5">What to Read Next on Medscape</div>
    <div class="related-links">
        
            <!-- col 1 -->

            
                
                    
                        <div class="rel-links-list" id="indications-card" data-max='6'>
                            <div class="rel-links-title-h6">Related Conditions and Diseases</div>
                            <ul>
                                
                                    <li>
                                        
                                            
                                                
                                                
                                                
                                                    <a onclick="wmdTrack('rl-disease')" href="https://emedicine.medscape.com/article/155919-overview">
                                                        <span>Myocardial Infarction</span>
                                                    </a>
                                                
                                            
                                        
                                    </li>
                                
                                    <li>
                                        
                                            
                                                
                                                
                                                
                                                    <a onclick="wmdTrack('rl-disease')" href="https://emedicine.medscape.com/article/164924-overview">
                                                        <span>Complications of Myocardial Infarction</span>
                                                    </a>
                                                
                                            
                                        
                                    </li>
                                
                                    <li>
                                        
                                            
                                                
                                                
                                                
                                                    <a onclick="wmdTrack('rl-disease')" href="https://emedicine.medscape.com/article/897453-overview">
                                                        <span>Myocardial Infarction in Childhood</span>
                                                    </a>
                                                
                                            
                                        
                                    </li>
                                
                                    <li>
                                        
                                            
                                                
                                                
                                                
                                                    <a onclick="wmdTrack('rl-disease')" href="https://emedicine.medscape.com/article/1960472-overview">
                                                        <span>Pathology of Acute Myocardial Infarction</span>
                                                    </a>
                                                
                                            
                                        
                                    </li>
                                
                                    <li>
                                        
                                            
                                                
                                                
                                                
                                                    <a onclick="wmdTrack('rl-disease')" href="https://emedicine.medscape.com/article/350175-overview">
                                                        <span>Acute Myocardial Infarction Imaging</span>
                                                    </a>
                                                
                                            
                                        
                                    </li>
                                
                                    <li>
                                        
                                            
                                                
                                                
                                                    <a onclick="wmdTrack('rl-disease')" href="https://reference.medscape.com/calculator/thrombolysis-myocardial-infarction-timi-unstable">
                                                        <span>Thrombolysis in Myocardial Infarction (TIMI) Score for Unstable Angina Non ST Elevation Myocardial Infarction</span>
                                                    </a>
                                                
                                                
                                            
                                        
                                    </li>
                                
                                    <li>
                                        
                                            
                                                
                                                
                                                    <a onclick="wmdTrack('rl-disease')" href="https://reference.medscape.com/calculator/thrombolysis-myocardial-infarction-timi-st">
                                                        <span>Thrombolysis in Myocardial Infarction (TIMI) Score for STEMI</span>
                                                    </a>
                                                
                                                
                                            
                                        
                                    </li>
                                
                            </ul>
                        </div>
                    
                
            


            <!-- /col 1 -->
            <!-- col 2 -->

            
                
                    <div class="rel-links-card" id="news-card">
                        <div class="rel-links-title-h6">News &amp; Perspective</div>
                        <ul>
                            
                                <li>
                                    
                                        
                                        
                                        
                                            
                                            <a onclick="wmdTrack('rl-news')" href="https://www.medscape.com/viewarticle/higher-dietary-cholesterol-intake-raises-risk-myocardial-2025a1000491">
                                                
                                                
                                                
                                                <span>Higher Dietary Cholesterol Intake Raises Risk for Myocardial Infarction in Veterans</span>
                                            </a>
                                            
                                </li>
                            
                                <li>
                                    
                                        
                                        
                                        
                                            
                                            <a onclick="wmdTrack('rl-news')" href="https://www.medscape.com/viewarticle/hospital-arn-inhibitors-reduce-major-cv-events-patients-2024a1000n6w">
                                                
                                                
                                                
                                                <span>In-Hospital ARN Inhibitors Reduce Major CV Events in Patients With Acute Myocardial Infarction</span>
                                            </a>
                                            
                                </li>
                            
                                <li>
                                    
                                        
                                        
                                        
                                            
                                            <a onclick="wmdTrack('rl-news')" href="https://www.medscape.com/viewarticle/treatment-prehospital-pulse-dose-glucocorticoid-fails-reduce-2024a1000g00">
                                                
                                                
                                                
                                                <span>Treatment With Prehospital Pulse-Dose Glucocorticoid Fails to Reduce Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction</span>
                                            </a>
                                            
                                </li>
                            
                                <li>
                                    
                                        
                                        
                                        
                                            
                                            <a onclick="wmdTrack('rl-news')" href="https://www.medscape.com/viewarticle/1002528">
                                                
                                                
                                                
                                                    
                                                        
                                                        
                                                        
                                                        
                                                            
                                                        
                                                        <span><img src="https://img.medscapestatic.com/pi/global/1x1.png" data-src="https://img.medscapestatic.com/thumbnail_library/TWIC_thumbnail_800x450.jpg?interpolation=lanczos-none&amp;resize=234:*" alt="May 09, 2025 This Week in Cardiology Podcast"></span>
                                                    
                                                
                                                <span>May 09, 2025 This Week in Cardiology Podcast</span>
                                            </a>
                                            
                                </li>
                            
                                <li>
                                    
                                        
                                        
                                        
                                            
                                            <a onclick="wmdTrack('rl-news')" href="https://www.medscape.com/viewarticle/1002487">
                                                
                                                
                                                
                                                    
                                                        
                                                        
                                                        
                                                        
                                                            
                                                        
                                                        <span><img src="https://img.medscapestatic.com/pi/global/1x1.png" data-src="https://img.medscapestatic.com/thumbnail_library/TWIC_thumbnail_800x450.jpg?interpolation=lanczos-none&amp;resize=234:*" alt="Apr 25, 2025 This Week in Cardiology Podcast"></span>
                                                    
                                                
                                                <span>Apr 25, 2025 This Week in Cardiology Podcast</span>
                                            </a>
                                            
                                </li>
                            
                                <li>
                                    
                                        
                                        
                                        
                                            
                                            <a onclick="wmdTrack('rl-news')" href="https://www.medscape.com/viewarticle/1002473">
                                                
                                                
                                                
                                                    
                                                        
                                                        
                                                        
                                                        
                                                            
                                                        
                                                        <span><img src="https://img.medscapestatic.com/pi/global/1x1.png" data-src="https://img.medscapestatic.com/thumbnail_library/TWIC_thumbnail_800x450.jpg?interpolation=lanczos-none&amp;resize=234:*" alt="Apr 18, 2025 This Week in Cardiology Podcast"></span>
                                                    
                                                
                                                <span>Apr 18, 2025 This Week in Cardiology Podcast</span>
                                            </a>
                                            
                                </li>
                            
                        </ul>
                    </div>
                
            

            <div class="rel-links-card" id="tools-card">
                <div class="rel-links-title-h6">Tools</div>
                <ul>
                    <li><a onclick="wmdTrack('rl-tools')" href="https://reference.medscape.com/drug-interactionchecker" class="interaction-checker">Drug Interaction Checker</a></li>
                    <li><a onclick="wmdTrack('rl-tools')"
                           href="https://reference.medscape.com/pill-identifier"
                           class="pill-id">Pill Identifier</a></li>
                    <li><a onclick="wmdTrack('rl-tools')" href="https://reference.medscape.com/guide/medical-calculators/alpha" class="calculators">Calculators</a></li>
                    <li><a onclick="wmdTrack('rl-tools')" href="https://reference.medscape.com/features/drugs/formulary-plans" class="formulary">Formulary</a></li>
                </ul>
            </div>
            <!-- /col 2 -->
            <!-- col 3 -->
            


            
                
                    <div class="rel-links-card" id="slideshow-card">
                        <div class="rel-links-title-h6">Slideshow</div>
                        
                        
                        
                        
                        <a onclick="wmdTrack('rl-ss')" href="https://reference.medscape.com/slideshow/broken-heart-syndrome-6012067">
                            
                            
                                
                                
                                    
                                        
                                        
                                        
                                        
                                            
                                        
                                        <span><img src="https://img.medscapestatic.com/pi/global/1x1.png"
                                                   data-src="https://img.medscapestatic.com/thumbnail_library/broken-heart-2025-thumb.jpg?interpolation=lanczos-none&amp;resize=234:*"
                                                   class="featimg" alt="Keys to Diagnosing Broken Heart Syndrome (Takotsubo Cardiomyopathy)"></span>
                                    
                                
                                <span>Keys to Diagnosing Broken Heart Syndrome (Takotsubo Cardiomyopathy)</span>
                            </a>
                            
                    </div>
                
            

            <!-- /col 3 -->

            <div class="rel-links-media"></div>
            


            
                
                    <div id="rel-recommend" class="rel-div" data-max='3'>
                        <div class="title-h3">Recommended</div>
                        <ul>
                            
                                <li>
                                    <div class="inactive">
                                            2002
                                            155919-overview
                                            Diseases & Conditions
                                        
                                            
                                                
                                                
                                                
                                                    
                                                
                                                
                                                
                                            
                                        
                                        
                                    </div>
                                    
                                        
                                        
                                            <span>Diseases & Conditions</span>
                                            <a onclick="wmdTrack('rl-rr')" href="https://emedicine.medscape.com/article/155919-overview">
                                                
                                                    
                                                        
                                                        
                                                        
                                                        
                                                            
                                                        
                                                        
                                                        
                                                            <img src="https://img.medscapestatic.com/pi/global/1x1.png"
                                                                 data-src="https://img.medscapestatic.com/pi/meds/ckb/17/34917tn.jpg?interpolation=lanczos-none&amp;resize=75:*"
                                                                 alt="Myocardial Infarction">
                                                        
                                                    
                                                
                                                <span>Myocardial Infarction</span>
                                            </a>
                                        
                                    
                                </li>
                            
                                <li>
                                    <div class="inactive">
                                            2003
                                            /viewarticle/1001233
                                            Clinical Case
                                        
                                            
                                                
                                                
                                                
                                                
                                                    
                                                
                                                
                                            
                                        
                                        
                                    </div>
                                    
                                        
                                            <a onclick="wmdPageLink('rl-rr_cme'); cmeLayer('https://www.medscape.org/viewarticle/1001233')" href="javascript:void(0)" rel="nofollow">
                                                
                                                    
                                                        
                                                        
                                                        
                                                        
                                                            
                                                        
                                                        <img src="https://img.medscapestatic.com/pi/global/1x1.png"
                                                             data-src="https://img.medscapestatic.com/thumbnail_library/Cardiology_Thumb_27.png?interpolation=lanczos-none&amp;resize=75:*"
                                                             alt="Cardiovascular Prevention in the Primary Care Clinic: Integrating Calcium Scoring Into Patient Risk Assessment and Treatment Decisions">
                                                    
                                                
                                                <span>Cardiovascular Prevention in the Primary Care Clinic: Integrating Calcium Scoring Into Patient Risk Assessment and Treatment Decisions</span>
                                            </a>
                                            <span class="cme-data">
                                    
                                        
                                        
                                        
                                        
                                            
                                                
                                                
                                                
                                                    
                                                
                                            
                                        
                                            
                                                
                                                
                                                
                                                    
                                                
                                            
                                        
                                        
                                            
                                                
                                                
                                            
                                        
                                        0.25 CME / ABIM MOC Credits
                                    
                                </span>
                                            <span class="ifibyline cme-byline">Clinical Case</span>
                                            <div id="cme-modal">
                                                <div id="cme-overlay">
                                                    <div class="cme-popup" id="cme-popup">
                                                        <div class="cross" id="cme-popup-close"></div>
                                                        <div class="cme-redirection-msg">You are being redirected to Medscape Education</div>
                                                        <a href="https://www.medscape.org/viewarticle/1001233" class="cme-redirection-button">
                                                            <span class="content">Yes, take me there</span>
                                                            <span class="progress">
                                                    <span class="progress-inner"></span>
                                                </span>
                                                        </a>
                                                        <div class="cme-redirection-content">
                                                            <div class="cme-redirection-content-subheader">0.25 CME / ABIM MOC</div>
                                                            <div class="cme-redirection-content-title">Cardiovascular Prevention in the Primary Care Clinic: Integrating Calcium Scoring Into Patient Risk Assessment and Treatment Decisions</div>
                                                            <div class="cme-redirection-content-img">
                                                                
                                                                    
                                                                        <img class="pers-img" src="https://img.medscapestatic.com/thumbnail_library/Cardiology_Thumb_27.png">
                                                                    
                                                                
                                                            </div>
                                                        </div>
                                                    </div>
                                                </div>
                                            </div>
                                        
                                        
                                    
                                </li>
                            
                                <li>
                                    <div class="inactive">
                                            2002
                                            164924-overview
                                            Diseases & Conditions
                                        
                                            
                                                
                                                
                                                
                                                    
                                                
                                                
                                                
                                            
                                        
                                        
                                    </div>
                                    
                                        
                                        
                                            <span>Diseases & Conditions</span>
                                            <a onclick="wmdTrack('rl-rr')" href="https://emedicine.medscape.com/article/164924-overview">
                                                
                                                    
                                                        
                                                        
                                                        
                                                        
                                                            
                                                        
                                                        
                                                        
                                                            <img src="https://img.medscapestatic.com/pi/global/1x1.png"
                                                                 data-src="https://img.medscapestatic.com/pi/meds/ckb/23/9623tn.jpg?interpolation=lanczos-none&amp;resize=75:*"
                                                                 alt="Complications of Myocardial Infarction">
                                                        
                                                    
                                                
                                                <span>Complications of Myocardial Infarction</span>
                                            </a>
                                        
                                    
                                </li>
                            
                                <li>
                                    <div class="inactive">
                                            2002
                                            1960472-overview
                                            Diseases & Conditions
                                        
                                            
                                                
                                                
                                                
                                                    
                                                
                                                
                                                
                                            
                                        
                                        
                                    </div>
                                    
                                        
                                        
                                            <span>Diseases & Conditions</span>
                                            <a onclick="wmdTrack('rl-rr')" href="https://emedicine.medscape.com/article/1960472-overview">
                                                
                                                    
                                                        
                                                        
                                                        
                                                        
                                                            
                                                        
                                                        
                                                        
                                                            <img src="https://img.medscapestatic.com/pi/global/1x1.png"
                                                                 data-src="https://img.medscapestatic.com/pi/meds/ckb/44/12844tn.jpg?interpolation=lanczos-none&amp;resize=75:*"
                                                                 alt="Pathology of Acute Myocardial Infarction">
                                                        
                                                    
                                                
                                                <span>Pathology of Acute Myocardial Infarction</span>
                                            </a>
                                        
                                    
                                </li>
                            
                        </ul>
                    </div>
                
            


        
    </div>
</div>



    </div>
        
    <script>
        if ($('.video-container, .multimedia').length > 0) {
            $.getScript('https://img.' + getDomain() + 'medscapestatic.com/medscape-core/reference/js/video/referenceVideo.bundle.js', function () {
                refVideoPlayer.init();
            });
        }
    </script>
    <!--  <script type="text/javascript" src="//img.medscapestatic.com/medscape-core/reference/js/video/referenceVideo.bundle.js"></script>-->

    </body> <!-- GLOBAL SSO FOOTER --> <script src="https://img.medscapestatic.com/medscape-core/shared-all/js/sso-footer.js" id="sso-footer" async> </script>
</html>
